

10/552,304

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances

10/552,304

NEWS 27 MAR 23 CA/CAPplus enhanced with more than 250,000 patent
equivalents from China

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:30:44 ON 24 MAR 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:31:02 ON 24 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAR 2009 HIGHEST RN 1125392-64-4
DICTIONARY FILE UPDATES: 22 MAR 2009 HIGHEST RN 1125392-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10552304.str

10/552,304



```
chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-10 8-11
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9 8-11
isolated ring systems :
containing 1 :
```


```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom
Generic attributes :
11:
Saturation : Unsaturated
```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

10/552,304

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:31:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 187 TO ITERATE

100.0% PROCESSED 187 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2920 TO 4560

PROJECTED ANSWERS: 257 TO 903


L2 29 SEA SSS SAM L1

=> d scan

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(6-quinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel-
MF C26 H27 N9 O2

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):28

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(2,4-
difluorophenyl)methyl]octahydro-, (7R,9aS)-rel-
MF C24 H27 F2 N9 O


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-methyl-4-oxazolyl)-5-phenoxy-
MF C14 H11 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chloro-2,6-difluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-
2-(2-furanyl)-


MF C20 H19 Cl F2 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]-
MF C23 H21 N7 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel-
MF C22 H25 N9 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7-cyclohexyl-2-phenyl-
MF C16 H19 N7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-1-piperazinyl]-2-(2-
furanyl)-
MF C17 H19 Cl N10 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Carbamic acid, [2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-yl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI)
MF C16 H22 N8 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]oxy]phenyl]ethyl]-2-(2-furanyl)-
MF C24 H19 N13 O3

PAGE 1-A



PAGE 1-B




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(6R,9aR)-6-[(3-aminophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-
yl]-2-(2-furanyl)-, rel-
MF C23 H27 N9 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-methoxyphenoxy)-
MF C15 H12 N6 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel-
MF C23 H25 F N8 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,3-difluorophenyl)methyl]-3-piperidinyl]methyl]-2-(2-furanyl)-
MF C21 H22 F2 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Phenol, 4-[2-[[5-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino]ethyl]-
MF C16 H15 N7 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
MF C20 H21 Cl N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5(1H)-one, 7-amino-2-(2-furanyl)-
MF C8 H6 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(4-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel-
MF C23 H25 F N8 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C11 H10 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1,2,3-thiadiazol-4-ylmethyl)-1-piperazinyl]-
MF C15 H16 N10 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(6-chloro-2-fluoro-3-methylphenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
MF C21 H22 Cl F N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(2-phenylethyl)thio]-
MF C16 H14 N6 O S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(2-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-
yl]-2-(2-furanyl)-, rel-
MF C23 H25 F N8 O2


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-propyl-
MF C11 H13 N7 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]-
MF C19 H21 N9 O


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(4-methylphenyl)methyl]-2-pyrrolidinyl)methyl]-
MF C21 H24 N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, N-ethyl-2-phenyl-
MF C12 H12 N6



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304


L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chlorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
MF C20 H21 Cl N8 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10/552,304

L2 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-methylphenoxy)-
MF C15 H12 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/552,304

=> s l1 sss ful
FULL SEARCH INITIATED 13:32:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3440 TO ITERATE

100.0% PROCESSED 3440 ITERATIONS 638 ANSWERS
SEARCH TIME: 00.00.01

L3 638 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 13:32:11 ON 24 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2009 VOL 150 ISS 13
FILE LAST UPDATED: 23 Mar 2009 (20090323/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 159 L3
=> d l4 1-159 bib hitstr

L4 ANSWER 1 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2009:86451 CAPLUS

DN 150:160095

TI Use of adenosine A2A receptor agonists and phosphodiesterase (PDE) inhibitors for the treatment of B-cell proliferative disorders, and combinations with other agents

IN Rickles, Richard; Lee, Margaret S.

PA Combinatorx, Incorporated, USA

SO PCT Int. Appl., 70pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009011893	A2	20090122	WO 2008-US8758	20080717
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20090053168	A1	20090226	US 2008-175219	20080717
PRAI	US 2007-950307P	P	20070717		
	US 2007-965587P	P	20070821		


IT 139180-30-6, ZM 241385

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A2A receptor agonists and phosphodiesterase inhibitors for treatment of B-cell proliferative disorders, and combinations with other agents)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2009:83374 CAPLUS
 DN 150:160094
 TI Combinations for the treatment of B-cell proliferative disorders
 IN Rickles, Richard; Pierce, Laura; Lee, Margaret S.
 PA Combinatorx, Incorporated, USA
 SO PCT Int. Appl., 79pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009011897	A1	20090122	WO 2008-US8764	20080717
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
	CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
	FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
	KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
	ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				
	PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,				
	TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				
	IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
	TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20090047243	A1	20090219	US 2008-175121	20080717
PRAI	US 2007-959877P	P	20070717		
	US 2007-965595P	P	20070821		
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				
	(Biological study); USES (Uses)				
	(combinations for treatment of B-cell proliferative disorders using PDE				
	inhibitors and A2A receptor agonists and antiproliferative compds.)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 3 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:8413 CAPLUS
DN 150:229188
TI Molecular modeling of A1 and A2A adenosine receptors: comparison of
rhodopsin- and β 2-adrenergic-based homology models through the
docking studies
AU Yuzlenko, Olga; Kiec-Kononowicz, Katarzyna
CS Department of Technology and Biotechnology of Drugs, Medical College,
Jagiellonian University, Krakow, Pol.
SO Journal of Computational Chemistry (2008), Volume Date 2009, 30(1), 14-32
CODEN: JCCHDD; ISSN: 0192-8651
PB John Wiley & Sons, Inc.
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(mol. modeling of A1 and A2A adenosine receptors in comparison of
rhodopsin- and β 2-adrenergic-based homol. models through the
docking studies)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1450294 CAPLUS
 DN 150:28941
 TI Methods and compositions for improving immune responses
 IN Sitkovsky, Michail; Ohta, Akio; Lukashev, Dmitriy
 PA Northeastern University, USA
 SO PCT Int. Appl., 140pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008147482	A2	20081204	WO 2008-US1891	20080213
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
	CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
	FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
	KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
	ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				
	PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				
	IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
	TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-901135P P 20070213
 US 2007-965155P P 20070817

IT 139180-30-6, ZM241385
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods and compns. for improving immune responses to vaccines using
 oxygen and adenosine pathway antagonist in treating cancer)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 5 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1389791 CAPLUS
DN 149:571867
TI The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist
AU Jaakola, Veli-Pekka; Griffith, Mark T.; Hanson, Michael A.; Cherezov, Vadim; Chien, Ellen Y. T.; Lane, J. Robert; IJzerman, Adriaan P.; Stevens, Raymond C.
CS Department of Molecular Biology, The Scripps Research Institute, La Jolla, CA, 92037 USA, USA
SO Science (Washington, DC, United States) (2008), 322(5905), 1211-1217
CODEN: SCIEAS; ISSN: 0036-8075
PB American Association for the Advancement of Science
DT Journal
LA English
IT 139180-30-6D, complex with adenosine receptor A2A
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(crystal structure of human A2A adenosine receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 6 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1380657 CAPLUS
DN 150:1444
TI Alcohol-induced retrograde memory impairment in rats: prevention by
caffeine
AU Spinetta, Michael J.; Woodlee, Martin T.; Feinberg, Leila M.; Stroud,
Chris; Schallert, Kellan; Cormack, Lawrence K.; Schallert, Timothy
CS Department of Psychology, The University of Texas at Austin, Austin, TX,
78712, USA
SO Psychopharmacology (Berlin, Germany) (2008), 201(3), 361-371
CODEN: PSCHDL; ISSN: 0033-3158
PB Springer GmbH
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(alc.-induced retrograde memory impairment in rats and prevention by
caffeine)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1316890 CAPLUS
 DN 150:98280
 TI Fused heterocyclic systems with s-triazine ring. Part 12. A convenient method for the synthesis of 7-amino-substituted 1,2,4-triazolo[1,5-a][1,3,5]triazine-5-amines
 AU Dolzhenko, Anton V.; Pastorin, Giorgia; Dolzhenko, Anna V.; Chui, Wai Keung
 CS Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, 117543, Singapore
 SO Tetrahedron Letters (2008), 49(50), 7180-7183
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Ltd.
 DT Journal
 LA English
 IT 1095051-18-5P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure; preparation of triazolotriazinediamines by chemo- and regioselective cyclization of guanidinotriazole with chloroacetonitrile)
 RN 1095051-18-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7,N7-dimethyl-2-phenyl- (CA INDEX NAME)




IT 28610-05-1P 1095050-86-4P 1095050-88-6P
 1095050-91-1P 1095050-93-3P 1095050-95-5P
 1095050-97-7P 1095050-99-9P 1095051-01-6P
 1095051-03-8P 1095051-06-1P 1095051-08-3P
 1095051-10-7P 1095051-13-0P 1095051-16-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of triazolotriazinediamines by chemo- and regioselective cyclization of guanidinotriazole with chloroacetonitrile)
 RN 28610-05-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-phenyl- (CA INDEX NAME)




RN 1095050-86-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7-methyl-2-phenyl- (CA INDEX NAME)


10/552,304




RN 1095050-88-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7-ethyl-2-phenyl- (CA INDEX NAME)



RN 1095050-91-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-cyclopentyl-2-phenyl- (CA INDEX NAME)




RN 1095050-93-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7-cyclohexyl-2-phenyl-
(CA INDEX NAME)




10/552,304


RN 1095050-95-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-[3-(dimethylamino)propyl]-2-phenyl- (CA INDEX NAME)



RN 1095050-97-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N7,2-diphenyl- (CA
INDEX NAME)




RN 1095050-99-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)




RN 1095051-01-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-(4-chlorophenyl)-2-phenyl- (CA INDEX NAME)

10/552,304




RN 1095051-03-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-phenyl-N7-(phenylmethyl)- (CA INDEX NAME)



RN 1095051-06-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-[(4-methoxyphenyl)methyl]-2-phenyl- (CA INDEX NAME)




RN 1095051-08-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N7-[(4-chlorophenyl)methyl]-2-phenyl- (CA INDEX NAME)


10/552,304



RN 1095051-10-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-phenyl-N7-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1095051-13-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-phenyl-N7-(2-phenylethyl)- (CA INDEX NAME)



RN 1095051-16-3 CAPLUS
CN Phenol, 4-[2-[(5-amino-2-phenyl[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)amino]ethyl]- (CA INDEX NAME)


10/552,304



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 8 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1163949 CAPLUS
DN 150:182969
TI Effects of creatine on the expression of adhesion molecules and their
mRNAs in cultured endothelial cells
AU Zhang, Min-jie; Deng, Yu
CS The Intensive Care Unit, the First Affiliated Hospital, Jinan University,
Guangzhou, 510632, Peop. Rep. China
SO Guangdong Yixue (2008), 29(7), 1112-1114
CODEN: GUYIEG; ISSN: 1001-9448
PB Guangdongsheng Yixue Qingbao Yanjiuso
DT Journal
LA Chinese
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(effects of creatine on expression of adhesion mols. and their mRNAs in
cultured endothelial cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




L4 ANSWER 9 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:1007107 CAPLUS
 DN 149:315569
 TI Therapeutic release agents, esters of alkylcarbamic acids, as inhibitors
 of fatty acid amide hydrolase activity
 IN Dasse, Olivier; Parrott, Jeff A.; Putman, David; Adam, Julia
 PA N.V. Organon, Neth.
 SO PCT Int. Appl., 250pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008100977	A2	20080821	WO 2008-US53785	20080213
	WO 2008100977	A3	20081218		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2007-889909P	P	20070214		
	US 2007-948082P	P	20070705		
OS	MARPAT 149:315569				
IT	139180-30-6D, ZM-241385, derivs.				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(therapeutic release agents, esters of alkylcarbamic acids, as inhibitors of fatty acid amide hydrolase activity)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304


L4 ANSWER 10 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:997080 CAPLUS
DN 149:259655
TI Co-evolving stability and conformational homogeneity of the human
adenosine A2a receptor
AU Magnani, Francesca; Shibata, Yoko; Serrano-Vega, Maria J.; Tate,
Christopher G.
CS Laboratory of Molecular Biology, Medical Research Council, Cambridge, CB2
0QH, UK
SO Proceedings of the National Academy of Sciences of the United States of
America (2008), 105(31), 10744-10749
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(human adenosine A2a receptor co-evolving stability and conformational
homogeneity in agonist and antagonist presence)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 11 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:776025 CAPLUS
DN 149:143534
TI Pharmacological blockade of A2A receptors prevents dermal fibrosis in a
model of elevated tissue adenosine
AU Fernandez, Patricia; Trzaska, Sean; Wilder, Tuere; Chiriboga, Luis;
Blackburn, Michael R.; Cronstein, Bruce N.; Chan, Edwin S. L.
CS Department of Medicine, Division of Clinical Pharmacology, New York
University School of Medicine, New York, NY, USA
SO American Journal of Pathology (2008), 172(6), 1675-1682
CODEN: AJPAA4; ISSN: 0002-9440
PB American Society for Investigative Pathology
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(activation of A2A adenosine receptor promoted collagen synthesis by
human dermal fibroblast and blockade of A2A receptor by its agonist
ZM-241385 prevented dermal fibrosis in mouse with elevated tissue
adenosine)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 12 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:673088 CAPLUS

DN 149:24951

TI Adenosine signaling in diagnosis, treatment and prevention of priapism and
erectile dysfunction

IN Yang, Xia; Kellems, Rodney; Blackburn, Michael

PA Board of Regents, The University of Texas System, USA

SO PCT Int. Appl., 82pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008066627	A2	20080605	WO 2007-US22520	20071024
	WO 2008066627	A3	20081211		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2006-862637P P 20061024


IT 139180-30-6, ZM 241385

RL: PAC (Pharmacological activity); BIOL (Biological study)

(adenosine signaling in diagnosis, treatment and prevention of priapism
and erectile dysfunction)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 13 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:568842 CAPLUS
DN 150:573
TI Involvement of the adenosine A1 and A2A receptors in the
antidepressant-like effect of zinc in the forced swimming test
AU Lobato, Kelly R.; Binfare, Ricardo W.; Budni, Josiane; Rosa, Angelo Oscar;
Santos, Adair Roberto S.; Rodrigues, Ana Lucia S.
CS Departamento de Bioquímica, Centro de Ciencias Biológicas, Universidade
Federal de Santa Catarina, Florianópolis-SC, 88040-900, Brazil
SO Progress in Neuro-Psychopharmacology & Biological Psychiatry (2008),
32(4), 994-999
CODEN: PNPPD7; ISSN: 0278-5846
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(involvement of adenosine A1 and A2A receptors in antidepressant-like
effect of zinc in forced swimming test)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2008:412188 CAPLUS
 DN 148:394429
 TI CXC chemokine-mediated signaling targeting for treatment of a myelin disorder
 IN Miller, Robert H.; Padovani-Claudio, Dolly A.
 PA Case Western Reserve University, USA
 SO PCT Int. Appl., 85pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008039876	A1	20080403	WO 2007-US79602	20070926
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20090041753	A1	20090212	US 2007-904634	20070926
PRAI	US 2006-847656P	P	20060926		
IT	319932-15-5				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(CXC chemokine-mediated signaling targeting for treatment of myelin disorder)				
RN	319932-15-5 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(3-methylphenyl)-5-(methylsulfonyl)- (CA INDEX NAME)				



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 15 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:321284 CAPLUS
DN 148:323145
TI Use of adenosine A2A modulators to treat spinal cord injury
IN Li, Yuesheng Jason; Linden, Joel M.; Rieger, Jayson M.
PA University of Virginia Patent Foundation, USA
SO U.S. Pat. Appl. Publ., 55pp.
CODEN: USXXCO

DT Patent
LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20080064653	A1	20080313	US 2007-765320	20070619
PRAI	US 2006-814713P	P	20060619		
OS	MARPAT 148:323145				
IT	139180-30-6, ZM241385				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2A modulators to treat central nervous system injury,
including spinal cord injury)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304

L4 ANSWER 16 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:169268 CAPLUS
DN 148:583132
TI Activation of adenosine 2A receptors preserves structure and function of podocytes
AU Awad, Alaa S.; Rouse, Michael; Liu, Lixia; Vergis, Amy L.; Rosin, Diane L.; Linden, Joel; Sedor, John R.; Okusa, Mark D.
CS Departments of Medicine and the Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
SO Journal of the American Society of Nephrology (2008), 19(1), 59-68
CODEN: JASNEU; ISSN: 1046-6673
PB American Society of Nephrology
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine 2A receptors mRNA, protein activation preserves structure, function of podocyte, attenuate podocyte injury, albuminuria, foot process fusion evident in mouse podocytes in vivo and podocyte cell line in vitro)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 17 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:72174 CAPLUS
DN 148:143548
TI Super-sweet sugar crystals and syrups for health and method
IN Badalov, Constantin
PA Can.
SO U.S. Pat. Appl. Publ., 14pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20080014331	A1	20080117	US 2006-487933	20060717
	CA 2559222	A1	20080117	CA 2006-2559222	20060912
PRAI	US 2006-487933	A	20060717		


IT 139180-30-6, ZM 241385

RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(super-sweet sugar crystals and syrups supplemented with high-intensity sweeteners for food and health products)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 18 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:14861 CAPLUS
DN 148:300230
TI Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour
AU Gessi, Stefania; Fogli, Eleonora; Sacchetto, Valeria; Varani, Katia; Merighi, Stefania; Leung, Edward; MacLennan, Stephen; Borea, Pier Andrea
CS Department of Clinical and Experimental Medicine, Pharmacology Unit and Interdisciplinary Center for the Study of Inflammation, Ferrara, Italy
SO Biochemical Pharmacology (2008), 75(2), 562-569
CODEN: BCPA6; ISSN: 0006-2952
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(thermodn. of adenosine A2B receptor binding discrimination agonistic from antagonistic activity)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 19 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1058916 CAPLUS
DN 147:378198
TI Anticonvulsant effect of A1 but not A2A adenosine receptors of piriform
cortex in amygdala-kindled rats
AU Rezvani, Mohammad Ebrahim; Mirnajafi-Zadeh, Javad; Fathollahi, Yaghoub;
Palizvan, Mohammad Reza
CS Department of Physiology, School of Medical Sciences, Tarbiat Modares
University, Tehran, Iran
SO Canadian Journal of Physiology and Pharmacology (2007), 85(6), 606-612
CODEN: CJPPA3; ISSN: 0008-4212
PB National Research Council of Canada
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(anticonvulsant effect of A1 but not A2A adenosine receptors of
piriform cortex in amygdala-kindled rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 20 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:999857 CAPLUS
DN 148:93445
TI The role of adenosine A1 and A2A receptors of entorhinal cortex on
piriform cortex kindled seizures in rats
AU Hosseinmardi, Narges; Mirnajafi-Zadeh, Javad; Fathollahi, Yaghoub;
Shahabi, Parviz
CS Department of Physiology, School of Medical Sciences, Tarbiat Modares
University, Tehran, Iran
SO Pharmacological Research (2007), 56(2), 110-117
CODEN: PHMREP; ISSN: 1043-6618
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(activation of adenosine A2A receptor of entorhinal cortex had
proconvulsive effect on piriform cortex kindled seizures in rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:993718 CAPLUS

DN 147:315046

TI Method of using adenosine receptor blockers during tissue ablation

IN Podhajsky, Ronald J.

PA Sherwood Services A.-G., Switz.

SO U.S. Pat. Appl. Publ., 6pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20070207979	A1	20070906	US 2006-367909	20060303
	US 20070208042	A1	20070906	US 2006-487223	20060714
	US 20080275068	A1	20081106	US 2008-174162	20080716
PRAI	US 2006-367909	A2	20060303		
	US 2006-487223	A3	20060714		

IT 139180-30-6, ZM 241385


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(method of using adenosine receptor blockers during tissue ablation)

RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




10/552,304

L4 ANSWER 22 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:993717 CAPLUS
DN 147:315045
TI Method of using vasoconstrictive agents during energy-based tissue therapy
IN Podhajsky, Ronald J.
PA Sherwood Services A.-G., Switz.
SO U.S. Pat. Appl. Publ., 8pp., Cont.-in-part of U.S. Ser. No. 367,909.
CODEN: USXXCO

DT Patent
LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20070208042	A1	20070906	US 2006-487223	20060714
	US 20070207979	A1	20070906	US 2006-367909	20060303
	US 20080275068	A1	20081106	US 2008-174162	20080716
PRAI	US 2006-367909	A2	20060303		
	US 2006-487223	A3	20060714		
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				
	(Biological study); USES (Uses)				
	(method of using vasoconstrictive agents during energy-based tissue				
	therapy)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-				
	yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304


L4 ANSWER 23 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:467247 CAPLUS
DN 146:435022
TI Interleukin-1 β but not tumor necrosis factor- α potentiates
neuronal damage by quinolinic acid: protection by an adenosine A2A
receptor antagonist
AU Stone, Trevor W.; Behan, Wilhelmina M. H.
CS Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow,
UK
SO Journal of Neuroscience Research (2007), 85(5), 1077-1085
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(interleukin-1 β but not tumor necrosis factor- α potentiates
neuronal damage by quinolinic acid and protection by an adenosine A2A
receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:464312 CAPLUS
 DN 146:448474
 TI Compounds for the treatment of auricular fibrillation
 IN Franco Fernandez, Rafael; Ciruela Alferez, Francisco; Lluís Biset, Carmen;
 Mueller, Christa; Cinca Cusculloa, Joan; Hove-Madsen, Leif
 PA Universidad de Barcelona, Spain
 SO PCT Int. Appl., 33pp.
 CODEN: PIXXD2
 DT Patent
 LA Spanish
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007045705	A2	20070426	WO 2006-ES564	20061010
	WO 2007045705	A3	20070614		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	ES 2273599	A1	20070501	ES 2005-2545	20051014
	ES 2273599	B1	20080601		
	AU 2006303240	A1	20070426	AU 2006-303240	20061010
	CA 2626020	A1	20070426	CA 2006-2626020	20061010
	EP 1949903	A2	20080730	EP 2006-830873	20061010
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2009511551	T	20090319	JP 2008-535047	20061010
	CN 101325956	A	20081217	CN 2006-80046601	20080612
PRAI	ES 2005-2545	A	20051014		
	WO 2006-ES564	W	20061010		
IT	146229-54-1 735316-63-9 934536-44-4 934536-45-5				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(compsds. for the treatment of auricular fibrillation)				
RN	146229-54-1 CAPLUS				
CN	Phenol, 4-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]- (CA INDEX NAME)				



RN 735316-63-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]- (CA


10/552,304

INDEX NAME)




RN 934536-44-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)- (CA INDEX NAME)



RN 934536-45-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[2-[1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)



L4 ANSWER 25 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:410253 CAPLUS
 DN 146:415128
 TI Enhancing treatment of cancer and HIF-1-mediated disorders with adenosine
 A3 receptor antagonists
 IN Borea, Pier Andrea; Baraldi, Pier Giovanni; Merighi, Stefania; MacLennan,
 Stephen; Leung, Edward; Moorman, Allan
 PA King Pharmaceuticals Research & Development, Inc., USA
 SO PCT Int. Appl., 184pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007040565	A2	20070412	WO 2005-US42551	20051122
	WO 2007040565	A9	20070705		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2005336924	A1	20070412	AU 2005-336924	20051122
	CA 2586420	A1	20070412	CA 2005-2586420	20051122
	EP 1827445	A2	20070905	EP 2005-858564	20051122
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008520746	T	20080619	JP 2007-543474	20051122
PRAI	US 2004-630557P	P	20041122		
	WO 2005-US42551	W	20051122		

OS MARPAT 146:415128

IT 139180-30-6, ZM 241385


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(adenosine A3 receptor antagonists for enhancing treatment of cancer and HIF-1-mediated disorders)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




10/552,304

L4 ANSWER 26 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:361074 CAPLUS
DN 146:454771
TI Attenuation of reperfusion lung injury and apoptosis by A2A adenosine
receptor activation is associated with modulation of BCL-2 and Bax
expression and activation of extracellular signal-regulated kinases
AU Rivo, Julia; Zeira, Evelyne; Galun, Eithan; Einav, Sharon; Linden, Joel;
Matot, Idit
CS Department of Anesthesiology and Critical Care Medicine, Hadassah
University Medical Center, The Hebrew University of Jerusalem, Jerusalem,
Israel
SO Shock (2007), 27(3), 266-273
CODEN: SAGUAI; ISSN: 1073-2322
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(A2A adenosine receptor agonist ATL313 induced protection was associated
with upregulation of antiapoptotic protein Bcl-2, downregulation of
proapoptotic protein Bax and activation of ERK1/2 in lung injury cat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4	ANSWER 27 OF 159	CAPLUS	COPYRIGHT 2009 ACS on STN
AN	2007:282587	CAPLUS	
DN	147:661		
TI	Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists		
AU	Yang, Ming; Soohoo, Daniel; Soelaiman, Sandriyana; Kalla, Rao; Zablocki, Jeff; Chu, Nancy; Leung, Kwan; Yao, Lina; Diamond, Ivan; Belardinelli, Luiz; Shryock, John C.		
CS	CV Therapeutics, Inc., Palo Alto, CA, 94304, USA		
SO	Naunyn-Schmiedeberg's Archives of Pharmacology (2007), 375(2), 133-144		
	CODEN: NSAPCC; ISSN: 0028-1298		
PB	Springer		
DT	Journal		
LA	English		
IT	735316-76-4, Biogen 34		
	RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)		
	(characterization of potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists)		
RN	735316-76-4 CAPLUS		
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[4-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)		



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 28 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:255121 CAPLUS
DN 146:454679
TI The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective
effect of adenosine agonist pretreatment in in vivo rat myocardium
AU Lasley, Robert D.; Kristo, Gentian; Keith, Byron J.; Mentzer, Robert M.,
Jr.
CS Department of Surgery, Division of Cardiothoracic Surgery, University of
Kentucky College of Medicine, Lexington, KY, USA
SO American Journal of Physiology (2007), 292(1, Pt. 2), H426-H431
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2a/A2b receptor antagonist ZM-241385 blocks cardioprotective effect
of adenosine agonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:248273 CAPLUS
DN 146:441760
TI Synthesis of 5,7-diamino[1,2,4]triazolo[1,2-a][1,3,5]triazines via
annulation of 1,3,5-triazine ring onto 3(5)-amino-1,2,4-triazoles
AU Dolzhenko, Anton V.; Dolzhenko, Anna V.; Chui, Wai-Keung
CS Department of Pharmacy, Faculty of Science, National University of
Singapore, Singapore, 117543, Singapore
SO Heterocycles (2007), 71(2), 429-436
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 146:441760
IT 28610-05-1P 934537-96-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of triazolotriazinediamines via cyclocondensation of
triazolamines with cyanoguanidine)
RN 28610-05-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-phenyl- (CA INDEX
NAME)




RN 934537-96-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(4-pyridinyl)- (CA
INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2007:245614 CAPLUS
 DN 146:454155
 TI 3D-Pharmacophore Models for Selective A2A and A2B Adenosine Receptor Antagonists
 AU Wei, Jing; Wang, Songqing; Gao, Shaofen; Dai, Xuedong; Gao, Qingzhi
 CS School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, Peop. Rep. China
 SO Journal of Chemical Information and Modeling (2007), 47(2), 613-625
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English
 IT 735316-76-4 735316-82-2 781638-59-3
 781638-67-3 935530-24-8
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (pharmacophore models for selective A2A and A2B adenosine receptor antagonists)
 RN 735316-76-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[4-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-82-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[4-[(3,5-dichloro-4-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 781638-59-3 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[(7R,9aS)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781638-67-3 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 935530-24-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(6-quinolinyloxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

10/552,304

L4 ANSWER 31 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:175656 CAPLUS
DN 146:221143
TI Compositions and methods for inhibiting neurodegeneration
IN Kalb, Robert Gordon; Mojsilovic-Petrovic, Jelena
PA USA
SO U.S. Pat. Appl. Publ., 36pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20070037833	A1	20070215	US 2006-500772	20060808
PRAI	US 2005-706278P	P	20050808		
	US 2005-719152P	P	20050921		

IT 139180-30-6, ZM241385


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(compns. and methods for inhibiting neurodegeneration by using
adenosine A2 receptor antagonists)

RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




L4 ANSWER 32 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:161789 CAPLUS
DN 146:198266
TI ZM241385, DPCPX, MRS1706 are inverse agonists with different relative
intrinsic efficacies on constitutively active mutants of the human
adenosine A2B receptor
AU Li, Qilan; Ye, Kai; Blad, Clara C.; den Dulk, Hans; Brouwer, Jaap;
IJzerman, Ad P.; Beukers, Margot W.
CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug
Research, Leiden Institute of Chemistry, Leiden University, Leiden, Neth.
SO Journal of Pharmacology and Experimental Therapeutics (2007), 320(2),
637-645
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(ZM241385, DPCPX, MRS1706 are inverse agonists on constitutively active
mutants of human adenosine A2B receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 33 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:73675 CAPLUS
DN 146:198630
TI Cell death in rat cerebellar granule neurons induced by hydrogen peroxide
in vitro: Mechanisms and protection by adenosine receptor ligands
AU Fatokun, Amos A.; Stone, Trevor W.; Smith, Robert A.
CS Division of Neuroscience and Biomedical Systems, Institute of Biomedical
and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO Brain Research (2007), 1132(1), 193-202
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Ltd.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(H2O2-induced cerebellar neuronal death: mechanisms and protection by
adenosine receptor ligands in relation to neurodegenerative disease
pathogenesis and treatment)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 34 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1190071 CAPLUS
DN 146:54726
TI Identification of non-furan containing A2A antagonists using database
mining and molecular similarity approaches
AU Richardson, Christine M.; Gillespie, Roger J.; Williamson, Douglas S.;
Jordan, Allan M.; Fink, Alexandra; Knight, Antony R.; Sellwood, Daniel M.;
Misra, Anil
CS Vernalis (R&D) Ltd, Cambridge, CB1 6GB, UK
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5993-5997
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
IT 139180-30-6 735316-55-9
RL PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2A receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RN 735316-55-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2,3,6-trichlorophenyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 35 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1047255 CAPLUS
DN 145:353569
TI Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction
AU Faria, Miguel; Magalhaes-Cardoso, Teresa; Lafuente-de-Carvalho, Jose-Maria; Correia-de-Sa, Paulo
CS Laboratorio de Farmacologia, Unidade Multidisciplinar de Investigacao Biomedica, Instituto de Ciencias Biomedicas de Abel Salazar, Universidade do Porto, Oporto, Port.
SO Journal of Pharmacology and Experimental Therapeutics (2006), 319(1), 405-413
CODEN: JPETAB; ISSN: 0022-3565
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
(corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 36 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1009835 CAPLUS
DN 145:369892
TI Adenosine 2a receptor signaling modulators for the treatment of
HIV-associated neuronal damage
IN Dewhurst, Stephen; Ramirez, Servio; Lu, Shao-Ming; Gelbard, Harris A.;
Maggirwar, Sanjay B.; Fan, Shongshan
PA University of Rochester, USA
SO PCT Int. Appl., 68pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006101920	A2	20060928	WO 2006-US9390	20060316
	WO 2006101920	A3	20070215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-663059P	P	20050318		
IT	139180-30-6, ZM241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(adenosine 2a receptor signaling modulators for treatment of HIV-associated neuronal damage)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 37 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:933602 CAPLUS
DN 145:416903
TI A2A adenosine receptor protects tumors from antitumor T cells
AU Ohta, Akio; Gorelik, Elieser; Prasad, Simon J.; Ronchese, Franca;
Lukashev, Dmitriy; Wong, Michael K. K.; Huang, Xiaojun; Caldwell, Sheila;
Liu, Kebin; Smith, Patrick; Chen, Jiang-Fan; Jackson, Edwin; Apasov,
Sergey; Abrams, Scott; Sitkovsky, Michail
CS Lab. Immunol., Natl. inst. Allergy and Infectious Diseases, Natl. Inst.
Health, Bethesda, MD, 20892, USA
SO Proceedings of the National Academy of Sciences of the United States of
America (2006), 103(35), 13132-13137
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT 139180-30-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor protects tumors from antitumor T cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 38 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:883497 CAPLUS
DN 145:328753
TI Expression and functional purification of a glycosylation deficient
version of the human adenosine 2a receptor for structural studies
AU Fraser, Niall J.
CS Division of Biochemistry and Molecular Biology, IBLS, Glasgow Biomedical
Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
SO Protein Expression and Purification (2006), 49(1), 129-137
CODEN: PEXPEJ; ISSN: 1046-5928
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL
(Biological study)
(expression/purification of a glycosylation deficient version of human
adenosine 2A receptor and their dynamic binding to selected antagonists
and agonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 39 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:854004 CAPLUS
DN 146:221614
TI Cloning and pharmacological characterization of the equine adenosine A3
receptor
AU Brandon, C. I.; Vandenplas, M.; Dookwah, H.; Murray, T. F.
CS Department of Physiology and Pharmacology, College of Veterinary Medicine,
University of Georgia, Athens, GA, USA
SO Journal of Veterinary Pharmacology and Therapeutics (2006), 29(4), 255-263
CODEN: JVPTD9; ISSN: 0140-7783
PB Blackwell Publishing Ltd.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(equilibrium competition binding assays for adenosine A3 receptor showed
rank order of antagonist potency to be MRS1220 > ZM241385 >
8-p-sulfophenyltheophylline in human embryonic kidney cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 40 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:854003 CAPLUS
DN 146:221613
TI Cloning and pharmacological characterization of the equine adenosine A2A
receptor: a potential therapeutic target for the treatment of equine
endotoxemia
AU Brandon, C. I.; Vandenplas, M.; Dookwah, H.; Linden, J.; Murray, T. F.
CS Departments of Physiology and Pharmacology, College of Veterinary
Medicine, University of Georgia, Athens, GA, USA
SO Journal of Veterinary Pharmacology and Therapeutics (2006), 29(4), 243-253
CODEN: JVPTD9; ISSN: 0140-7783
PB Blackwell Publishing Ltd.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(binding potentials of equine adenosine A2A receptor were determined by
using adenosine A2A receptor antagonist ZM241385 in human embryonic
kidney cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:837021 CAPLUS
DN 145:285428
TI Mouse spinal cord compression injury is reduced by either activation of the adenosine A2A receptor on bone marrow-derived cells or deletion of the A2A receptor on non-bone marrow-derived cells
AU Li, Y.; Oskouian, R. J.; Day, Y.-J.; Rieger, J. M.; Liu, L.; Kern, J. A.; Linden, J.
CS Department of Medicine, University of Virginia Health System, Charlottesville, VA, 22908, USA
SO Neuroscience (San Diego, CA, United States) (2006), 141(4), 2029-2039
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A2A receptor agonist; mouse spinal cord compression injury is reduced by either activation of adenosine A2A receptor on bone marrow-derived cells or deletion of A2A receptor on non-bone marrow-derived cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:790659 CAPLUS

DN 145:202900

TI Sepsis prevention through adenosine receptor modulation

IN Hasko, Gyorgy; Nemeth, Zoltan; Bleich, David; Deitch, Edwin

PA University of Medicine and Dentistry of New Jersey, USA

SO PCT Int. Appl., 45pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006083949	A2	20060810	WO 2006-US3523	20060201
	WO 2006083949	A3	20070125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20090041751	A1	20090212	US 2007-815276	20070801
PRAI	US 2005-648809P	P	20050201		
	WO 2006-US3523	W	20060201		
IT	139180-30-6, ZM241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(sepsis prevention through adenosine receptor modulation)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304


L4 ANSWER 43 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:756818 CAPLUS
DN 145:203066
TI Functional coupling of the Gαolf variant XLGαolf with the
human adenosine A2A receptor
AU Ravyn, Vipa; Bostwick, J. Robert
CS Lead Discovery, AstraZeneca Pharmaceuticals, Wilmington, DE, USA
SO Journal of Receptors and Signal Transduction (2006), 26(4), 241-258
CODEN: JRSTCT
PB Taylor & Francis, Inc.
DT Journal
LA English
IT 904875-36-1
RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); BIOL
(Biological study)
(functional coupling of Gαolf variant XLGαolf with the
human adenosine A2A receptor)
RN 904875-36-1 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]-, labeled with tritium (9CI) (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 44 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2006:736180 CAPLUS
 DN 145:180997
 TI mitochondrial hyperpolarization inhibitors for treatment of HIV
 neurotoxin-induced neurol. disease
 IN Perry, Seth W.; Norman, John Phillip; Dewhurst, Stephen; Gelbard, Harris
 A.
 PA University of Rochester, USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006078876	A2	20060727	WO 2006-US1987	20060119
	WO 2006078876	A9	20060928		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006206399	A1	20060727	AU 2006-206399	20060119
	CA 2594910	A1	20060727	CA 2006-2594910	20060119
	EP 1845969	A2	20071024	EP 2006-733772	20060119
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	US 20080269161	A1	20081030	US 2008-795664	20080530
PRAI	US 2005-645426P	P	20050120		
	US 2005-663424P	P	20050318		
	WO 2006-US1987	W	20060119		
IT	139180-30-6, ZM241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(mitochondrial hyperpolarization inhibitors for treatment of HIV neurotoxin-induced neurol. disease)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304


L4 ANSWER 45 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:709322 CAPLUS
DN 146:92538
TI A novel cell-based assay for G-protein-coupled receptor-mediated cyclic
adenosine monophosphate response element binding protein phosphorylation
AU Selkirk, Julie V.; Nottebaum, Lisa M.; Ford, Ian C.; Santos, Mark; Malany,
Siobhan; Foster, Alan C.; Lechner, Sandra M.
CS Department of Nueroscience, Neurocrine Biosciences Inc., San Diego, CA,
USA
SO Journal of Biomolecular Screening (2006), 11(4), 351-358
CODEN: JBISF3; ISSN: 1087-0571
PB Sage Publications
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(cell-based assay for G-protein-coupled receptor-mediated cyclic
adenosine monophosphate response element binding protein
phosphorylationy)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 46 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:709321 CAPLUS
DN 146:92537
TI Assay development and screening of a serine/threonine kinase in an on-chip
mode using caliper nanofluidics technology
AU Perrin, Dominique; Fremaux, Christele; Scheer, Alexander
CS Molecular Screening and Cellular Pharmacology Department, Serono
Pharmaceutical Research Institute, Geneva, Switz.
SO Journal of Biomolecular Screening (2006), 11(4), 359-368
CODEN: JBISF3; ISSN: 1087-0571
PB Sage Publications
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(assay development and screening of a serine/threonine kinase in an
on-chip mode using caliper nanofluidics technol.)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 47 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:628111 CAPLUS
DN 145:96747
TI Characterization of [125I]ZM 241385 binding to adenosine A2A receptors in
the pineal of sheep brain
AU Yan, X.; Koos, B. J.; Kruger, L.; Linden, J.; Murray, T. F.
CS Department of Pharmacology, Creighton University School of Medicine,
Omaha, NE, 68178, USA
SO Brain Research (2006), 1096(1), 30-39
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6D, ZM 241385, iodo derivs., iodine-125 labeled
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);
BIOL (Biological study); USES (Uses)
(characterization of [125I]ZM 241385 binding to adenosine A2A receptors
in pineal of sheep brain in relation to melatonin secretion)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 48 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:596148 CAPLUS
DN 145:160045
TI Adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in the globus pallidus of the rat
AU Gonzalez, Brenda; Paz, Francisco; Floran, Leonor; Aceves, Jorge; Erlij, David; Floran, Benjamin
CS Biofisica y Neurociencias, Centro de Investigacion y de Estudios Avanzados, Departamento de Fisiologia, Mexico City, 07000, Mex.
SO Neuropharmacology (2006), 51(1), 154-159
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(A2A antagonist; adenosine A2A receptor stimulation decreases GAT-1-mediated GABA uptake in globus pallidus of rat through mechanism involving protein kinase A)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 49 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:107465 CAPLUS
DN 144:286058
TI The effect of intraentorhinal injection of selective A2A receptor agonist
on pyriform cortex-kindled seizures in rats
AU Hosseinmardi, N.; Mirnajafi-Zadeh, J.; Fathollahi, Y.; Shahabi, P.;
Rezvani, M. E.; Namvar, S.
CS Dept. Physiol., Sch. Med. Sci., Tarbiat Modares Univ., Tehran, Iran
SO Fiziolozi va Farmakolozi (2005), 9(1), 41-46
CODEN: PPHHAM; ISSN: 1735-0581
PB Iranian Society of Physiology and Pharmacology
DT Journal
LA Persian
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(effect of intraentorhinal injection of selective A2A receptor agonist
on pyriform cortex-kindled seizures in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



L4 ANSWER 50 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:75101 CAPLUS

DN 144:143078

TI Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior

IN Diamond, Ivan F.; Gordon, Adrienne S.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 67 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006009698	A2	20060126	WO 2005-US20992	20050614
	WO 2006009698	A3	20070628		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2005264960	A1	20060126	AU 2005-264960	20050614
	CA 2571242	A1	20060126	CA 2005-2571242	20050614
	US 20060128708	A1	20060615	US 2005-153725	20050614
	EP 1765352	A2	20070328	EP 2005-761538	20050614
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	CN 101060841	A	20071024	CN 2005-80028252	20050614
	JP 2008503464	T	20080207	JP 2007-516649	20050614
PRAI	US 2004-581143P	P	20040617		
	WO 2005-US20992	W	20050614		
IT	139180-30-6				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(adenosine A2A receptor antagonists for amelioration of one or more components of addictive behavior)			
RN	139180-30-6	CAPLUS			
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-	(CA INDEX NAME)			



L4 ANSWER 51 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:1218618 CAPLUS
 DN 143:472578
 TI Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
 IN Okusa, Mark D.; Linden, Joel M.; MacDonald, Timothy L.; Awad, Alaa S.
 PA University of Virginia Patent Foundation, USA
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005107463	A1	20051117	WO 2005-US15241	20050503
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050261236	A1	20051124	US 2005-121169	20050503
	US 7396825	B2	20080708		
	EP 1746885	A1	20070131	EP 2005-756108	20050503
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2007536241	T	20071213	JP 2007-511486	20050503
PRAI	US 2004-567465P	P	20040503		
	WO 2005-US15241	W	20050503		


OS MARPAT 143:472578

IT 139180-30-6, ZM 241385

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (A2A adenosine receptor agonists for treatment of diabetic nephropathy)

RN 139180-30-6 CAPLUS


CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 52 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:978112 CAPLUS
DN 144:122110
TI Involvement of 5-HT1A receptors in the antidepressant-like effect of
adenosine in the mouse forced swimming test
AU Kaster, Manuella P.; Santos, Adair R. S.; Rodrigues, Ana L. S.
CS Departamento de Bioquímica, Centro de Ciências Biológicas, Universidade
Federal de Santa Catarina, Florianópolis, 88040-900, Brazil
SO Brain Research Bulletin (2005), 67(1-2), 53-61
CODEN: BRBUDU; ISSN: 0361-9230
PB Elsevier Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(involvement of 5-HT1A receptors in the antidepressant-like effect of
adenosine in the mouse forced swimming test)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 53 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:520544 CAPLUS
DN 143:339402
TI Antagonistic interaction between adenosine A2A and dopamine D2 receptors
modulates the social recognition memory in reserpine-treated rats
AU Prediger, R. D. S.; Da Cunha, C.; Takahashi, R. N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas Universidade
Federal de Santa Catarina, UFSC, Universidade Federal de Santa Catarina,
UFSC, Brazil
SO Behavioural Pharmacology (2005), 16(4), 209-218
CODEN: BPHAEI; ISSN: 0955-8810
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(reserpine induced social recognition disruption was reversed by acute
treatment with adenosine A2A receptor antagonist ZM241385 and
'non-effective' doses of ZM241385 combined with quinpirole showed
synergistic response in rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 54 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2005:495122 CAPLUS
 DN 143:146976
 TI Expression, pharmacological profile, and functional coupling of A2B
 receptors in a recombinant system and in peripheral blood cells using a
 novel selective antagonist radioligand, [3H]MRE 2029-F20
 AU Gessi, Stefania; Varani, Katia; Merighi, Stefania; Cattabriga, Elena;
 Pancaldi, Cecilia; Szabadkai, Youri; Rizzuto, Rosario; Klotz,
 Karl-Norbert; Leung, Edward; Mac Lennan, Stephen; Baraldi, Pier Giovanni;
 Borea, Pier Andrea
 CS Department of Clinical and Experimental Medicine, Pharmacology Unit,
 University of Ferrara, Italy
 SO Molecular Pharmacology (2005), 67(6), 2137-2147
 CODEN: MOPMA3; ISSN: 0026-895X
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 IT 139180-30-6, ZM241385
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (A2B antagonist; expression, pharmacol. profile, and functional
 coupling of A2B receptors in recombinant system and in peripheral blood
 cells using novel selective antagonist radioligand, [3H]MRE 2029-F20)
 RN 139180-30-6 CAPLUS
 CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 55 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:442161 CAPLUS
DN 143:278709
TI Involvement of Adenosine in the Antiinflammatory Action of Ketamine
AU Mazar, Julia; Rogachev, Boris; Shaked, Gad; Ziv, Nadav Y.; Czeiger, David;
Chaimovitz, Cidio; Zlotnik, Moshe; Mukmenev, Igor; Byk, Gerardo;
Douvdevani, Amos
CS Department of Nephrology, Sorokaa University Medical Center, Ben-Gurion
University of The Negev, Beer-Sheve, Israel
SO Anesthesiology (2005), 102(6), 1174-1181
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); BIOL (Biological study)
(adenosine receptor antagonist DMPX and ZM 241385 blocked
anti-inflammatory effects in mouse peritonitis model)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 56 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:442159 CAPLUS
DN 143:279038
TI Effect of Sleep Deprivation on Righting Reflex in the Rat Is Partially
Reversed by Administration of Adenosine A1 and A2 Receptor Antagonists
AU Tung, Avery; Herrera, Stacy; Szafran, Martin J.; Kasza, Kristen;
Mendelson, Wallace B.
CS Department of Anesthesia and Critical Care, Biostatistics, and Psychiatry,
the University of Chicago, Chicago, IL, USA
SO Anesthesiology (2005), 102(6), 1158-1164
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2a receptor antagonist ZM241385 partially reversed effect
of sleep deprivation on isoflurane-induced loss of righting reflex and
dose dependently shortened time of recovery in sleep deprived rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 57 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:413328 CAPLUS
DN 143:38317
TI Adenosine A2A receptor stimulation increases angiogenesis by
down-regulating production of the antiangiogenic matrix protein
thrombospondin 1
AU Desai, Avani; Victor-Vega, Cassandre; Gadangi, Swathi; Montesinos, M.
Carmen; Chu, Charles C.; Cronstein, Bruce N.
CS Department of Medicine, New York University School of Medicine, New York,
NY, USA
SO Molecular Pharmacology (2005), 67(5), 1406-1413
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(adenosine A2A receptor stimulation increases angiogenesis by
down-regulating thrombospondin 1)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 58 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:387578 CAPLUS
DN 143:380086
TI Kinetic and functional properties of [3H]ZM241385, a high affinity antagonist for adenosine A2A receptors. [Erratum to document cited in CA142:310219]
AU Uustare, Ain; Vonk, Argo; Terasmaa, Anton; Fuxe, Kjell; Rinken, Ago
CS Institute of Organic and Bioorganic Chemistry, University of Tartu, Tartu, EE-51014, Estonia
SO Life Sciences (2005), 77(3), 359
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study) (kinetic and functional properties of high affinity antagonist [3H]ZM241385 for adenosine A2A receptors (Erratum))
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 59 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:326031 CAPLUS
DN 143:146380
TI Blockade of adenosine A2A receptors reverses short-term social memory
impairments in spontaneously hypertensive rats
AU Prediger, Rui D. S.; Fernandes, Daniel; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, Universidade
Federal de Santa Catarina, Florianopolis, 88049-900, Brazil
SO Behavioural Brain Research (2005), 159(2), 197-205
CODEN: BBREDI; ISSN: 0166-4328
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adenosine A2A receptor antagonist ZM241385 reversed social memory
impairment in spontaneously hypertensive rat indicating involvement of
adenosine A2A receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 60 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:163161 CAPLUS
DN 142:348881
TI Effects of adenosine and adenosine A2A receptor agonist on motor nerve
conduction velocity and nerve blood flow in experimental diabetic
neuropathy
AU Kumar, Sokindra; Arun, K. H. S.; Kaul, Chaman L.; Sharma, Shyam S.
CS Department of Pharmacology and Toxicology, National Institute of
Pharmaceutical Education and Research, Punjab, India
SO Neurological Research (2005), 27(1), 60-66
CODEN: NRESZD; ISSN: 0161-6412
PB Maney Publishing
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CGS 21680 hydrochloride failed to produce protective effect on sciatic
MNCV but improved NBF in diabetic rat model was inhibited by adenosine
A2A receptor antagonist ZM 241385 suggesting involvement of adenosine
receptor mechanism in DN)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 61 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:149004 CAPLUS
DN 142:456798
TI Caffeine reverses age-related deficits in olfactory discrimination and
social recognition memory in rats
AU Prediger, Rui D. S.; Batista, Luciano C.; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, UFSC, Campus
Trindade, Universidade Federal de Santa Catarina, Florianopolis, Santa
Catarina, 88049-900, Brazil
SO Neurobiology of Aging (2005), 26(6), 957-964
CODEN: NEAGDO; ISSN: 0197-4580
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(acute ZM241385 reversed age-related olfactory discrimination and
social recognition memory in rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 62 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:137653 CAPLUS
DN 142:255028
TI Modulation of short-term social memory in rats by adenosine A1 and A2A
receptors
AU Prediger, Rui D. S.; Takahashi, Reinaldo N.
CS Departamento de Farmacologia, Centro de Ciencias Biologicas, Universidade
Federal de Santa Catarina, UFSC, Florianopolis, 88049-900, Brazil
SO Neuroscience Letters (2005), 376(3), 160-165
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(adenosine A1 and A2A receptor modulation of short-term social memory
in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 63 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:70069 CAPLUS
DN 142:310219
TI Kinetic and functional properties of [3H]ZM241385, a high affinity
antagonist for adenosine A2A receptors
AU Uustare, Ain; Vonk, Argo; Terasmaa, Anton; Fuxe, Kjell; Rinken, Ago
CS Institute of Organic and Bioorganic Chemistry, University of Tartu, Tartu,
EE-51014, Estonia
SO Life Sciences (2005), 76(13), 1513-1526
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(kinetic and functional properties of high affinity antagonist
[3H]ZM241385 for adenosine A2A receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 64 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:8089 CAPLUS
DN 142:232790
TI A2A adenosine receptor induction inhibits IFN- γ production in murine
CD4+ T cells
AU Lappas, Courtney M.; Rieger, Jayson M.; Linden, Joel
CS Department of Pharmacology, University of Virginia, Charlottesville, VA,
22908, USA
SO Journal of Immunology (2005), 174(2), 1073-1080
CODEN: JOIMA3; ISSN: 0022-1767
PB American Association of Immunologists
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(A2A adenosine receptor induction inhibits IFN- γ production in murine
CD4+ T cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 65 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1050225 CAPLUS
DN 142:211236
TI Adenosine A2A receptor antagonism and neuroprotection: mechanisms, lights,
and shadows
AU Popoli, Patrizia; Minghetti, Luisa; Tebano, Maria Teresa; Pintor, Annita;
Domenici, Maria Rosaria; Massotti, Marino
CS Department of Drug Research and Evaluation, Istituto Superiore di Sanita,
Rome, Italy
SO Critical Reviews in Neurobiology (2004), 16(1&2), 99-106
CODEN: CCNBE8; ISSN: 0892-0915
PB Begell House, Inc.
DT Journal; General Review
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(A2A receptor antagonist ZM 241385 may have either potentially
beneficial or detrimental influence in neurodegenerative mouse models
that are mainly due to increased glutamate levels or enhanced
sensitivity of NMDA receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 66 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:913079 CAPLUS
DN 142:48803
TI Modification of cytokine milieu by A2A adenosine receptor
signaling-possible application for inflammatory diseases
AU Koshiba, M.; Nakamachi, Y.; Kosaka, H.; Nakazawa, T.; Tsuji, G.; Kumagai,
S.
CS Clinical Pathology and Immunology, Department Biomedical Informatics, Kobe
University Graduate School of Medicine, Kobe, Japan
SO Nucleosides, Nucleotides & Nucleic Acids (2004), 23(8 & 9), 1101-1106
CODEN: NNNAFY; ISSN: 1525-7770
PB Marcel Dekker, Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(modification of cytokine milieu by A2A adenosine receptor signaling)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 67 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:908902 CAPLUS
 DN 142:93773
 TI Novel Bicyclic Piperazine Derivatives of Triazolotriazine and
 Triazolopyrimidines as Highly Potent and Selective Adenosine A2A Receptor
 Antagonists
 AU Peng, Hairuo; Kumaravel, Gnanasambandam; Yao, Gang; Sha, Li; Wang, Joy;
 Van Vlijmen, Herman; Bohnert, Tonika; Huang, Carol; Vu, Chi B.; Ensinger,
 Carol L.; Chang, Hexi; Engber, Thomas M.; Whalley, Eric T.; Petter,
 Russell C.
 CS Departments of Medicinal Chemistry, Pharmacology, and Computational Drug
 Design, Biogen Idec Inc., Cambridge, MA, 02142, USA
 SO Journal of Medicinal Chemistry (2004), 47(25), 6218-6229
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:93773
 IT 781638-51-5P 781638-67-3P 781638-88-8P
 781639-76-7P 816429-32-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant
 or reagent)
 (preparation of pyridopyrazine derivs. of triazolotriazine and
 triazolopyrimidines as highly potent and selective adenosine A2A
 receptor antagonists)
 RN 781638-51-5 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
 2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-67-3 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
 2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781638-88-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-76-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816429-32-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-6-methanol,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-, (6R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 735316-45-7P 781638-59-3P 781638-61-7P
 781638-65-1P 781638-82-2P 781638-85-5P
 781639-21-2P 781639-22-3P 781639-24-5P
 781639-25-6P 781639-26-7P 781639-27-8P
 781639-30-3P 781639-31-4P 781639-32-5P
 781639-36-9P 781639-37-0P 781639-38-1P
 781639-39-2P 781639-40-5P 781639-41-6P
 781639-46-1P 781639-47-2P 781639-49-4P
 781639-51-8P 781639-54-1P 781639-55-2P
 781639-56-3P 781639-87-0P 781640-09-3P
 781640-10-6P 781640-11-7P 781640-12-8P
 781640-13-9P 781640-20-8P 781640-61-7P
 816429-28-4P 816429-33-1P 816429-35-3P
 816429-37-5P 816429-38-6P 816429-40-0P
 816429-41-1P 816429-42-2P 816429-43-3P
 816429-44-4P 816429-45-5P 816429-46-6P
 816429-49-9P 816429-51-3P 816429-55-7P
 816429-57-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyridopyrazine derivs. of triazolo[1,5-a]triazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists)

RN 735316-45-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-(1-piperazinyl)- (CA INDEX NAME)




RN 781638-59-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[(7R,9aS)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781638-61-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(7R,9aR)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-65-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(7R,9aS)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




10/552,304

RN 781638-82-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)- (CA INDEX NAME)




RN 781638-85-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 781639-21-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(6-quinolinyl)oxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-22-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(phenoxymethyl)-2H-pyrido[1,2-
a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781639-24-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(2-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-25-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-26-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(4-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-

10/552,304

yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-27-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(4-methoxyphenoxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-30-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(2-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

The chemical structure shows a pyridine ring connected via an ether linkage to a 7-membered oxazepine ring. The oxazepine ring has two stereocenters, both labeled 'R', and a hydrogen atom at the bottom position. The nitrogen of the oxazepine ring is connected to a quinazoline system, which is further substituted with an amino group (NH₂) and a furan ring.

Relative stereochemistry.



Relative stereochemistry.




10/552,304

RN 781639-36-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(3-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-37-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(5-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-38-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(1H-pyrazolo[3,4-d]pyrimidin-4-
yloxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



10/552,304


RN 781639-39-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-imidazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-40-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-1,2,4-triazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-41-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-tetrazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-46-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(4-methoxyphenoxy)methyl]-2H-

10/552,304

pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-47-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-(phenoxy)methyl]-2H-pyrido[1,2-
a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-49-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



10/552,304


RN 781639-51-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(4-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-54-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-quinolinylloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-55-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(3-isoquinolinylloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-56-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyloxy)-5-[(7R,9aS)-octahydro-7-[(5-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-87-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyloxy)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N,N-bis(3-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



10/552,304


RN 781640-09-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(4-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781640-10-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-(4-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-11-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(3-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781640-12-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-(3-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-13-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis(2-furanylmethyl)octahydro-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781640-20-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 781640-61-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(2,4-difluorophenoxy)methyl]octahydro-2H-pyrido[1,2-
a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-28-4 CAPLUS

10/552,304


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(3R,8aR)-hexahydro-3-(phenylmethyl)pyrrolo[1,2-a]pyrazin-
2(1H)-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816429-33-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(6R,9aS)-octahydro-6-(phenoxymethyl)-2H-pyrido[1,2-
a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 816429-35-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(6R,9aS)-octahydro-6-[(1H-indol-5-yloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 816429-37-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(4-quinazolin-2-yl)oxy]methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 816429-38-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(4-quinazolin-2-yl)oxy]methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-40-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[(2,4-difluorophenyl)methyl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 816429-41-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(2,4-difluorophenyl)methyl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-42-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl]octahydro-,
(7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 816429-43-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(5-
chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl]octahydro-, (7R,9aS)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 816429-44-4 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(2-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 816429-45-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N-(2-pyrimidinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 816429-46-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N-(2-pyrimidinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-49-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(7R,9aS)-2-(3,5-difluorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-7-

10/552,304

yl)methyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 816429-51-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[[7R,9aS)-2-[(2,4-difluorophenyl)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl)methyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 816429-55-7 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-amino-5-[(7R,9aS)-7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-6-chloro-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 816429-57-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(7R,9aR)-2-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-,
rel- (CA INDEX NAME)

Relative stereochemistry.




IT 139181-28-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyridopyrazine derivs. of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists)

RN 139181-28-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



10/552,304

IT 816429-65-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyridopyrazine derivs. of triazolotriazine and
triazolopyrimidines as highly potent and selective adenosine A2A
receptor antagonists)
RN 816429-65-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid,
7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]methyl]octahydro-, 1,1-dimethylethyl ester, (7R,9aR)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 68 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:908013 CAPLUS
DN 142:1190
TI Biochemical identification of the dopamine D2 receptor domains interacting
with the adenosine A2A receptor
AU Torvinen, Maria; Kozell, Laura B.; Neve, Kim A.; Agnati, Luigi F.; Fuxe,
Kjell
CS Department of Neuroscience, Karolinska Institute, Stockholm, 171 77, Swed.
SO Journal of Molecular Neuroscience (2004), 24(2), 173-180
CODEN: JMNEES; ISSN: 0895-8696
PB Humana Press Inc.
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(biochem. identification of dopamine D2 receptor domains interacting
with the adenosine A2A receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 69 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:902383 CAPLUS
 DN 141:379947
 TI Preparation of triazolotriazines and related derivatives as A2a adenosine
 receptor antagonists
 IN Peng, Hairuo; Yao, Gang; Vu, Chi; Petter, Russell C.; Kumaravel,
 Gnanasambandam
 PA Biogen Idec Ma Inc., USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092173	A2	20041028	WO 2004-US11009	20040409
	WO 2004092173	A3	20041209		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1633756	A2	20060315	EP 2004-759359	20040409
	EP 1633756	B1	20081224		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	AT 418555	T	20090115	AT 2004-759359	20040409
	US 20070173505	A1	20070726	US 2006-552304	20060726
PRAI	US 2003-461484P	P	20030409		
	WO 2004-US11009	W	20040409		
OS	CASREACT 141:379947; MARPAT 141:379947				
IT	781638-51-5P 781638-53-7P 781638-59-3P 781638-61-7P 781638-63-9P 781638-65-1P 781638-67-3P 781638-69-5P 781638-71-9P 781638-72-0P 781638-74-2P 781638-75-3P 781638-76-4P 781638-77-5P 781638-82-2P 781638-84-4P 781638-85-5P 781638-87-7P 781638-88-8P 781639-21-2P 781639-22-3P 781639-23-4P 781639-24-5P 781639-25-6P 781639-26-7P 781639-27-8P 781639-28-9P 781639-29-0P 781639-30-3P 781639-31-4P 781639-32-5P 781639-33-6P 781639-34-7P 781639-35-8P 781639-36-9P 781639-37-0P 781639-38-1P 781639-39-2P 781639-40-5P 781639-41-6P 781639-45-0P 781639-46-1P 781639-47-2P 781639-48-3P 781639-49-4P 781639-50-7P 781639-51-8P 781639-52-9P 781639-53-0P 781639-54-1P 781639-55-2P 781639-56-3P 781639-57-4P 781639-58-5P 781639-63-2P 781639-64-3P 781639-65-4P 781639-66-5P 781639-67-6P 781639-68-7P 781639-70-1P 781639-71-2P 781639-73-4P 781639-76-7P 781639-78-9P 781639-79-0P 781639-80-3P 781639-81-4P 781639-82-5P				

781639-83-6P 781639-84-7P 781639-85-8P
 781639-86-9P 781639-87-0P 781639-88-1P
 781639-89-2P 781639-90-5P 781639-91-6P
 781639-92-7P 781639-93-8P 781639-94-9P
 781639-95-0P 781639-96-1P 781639-97-2P
 781639-98-3P 781639-99-4P 781640-08-2P
 781640-09-3P 781640-10-6P 781640-11-7P
 781640-12-8P 781640-13-9P 781640-14-0P
 781640-15-1P 781640-16-2P 781640-20-8P
 781640-22-0P 781640-28-6P 781640-61-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of triazolotriazines and related derivs. as A2a adenosine
 receptor antagonists for the treatment of, e.g., Parkinson's disease)

RN 781638-51-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
 2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-53-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-6-methanol,
 2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]octahydro-, (6R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781638-59-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[(7R,9aS)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-
 yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


10/552,304

Relative stereochemistry.



RN 781638-61-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(7R,9aR)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-
a]pyrazin-7-yl]methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-63-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(7R,9aS)-2-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-
yl]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-,
rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781638-65-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(7R,9aS)-octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-
a]pyrazin-7-yl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781638-67-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781638-69-5 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(4-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


10/552,304

Relative stereochemistry.



RN 781638-71-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-2-pyrimidinyl-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.




RN 781638-72-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-(4-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304




RN 781638-74-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[5-[(5-methyl-3-isoxazolyl)methyl]-2,5-
diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)



RN 781638-75-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[5-[(4-fluorophenyl)methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 781638-76-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[5-[(4-chlorophenyl)methyl]hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 781638-77-5 CAPLUS

10/552,304


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[1-[(2,6-dichlorophenyl)methyl]hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl]-2-(2-furanyl)- (CA INDEX NAME)



RN 781638-82-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)- (CA INDEX NAME)




RN 781638-84-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)- (CA INDEX NAME)



RN 781638-85-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 781638-87-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(3S,8aS)-hexahydro-3-(phenylmethyl)pyrrolo[1,2-a]pyrazin-
2(1H)-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 781638-88-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-21-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(6-quinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-22-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(phenoxymethyl)-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-23-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-24-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,

10/552,304


5-[(7R,9aR)-7-[(2-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-25-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(3-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-26-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(4-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-27-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(4-methoxyphenoxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-28-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(2,3,5-trifluorophenoxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-29-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(2,4,6-trifluorophenoxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-30-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-pyridinyloxy)-5-[(7R,9aR)-octahydro-7-[(2-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.

The chemical structure shows a pyridine ring connected via an ether linkage to a 7-membered oxazepine ring. The oxazepine ring has two stereocenters, both labeled 'R', and a hydrogen atom at the bottom position. The nitrogen of the oxazepine ring is connected to a quinazoline system, which is further substituted with an amino group (NH₂) and a furan ring.

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(3-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Nc1nc2nc(NC3CC[C@H](C3)COC4=CC=CC=N4)cnc2n1C5=CC=COC5


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(4-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Chemical structure of a pyridine-4-ylmethyl substituted piperazine derivative. The structure shows a piperazine ring with a 4-pyridylmethoxy group at position 1, a substituent R at position 2, and a 4-amino-2-furylmethyl group at position 4. The stereochemistry at position 2 is indicated with a wedge bond for R and a dashed bond for H.

10/552,304


RN 781639-33-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[[[4-(trifluoromethyl)-2-
pyrimidinyl]oxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.



RN 781639-34-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[[[6-(trifluoromethyl)-4-
pyrimidinyl]oxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX
NAME)


Relative stereochemistry.



RN 781639-35-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(2-quinazolin-2-yl)oxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-36-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(3-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-37-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(5-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-38-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(1H-pyrazolo[3,4-d]pyrimidin-4-

10/552,304

yl oxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-39-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-imidazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-40-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-1,2,4-triazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-41-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-(1H-tetrazol-1-ylmethyl)-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781639-45-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(2,4-difluorophenoxy)methyl]octahydro-2H-pyrido[1,2-
a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-46-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(4-methoxyphenoxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-47-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-(phoxymethyl)-2H-pyrido[1,2-

10/552,304

a[pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-48-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]methyl]-2H-pyrido[1,2-a]pyrazin-2-yl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-49-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-pyridinyloxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl-, rel- (CA INDEX NAME)

Relative stereochemistry.




10/552,304

RN 781639-50-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(3-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-51-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(4-pyridinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-52-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(1,3-benzodioxol-5-yloxy)methyl]octahydro-2H-pyrido[1,2-
a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-53-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-quinazolin-2-yl)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-54-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(2-quinazolin-2-yl)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



10/552,304


RN 781639-55-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(3-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-56-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aS)-octahydro-7-[(5-isoquinolinyloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-57-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(2-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-
yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-58-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aS)-7-[(4-fluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-63-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(6R,9aR)-octahydro-6-(phenoxy)methyl)-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



10/552,304


RN 781639-64-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(6R,9aR)-octahydro-6-[[(5,6,7,8-tetrahydro-1-
naphthalenyl)oxy]methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX
NAME)

Relative stereochemistry.



RN 781639-65-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(6R,9aR)-6-[(3-aminophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-
yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-66-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(6R,9aR)-6-[(1,3-benzodioxol-5-yloxy)methyl]octahydro-2H-pyrido[1,2-

10/552,304

a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-67-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(6R,9aR)-octahydro-6-[(1H-indol-5-yloxy)methyl]-2H-
pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-68-7 CAPLUS

CN 1H-Indol-5-yl, 1-[[(6R,9aR)-2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5-yl]octahydro-2H-pyrido[1,2-a]pyrazin-6-yl]methyl]-,
rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-70-1 CAPLUS

CN 2-Pyrazinecarboxylic acid, 3-amino-5-[(7R,9aR)-7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-6-chloro-, methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-71-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[[(7R,9aR)-2-(3,5-difluorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304




RN 781639-73-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(7R,9aR)-2-[(2,4-difluorophenyl)methyl]octahydro-2H-pyrido[1,2-
a]pyrazin-7-yl]methyl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-76-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-78-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,

10/552,304


2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(2-fluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 781639-79-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(2,4-difluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-80-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(2,4-difluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-81-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N,N-bis[(2,4,6-trifluorophenyl)methyl]-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-82-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(2,3-difluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




10/552,304

RN 781639-83-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[(2,6-difluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-84-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[(3,5-difluorophenyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-85-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[(5-chloro-2-furanyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-86-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(2-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-87-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(3-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-88-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N-(3-pyridinylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-89-2 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[[2-chloro-1-methyl-4-(trifluoromethyl)-1H-pyrrol-3-yl]methyl]octahydro-
, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-90-5 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis[(3,5-dimethyl-4-isoxazolyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX
NAME)

Relative stereochemistry.




RN 781639-91-6 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(3,5-
dimethyl-4-isoxazolyl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781639-92-7 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis(cyclohexylmethyl)octahydro-, (7R,9aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781639-93-8 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-
bis(2-furanylmethyl)octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-94-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N,N-bis(1H-pyrrol-2-ylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-95-0 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl]octahydro-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-96-1 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(5-
chloro-1,3-dimethyl-1H-pyrazol-4-yl)methyl]octahydro-, (7R,9aR)-rel- (CA
INDEX NAME)


Relative stereochemistry.



RN 781639-97-2 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(2-thiazolylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781639-98-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N,N-bis(2-thienylmethyl)-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781639-99-4 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N,N-bis[(5-methyl-2-thienyl)methyl]-, (7R,9aR)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781640-08-2 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-2-pyrimidinyl-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-09-3 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(4-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781640-10-6 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N-(4-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-11-7 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]octahydro-N,N-bis(3-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.

10/552,304



RN 781640-12-8 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-N-(3-pyridinylmethyl)-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-13-9 CAPLUS
CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis(2-furanylmethyl)octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781640-14-0 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-(2-furanylmethyl)octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 781640-15-1 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N,N-bis[(3,5-dimethyl-4-isoxazolyl)methyl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.


10/552,304



RN 781640-16-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-7-methanamine,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-N-[(3,5-
dimethyl-4-isoxazolyl)methyl]octahydro-, (7R,9aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-20-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 781640-22-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,

10/552,304


2-(2-furanyl)-5-[hexahydro-1-(2-quinolinylmethyl)pyrrolo[3,4-b]pyrrol-5(1H)-yl]- (CA INDEX NAME)



RN 781640-28-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(7R,9aR)-octahydro-7-[(7-quinolinyl)oxy)methyl]-2H-pyrido[1,2-a]pyrazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 781640-61-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(7R,9aR)-7-[(2,4-difluorophenoxy)methyl]octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]-2-(2-furanyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 139181-28-5, [2-(Furan-2-yl)-5-(methylsulfonyl)-

10/552,304


[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amine 781640-34-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of triazolotriazines and related derivs. as A2a adenosine receptor antagonists for the treatment of, e.g., Parkinson's disease)

RN 139181-28-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



RN 781640-34-4 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazine-2-carboxylic acid,
7-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]octahydro-, 1,1-dimethylethyl ester, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 781640-30-0P 781640-32-2P,
[5-(2,5-Diazabicyclo[2.2.1]hept-2-yl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of triazolotriazines and related derivs. as A2a adenosine receptor antagonists for the treatment of, e.g., Parkinson's disease)

RN 781640-30-0 CAPLUS


CN 2H-Pyrido[1,2-a]pyrazine-7-methanol,
2-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]octahydro-, 7-methanesulfonate, (7R,9aS)-rel- (CA INDEX NAME)

Relative stereochemistry.

10/552,304



RN 781640-32-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2,5-diazabicyclo[2.2.1]hept-2-yl)-2-(2-furanyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 70 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:902380 CAPLUS
 DN 141:395582
 TI Preparation of triazolotriazines and pyrazolotriazines as A2a adenosine
 receptor antagonists for the treatment of Parkinson's disease
 IN Vu, Chi; Petter, Russell C.; Kumaravel, Gnanasambandam
 PA Biogen Idec Ma Inc., USA
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004092170	A2	20041028	WO 2004-US11005	20040409
	WO 2004092170	A3	20050331		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1615930	A2	20060118	EP 2004-759355	20040409
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	US 20060276475	A1	20061207	US 2006-552303	20060726
	US 7285550	B2	20071023		
PRAI	US 2003-461356P	P	20030409		
	WO 2004-US11005	W	20040409		
OS	MARPAT 141:395582				
IT	735316-64-0P	735316-65-1P	735316-66-2P		
	735316-68-4P	735316-69-5P	735316-70-8P		
	735316-71-9P	735316-72-0P	735316-73-1P		
	735316-74-2P	735316-76-4P	735316-77-5P		
	735316-78-6P	735316-79-7P	735316-80-0P		
	735316-81-1P	735316-82-2P	735316-83-3P		
	735316-84-4P	735316-85-5P	735316-86-6P		
	735316-87-7P	745072-65-5P	745072-66-6P		
	745072-67-7P	745072-68-8P	745072-69-9P		
	745072-70-2P	745072-73-5P	745072-74-6P		
	745072-75-7P	745072-76-8P	745072-80-4P		
	745073-05-6P	760988-74-7P	760988-77-0P		
	760988-81-6P	760995-64-0P	785823-44-1P		
	785823-46-3P	785823-50-9P	785823-52-1P		
	785823-54-3P	785823-56-5P	785823-71-4P		
	785823-73-6P	785823-75-8P	785823-79-2P		
	785823-80-5P	785823-81-6P	785823-82-7P		
	785823-83-8P	785823-84-9P	785823-85-0P		
	785823-86-1P	785823-87-2P	785823-88-3P		
	785823-89-4P	785823-90-7P	785823-91-8P		
	785823-92-9P	785823-93-0P	785823-94-1P		
	785823-95-2P	785823-96-3P	785823-97-4P		
	785823-98-5P	785823-99-6P	785824-00-2P		
	785824-01-3P	785824-02-4P	785824-03-5P		
	785824-04-6P	785824-05-7P	785824-06-8P		


785824-08-0P 785824-09-1P 785824-10-4P
 785824-11-5P 785824-12-6P 785824-13-7P
 785824-14-8P 785824-15-9P 785824-16-0P
 785824-17-1P 785824-18-2P 785824-19-3P
 785824-20-6P 785824-21-7P 785824-22-8P
 785824-23-9P 785824-24-0P 785824-25-1P
 785824-26-2P 785824-27-3P 785824-28-4P
 785824-29-5P 785824-30-8P 785824-31-9P
 785824-32-0P 785824-33-1P 785824-34-2P
 785824-35-3P 785824-36-4P 785824-37-5P
 785824-38-6P 785824-39-7P 785824-40-0P
 785824-41-1P 785824-42-2P 785824-43-3P
 785824-44-4P 785824-45-5P 785824-46-6P
 785824-47-7P 785824-48-8P 785824-49-9P
 785824-50-2P 785824-51-3P 785824-52-4P
 785824-53-5P 785824-54-6P 785824-55-7P
 785824-56-8P 785824-57-9P 785824-58-0P
 785824-59-1P 785824-60-4P 785824-61-5P
 785824-62-6P 785824-63-7P 785824-64-8P
 785824-65-9P 785824-66-0P 785824-67-1P
 785824-68-2P 785824-69-3P 785824-70-6P
 785824-71-7P 785824-72-8P 785824-73-9P
 785824-74-0P 785824-75-1P 785824-76-2P
 785824-77-3P 785824-78-4P 785824-79-5P
 785824-80-8P 785824-81-9P 785824-82-0P
 785824-83-1P 785824-84-2P 785824-85-3P
 785824-86-4P 785824-87-5P 785824-88-6P
 785824-89-7P 785824-90-0P 785824-91-1P
 785824-92-2P 785824-93-3P 785824-94-4P
 785824-95-5P 785824-96-6P 785824-97-7P
 785824-98-8P 785824-99-9P 785825-00-5P
 785825-01-6P 785825-02-7P 785825-03-8P
 785825-04-9P 785825-05-0P 785825-06-1P
 785825-07-2P 785825-08-3P 785825-09-4P
 785825-10-7P 785825-11-8P 785825-12-9P
 785825-13-0P 785825-14-1P 785825-15-2P
 785825-16-3P 785825-17-4P 785825-18-5P
 785825-19-6P 785825-20-9P 785825-21-0P
 785825-22-1P 785825-23-2P 785825-24-3P
 785825-25-4P 785825-26-5P 785825-33-4P
 785825-34-5P 785825-35-6P 785826-57-5P
 785826-59-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of triazolotriazines and pyrazolotriazines as A2a adenosine
 receptor antagonists for the treatment of Parkinson's disease)

RN 735316-64-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[4-(1H-imidazol-5-ylmethyl)-1-piperazinyl]- (CA INDEX
 NAME)



10/552,304


RN 735316-65-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1,2,3-thiadiazol-4-ylmethyl)-1-piperazinyl]- (CA
INDEX NAME)




RN 735316-66-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-furanylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-68-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-(2-benzofuranylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 735316-69-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-70-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[[2-(methylthio)-3-thienyl]methyl]-1-piperazinyl]- (CA


10/552,304

INDEX NAME)




RN 735316-71-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-[4-[(2-methyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-
(CA INDEX NAME)




RN 735316-72-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-[4-[(4-methyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-
(CA INDEX NAME)



RN 735316-73-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]-
(CA INDEX NAME)



RN 735316-74-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3,5-dimethyl-4-isoxazolyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)

10/552,304




RN 735316-76-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-1-
piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-77-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-78-6 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-79-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(4-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)


10/552,304




RN	735316-80-0	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[4-[(2-methyl-3-pyridinyl)methyl]-1-piperazinyl]- (CA INDEX NAME)		



RN	735316-81-1	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[4-[(2,4-dimethyl-3-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)-	(CA	
	INDEX NAME)		




RN	735316-82-2	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-[4-[(3,5-dichloro-4-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)		




RN	735316-83-3	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,		
	2-(2-furanyl)-5-[4-(2-quinolinylmethyl)-1-piperazinyl]-	(CA INDEX NAME)	


10/552,304




RN 735316-84-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(4-quinolinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-85-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-quinolinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-86-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-3-quinolinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 735316-87-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-6-methyl-3-quinolinyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)

10/552,304




RN 745072-65-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(5-methyl-3-isoxazolyl)methyl]-1H-1,4-diazepin-1-yl]- (CA INDEX NAME)




RN 745072-66-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[[5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (CA INDEX NAME)



RN 745072-67-7 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (CA INDEX NAME)




RN 745072-68-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]- (CA INDEX NAME)


10/552,304




RN 745072-69-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[3-[[5-methyl-3-isoxazolyl)methyl]amino]propyl]- (CA
INDEX NAME)



RN 745072-70-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2,2-dimethyl-3-[[5-methyl-3-isoxazolyl)methyl]amino]propyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 745072-73-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[[5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]- (CA
INDEX NAME)




RN 745072-74-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[[5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]- (CA
INDEX NAME)

10/552,304




RN 745072-75-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl)methyl]-
(CA INDEX NAME)



RN 745072-76-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl)methyl]-
(CA INDEX NAME)



RN 745072-80-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl)methyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 745073-05-6 CAPLUS


10/552,304

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 760988-74-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (CA INDEX NAME)



RN 760988-77-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 760988-81-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N5-methyl- (CA INDEX NAME)




10/552,304

RN 760995-64-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,6-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 785823-44-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,6-dichloro-4-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)



RN 785823-46-3 CAPLUS


CN Methanone, [4-[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]-1-piperazinyl](2,6-dichloro-4-pyridinyl)- (CA INDEX NAME)




RN 785823-50-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chlorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
(CA INDEX NAME)


10/552,304




RN 785823-52-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(2-pyridinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)



RN 785823-54-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3,5-dimethyl-4-isoxazolyl)methyl]-1-piperazinyl]-2-(3-fluorophenyl)-
(CA INDEX NAME)




RN 785823-56-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-[(5-methyl-4-isoxazolyl)methyl]-1-piperazinyl]-
(CA INDEX NAME)




RN 785823-71-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)


10/552,304



RN 785823-73-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-(phenylmethyl)-3-pyrrolidinyl]- (CA INDEX NAME)




RN 785823-75-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 785823-79-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinylmethyl]- (CA INDEX NAME)

10/552,304




RN 785823-80-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1H-imidazol-2-ylmethyl)-1-piperazinyl]- (CA INDEX
NAME)




RN 785823-81-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(1-methyl-1H-imidazol-2-yl)methyl]-1-piperazinyl]-
(CA INDEX NAME)



RN 785823-82-7 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(5-chloro-2-thienyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)



10/552,304


RN 785823-83-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1H-pyrrol-2-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 785823-84-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]cyclohexyl]- (CA INDEX NAME)



RN 785823-85-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)



10/552,304


RN 785823-86-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(3-phenylpropyl)-1H-1,4-diazepin-1-yl]- (CA
INDEX NAME)




RN 785823-87-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,6-dichlorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-
furanyl)- (CA INDEX NAME)



RN 785823-88-3 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(3-pyridinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)




RN 785823-89-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(4-pyridinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)


10/552,304




RN 785823-90-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(4-quinolinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)



RN 785823-91-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(2-quinolinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)




RN 785823-92-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-furanylmethyl)hexahydro-1H-1,4-diazepin-1-yl]- (CA
INDEX NAME)



RN 785823-93-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-


10/552,304

furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino)methyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)




RN 785823-94-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(5-methyl-4-isoxazolyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)



RN 785823-95-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[hexahydro-4-[(5-methyl-4-isoxazolyl)methyl]-1H-1,4-
diazepin-1-yl]- (CA INDEX NAME)




RN 785823-96-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[hexahydro-4-[(5-methyl-3-isoxazolyl)methyl]-1H-1,4-
diazepin-1-yl]- (CA INDEX NAME)


10/552,304



RN 785823-97-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(3-fluorophenyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-
 pyrrolidinyl]methyl]- (CA INDEX NAME)




RN 785823-98-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[4-[(5-chloro-2-furanyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
 NAME)




RN 785823-99-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[4-[(6-bromo-2-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
 INDEX NAME)


10/552,304




RN 785824-00-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-8-methyl-3-quinolinyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 785824-01-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(5-methyl-2-furanyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)




RN 785824-02-4 CAPLUS
CN 2-Furanmethanol, 5-[4-[(7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)-1-piperazinyl]methyl]- (CA INDEX NAME)




RN 785824-03-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3,5-dimethyl-4-isoxazolyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 785824-04-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-(3-quinolinylmethyl)-1H-1,4-diazepin-1-yl]-
(CA INDEX NAME)



RN 785824-05-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(2-methyl-3-furanyl)methyl]-1H-1,4-diazepin-
1-yl]- (CA INDEX NAME)




RN 785824-06-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2-methyl-3-furanyl)methyl]-1-piperazinyl]- (CA INDEX
NAME)



RN 785824-08-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA


10/552,304

INDEX NAME)




RN 785824-09-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(3-methyl-2-thienyl)methyl]-1H-1,4-diazepin-1-yl]- (CA INDEX NAME)



RN 785824-10-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(1-methyl-1H-imidazol-2-yl)methyl]-1H-1,4-diazepin-1-yl]- (CA INDEX NAME)




RN 785824-11-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-12-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(6-bromo-2-pyridinyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 785824-13-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-(3-pyridinylmethyl)-2-pyrrolidinyl]methyl)- (CA
INDEX NAME)




RN 785824-14-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(5-chloro-2-furanyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-
furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-15-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)




RN 785824-16-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chloro-2,6-difluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 785824-17-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(6-chloro-2-fluoro-3-methylphenyl)methyl]hexahydro-1H-1,4-diazepin-1-
yl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-18-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-6-fluoro-3-methylphenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-19-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-8-methyl-3-quinolinyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-20-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-6-methyl-3-quinolinyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-21-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-bromophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 785824-22-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 785824-23-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA
INDEX NAME)

10/552,304




RN 785824-24-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)




RN 785824-25-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(2-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)




10/552,304


RN 785824-26-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(2-furanylmethyl)-2-pyrrolidinyl]methyl]- (CA INDEX
NAME)



RN 785824-27-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(5-bromo-2-furanyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 785824-28-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(2-methylphenyl)methyl]-1H-1,4-diazepin-1-
yl]- (CA INDEX NAME)




RN 785824-29-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(3-methylphenyl)methyl]-1H-1,4-diazepin-1-
yl]- (CA INDEX NAME)


10/552,304




RN 785824-30-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[hexahydro-4-[(4-methylphenyl)methyl]-1H-1,4-diazepin-1-yl]- (CA INDEX NAME)



RN 785824-31-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chlorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-32-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-chlorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-33-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-bromophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-


10/552,304

(CA INDEX NAME)




RN 785824-34-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-bromophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-35-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-bromophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-36-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-fluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-2-(2-furanyl)-
(CA INDEX NAME)




10/552,304


RN 785824-37-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chloro-2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-38-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-39-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(5-chloro-2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-40-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304

furanyl)- (CA INDEX NAME)




RN 785824-41-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-bromo-1-methyl-1H-pyrazol-3-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-42-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-bromo-1H-pyrazol-3-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-43-3 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-44-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]- (CA INDEX NAME)


10/552,304



RN 785824-45-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(2-methylphenyl)methyl]-2-pyrrolidinylmethyl]- (CA
INDEX NAME)




RN 785824-46-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(3-methylphenyl)methyl]-2-pyrrolidinylmethyl]- (CA
INDEX NAME)




RN 785824-47-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(2-chloro-6-fluoro-3-methylphenyl)methyl]-2-pyrrolidinylmethyl]-2-
(2-furanyl)- (CA INDEX NAME)

10/552,304




RN 785824-48-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 785824-49-9 CAPLUS


CN Carbamic acid, [2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



RN 785824-50-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

10/552,304




RN 785824-51-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(3,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-52-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA
INDEX NAME)




10/552,304

RN 785824-53-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-54-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,4-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-55-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(4-methylphenyl)methyl]-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)


10/552,304



RN 785824-56-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(3,5-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-57-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)



10/552,304


RN 785824-58-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]methylamino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 785824-59-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-60-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[(2,6-dimethylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)

10/552,304




RN 785824-61-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(2-chloro-3-quinolinyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)



RN 785824-62-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[(5-chloro-2-furanyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785824-63-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(2,3,6-trifluorophenyl)methyl]-2-


10/552,304

pyrrolidinyl)methyl]- (CA INDEX NAME)



RN 785824-64-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(2,4,6-trifluorophenyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 785824-65-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(2,4,5-trifluorophenyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)


10/552,304



RN 785824-66-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 785824-67-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[[1-[[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785824-68-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,


10/552,304

N5-[[1-[(4-chlorophenyl)methyl]-3-piperidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-69-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)-
N5-methyl- (CA INDEX NAME)



RN 785824-70-6 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)-N5-methyl- (CA INDEX NAME)




RN 785824-71-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-72-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(3-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)




RN 785824-73-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[[3-chloro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 785824-74-0 CAPLUS

10/552,304

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(4-fluoro-3-methylphenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 785824-75-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-bromo-5-fluorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 785824-76-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(4-chloro-3-fluorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-
furanyl)- (CA INDEX NAME)


10/552,304



RN 785824-77-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-
methyl- (CA INDEX NAME)




RN 785824-78-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chloro-2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)



10/552,304


RN 785824-79-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-
2-(2-furanyl)- (CA INDEX NAME)



RN 785824-80-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-pyrrolidinyl]methyl]-
2-(2-furanyl)- (CA INDEX NAME)



RN 785824-81-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(4-quinolinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)

10/552,304




RN 785824-82-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(2-quinolinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)



RN 785824-83-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(3-quinolinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)




RN 785824-84-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(4-quinolinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)


10/552,304




RN 785824-85-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(2-pyridinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)



RN 785824-86-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(3-pyridinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)




RN 785824-87-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-(4-pyridinylmethyl)-1-piperazinyl]- (CA INDEX
NAME)




RN 785824-88-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
N5-methyl- (CA INDEX NAME)

10/552,304




RN 785824-89-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chloro-2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (CA INDEX NAME)



RN 785824-90-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-N5-methyl- (CA INDEX NAME)



10/552,304


RN 785824-91-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[1-[(2,3,6-trifluorophenyl)methyl]-2-pyrrolidinyl)methyl]- (CA INDEX NAME)




RN 785824-92-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,3-difluorophenyl)methyl]-3-piperidinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 785824-93-3 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(2-quinolinylmethyl)-3-piperidinyl)methyl]- (CA
INDEX NAME)




RN 785824-94-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
2-(2-furanyl)-5-[4-(2-thiazolylmethyl)-1-piperazinyl]- (CA INDEX NAME)


10/552,304




RN 785824-95-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1H-indol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 785824-96-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(1-methyl-1H-indol-2-yl)methyl]-1-piperazinyl]- (CA
INDEX NAME)




RN 785824-97-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(6-methyl-2-pyridinyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)



RN 785824-98-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,


10/552,304

5-[4-[(2-chloro-6-methoxy-3-quinolinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785824-99-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(5-methyl-1H-indol-2-yl)methyl]-1-piperazinyl]- (CA
INDEX NAME)



RN 785825-00-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(5-chloro-1H-indol-2-yl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 785825-01-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-(2-benzofuranylmethyl)-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA
INDEX NAME)

10/552,304




RN 785825-02-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-2-pyrrolidinyl]methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 785825-03-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(4-bromo-1-methyl-1H-pyrazol-3-yl)methyl]-2-pyrrolidinyl]methyl]-2-
(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 785825-04-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785825-05-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(3-methyl-2-pyridinyl)methyl]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)



10/552,304


RN 785825-06-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,6-dichloro-5-fluoro-3-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785825-07-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[1-[(3,6-dichloro-5-fluoro-2-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785825-08-3 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[1-[(2,4-dimethyl-3-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



10/552,304


RN 785825-09-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,6-dichlorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785825-10-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chloro-6-fluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 785825-11-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-fluorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 785825-12-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chlorophenyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)


10/552,304

INDEX NAME)




RN 785825-13-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[1-[1-[(6-chloro-3-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 785825-14-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-3-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 785825-15-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(4-methyl-2-pyridinyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)


10/552,304



RN 785825-16-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chloro-2-fluoro-4-methylphenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785825-17-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-fluoro-5-methylphenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785825-18-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-fluoro-4-methylphenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

10/552,304



RN 785825-19-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-bromo-4-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)




RN 785825-20-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[1-[(2,4,6-trifluorophenyl)methyl]-2-
pyrrolidinyl]methyl]- (CA INDEX NAME)

CN1C=NC2=C(N1)N=CN=C2CNC(C3CCCC3)CNC(F)(F)FCc1cc(CCN(C2CCCCC2)CC3=NC4=NC(=C(C=C4)N5C(=N3)N=C(N)N5C6=CC=CC=C6O5)O)cn1Nc1nc2nc3c(ncn3c2NCCN(CCN1CCCCC1)Cc2ccc3ccccc3n2)c4ccoc4

10/552,304


RN 785825-23-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-(2-pyridinylmethyl)-2-piperidinyl]methyl]- (CA INDEX
NAME)




RN 785825-24-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2,6-dichloro-5-fluoro-3-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 785825-25-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3,5-dichloro-4-pyridinyl)methyl]-2-piperidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 785825-26-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,

10/552,304

2-(2-furanyl)-N5-methyl-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-2-piperidinyl)methyl]- (CA INDEX NAME)




RN 785825-33-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-2-pyrrolidinyl)methyl]-
2-(2-furanyl)- (CA INDEX NAME)




RN 785825-34-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)

10/552,304




RN 785825-35-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[2-[4-(2,4,6-trifluorophenyl)-1-
piperazinyl]ethyl]- (CA INDEX NAME)



RN 785826-57-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-fluorophenyl)-5-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]-
(CA INDEX NAME)




RN 785826-59-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[1-[(6-chloro-2-fluoro-3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-2-
(2-furanyl)- (CA INDEX NAME)


10/552,304



IT 785825-36-7 785825-39-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazolotriazines and pyrazolotriazines as A2a adenosine
receptor antagonists for the treatment of Parkinson's disease)
RN 785825-36-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5-ol, 7-amino-2-(2-furanyl)-,
5-methanesulfonate (CA INDEX NAME)




RN 785825-39-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5-ol, 7-amino-2-(3-fluorophenyl)-,
5-methanesulfonate (CA INDEX NAME)



IT 735316-45-7P 785825-38-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of triazolotriazines and pyrazolotriazines as A2a adenosine
receptor antagonists for the treatment of Parkinson's disease)
RN 735316-45-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,

10/552,304


2-(2-furanyl)-5-(1-piperazinyl)- (CA INDEX NAME)



RN 785825-38-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 71 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:892419 CAPLUS
DN 141:360784
TI Characterization of [3H]ZM 241385 binding in wild-type and adenosine A2A
receptor knockout mice
AU Kelly, Mary; Bailey, Alexis; Ledent, Catherine; Kitchen, Ian; Hourani,
Susanna
CS School of Biomedical and Molecular Sciences, University of Surrey, Surrey,
GU2 7XH, UK
SO European Journal of Pharmacology (2004), 504(1-2), 55-59
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6D, ZM 241385, Tritium-labeled
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(characterization of [3H]ZM 241385 binding in wild-type and adenosine
A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(characterization of [3H]ZM 241385 binding in wild-type and adenosine
A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 72 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:729831 CAPLUS
 DN 141:271406
 TI Triamino derivatives of triazolotriazine and triazolopyrimidine as
 adenosine A2a receptor antagonists
 AU Vu, Chi B.; Shields, Pamela; Peng, Bo; Kumaravel, Gnanasambandam; Jin,
 Xiaowei; Phadke, Deepali; Wang, Joy; Engber, Thomas; Ayyub, Eman; Petter,
 Russell C.
 CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA,
 02142, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4835-4838
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:271406
 IT 760988-72-5P 760988-73-6P 760988-74-7P
 760988-76-9P 760988-77-0P 760988-78-1P
 760988-79-2P 760988-81-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (triamino derivs. of triazolotriazine and triazolopyrimidine as
 adenosine A2a receptor antagonists)
 RN 760988-72-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 760988-73-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-[3-(4-phenyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 760988-74-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-[2-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]ethyl]- (CA
 INDEX NAME)


Nc1nc2nc3c(nc12)c4ccoc4n3CCN4CCN(C4)c5cc(F)c(F)c(F)c5Fc1cc(F)c(N2CCN(CC2)CCCCNC3=NC4=NC(=C3)C(=N4)C5=CC=CC=C5O)c(F)c1Fc1ccc(cc1F)N2CCN(CC2)CCNc3nc(N)cnc3c4ccoc4Fc1ccc(cc1F)N2CCN(CC2)NCCCNc3nc4nc5c(nc34)C=C5

RN	760988-79-2	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-methyl-N5-[2-(4-phenyl-1-piperazinyl)ethyl]- (CA INDEX NAME)		

10/552,304




RN 760988-81-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]-2-(2-furanyl)-N5-methyl-
(CA INDEX NAME)




IT 735316-63-9 760988-70-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(triamino derivs. of triazolotriazine and triazolopyrimidine as
adenosine A2a receptor antagonists)

RN 735316-63-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)



RN 760988-70-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2,4,6-trifluorophenyl)-1-piperazinyl]- (CA INDEX
NAME)




IT 139181-28-5

10/552,304

RL: RCT (Reactant); RACT (Reactant or reagent)
(triamino derivs. of triazolotriazine and triazolopyrimidine as
adenosine A2a receptor antagonists)

RN 139181-28-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




IT 760988-71-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(triamino derivs. of triazolotriazine and triazolopyrimidine as
adenosine A2a receptor antagonists)

RN 760988-71-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(2,2-dimethoxyethyl)-2-(2-furanyl)- (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 73 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:729830 CAPLUS
 DN 141:271008
 TI Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles
 AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Sha, Li; Kumaravel, Gnanasambandam; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Petter, Russell C.
 CS Department of Medicinal Chemistry, Biogen Idec, Inc., Cambridge, MA, 02142, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(19), 4831-4834
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 141:271008
 IT 745072-78-0 745072-80-4 745072-82-6
 745073-04-5 745073-09-0 745073-10-3
 760995-64-0 760995-69-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure activity of adenosine A2a receptor antagonists)
 RN 745072-78-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-80-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



10/552,304


RN 745072-82-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 745073-04-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 745073-09-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745073-10-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)

10/552,304


Absolute stereochemistry.



RN 760995-64-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,6-dichlorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 760995-69-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2-fluorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 74 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:681669 CAPLUS

DN 141:185088

TI Inhibitory effects of adenosine receptor antagonists and HTLV-I-cell binding to treat HLV-1 infection

IN Hague, Bishop F.; Zhao, Tong-Mao; Kindt, Thomas J.

PA The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, USA

SO PCT Int. Appl., 49 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004070000	A2	20040819	WO 2003-US35431	20031030
	WO 2004070000	A3	20050224		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003291346	A1	20040830	AU 2003-291346	20031030
PRAI	US 2002-422803P	P	20021030		
	WO 2003-US35431	W	20031030		
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(inhibitory effects of adenosine receptor antagonists and HTLV-I-cell binding to treat HLV-1 infection)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



L4 ANSWER 75 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:646209 CAPLUS
 DN 142:211382
 TI Novel Diamino Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as
 Potent and Selective Adenosine A2a Receptor Antagonists
 AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Kumaravel, Gnanasambandam; Smits,
 Glenn; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol;
 Reilly, Jennifer; Tam, Stacy; Grant, Donna; Hetu, Gregg; Petter, Russell
 C.
 CS Department of Medicinal Chemistry, Biogen Idec Inc., Cambridge, MA, 02142,
 USA
 SO Journal of Medicinal Chemistry (2005), 48(6), 2009-2018
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:211382
 IT 745072-65-5P 745072-67-7P 745072-72-4P
 745072-73-5P 745072-74-6P 745072-77-9P
 745072-78-0P 745072-80-4P 745072-82-6P
 745072-88-2P 745072-94-0P 745072-97-3P
 745073-02-3P 745073-05-6P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as
 potent and selective adenosine A2a receptor antagonists)
 RN 745072-65-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[hexahydro-4-[(5-methyl-3-isoxazolyl)methyl]-1H-1,4-
 diazepin-1-yl]- (CA INDEX NAME)



RN 745072-67-7 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-methyl-N5-[2-[methyl[(5-methyl-3-
 isoxazolyl)methyl]amino]ethyl]- (CA INDEX NAME)




RN 745072-72-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[(1R,4R)-5-[(5-methyl-3-isoxazolyl)methyl]-2,5-

10/552,304


diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 745072-73-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidinyl]- (CA
INDEX NAME)



RN 745072-74-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidinyl]- (CA
INDEX NAME)




RN 745072-77-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(3S)-1-[(5-methyl-3-isoxazolyl)methyl]-3-pyrrolidinyl]-
(CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745072-78-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-80-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-82-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2-chlorophenyl)methyl]-2-pyrrolidinyl)methyl]-2-(2-furanyl)-
(CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745072-88-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 745072-94-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-97-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-[(2,4,6-trifluorophenyl)methyl]-2-
pyrrolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745073-02-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(2-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 745073-05-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]-2-
(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 735316-51-5P 735316-52-6P 735316-63-9P
735316-73-1P 735316-74-2P 745072-68-8P
745072-69-9P 745072-70-2P 745072-71-3P
745072-75-7P 745072-76-8P 745072-79-1P
745072-81-5P 745072-83-7P 745072-84-8P
745072-85-9P 745072-86-0P 745072-87-1P
745072-89-3P 745072-90-6P 745072-91-7P
745072-92-8P 745072-93-9P 745072-95-1P
745072-96-2P 745072-98-4P 745072-99-5P
745073-00-1P 745073-01-2P 745073-03-4P


745073-04-5P 745073-06-7P 745073-07-8P
 745073-08-9P 745073-09-0P 745073-10-3P
 745073-11-4P 745073-12-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists)


RN 735316-51-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-52-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 5-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 735316-63-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 735316-73-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

10/552,304




RN 735316-74-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
5-[4-[(3,5-dimethyl-4-isoxazolyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 745072-68-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[methyl[(5-methyl-3-isoxazolyl)methyl]amino]ethyl]-
(CA INDEX NAME)



RN 745072-69-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[3-[[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]-
(CA INDEX NAME)



RN 745072-70-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2,2-dimethyl-3-[[[(5-methyl-3-isoxazolyl)methyl]amino]propyl]-2-(2-furanyl)-
(CA INDEX NAME)


10/552,304



RN 745072-71-3 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[(1S,2S)-2-[methyl[(5-methyl-3-
isoxazolyl)methyl]amino]cyclohexyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 745072-75-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-4-piperidiny]methyl]-
(CA INDEX NAME)



RN 745072-76-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[1-[(5-methyl-3-isoxazolyl)methyl]-3-piperidiny]methyl]-
(CA INDEX NAME)




RN 745072-79-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,

10/552,304

2-(2-furanyl)-N5-[[(2S)-1-[(5-methyl-3-isoxazolyl)methyl]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-81-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-[[(2R)-1-[(5-methyl-3-isoxazolyl)methyl]-2-piperidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-83-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 745072-84-8 CAPLUS

10/552,304


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(4-chlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 745072-85-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3,5-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 745072-86-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,4-dichlorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 745072-87-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,

10/552,304

2-(2-furanyl)-N5-[[(2R)-1-[(3-methylphenyl)methyl]-2-pyrrolidinyl]methyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 745072-89-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-90-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,5-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 745072-91-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,

10/552,304

N5-[[(2R)-1-[(2,4-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-92-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2,3-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-93-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3-chloro-2-fluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 745072-95-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-[(2,4,5-trifluorophenyl)methyl]-2-pyrrolidinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745072-96-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-[(2,3,6-trifluorophenyl)methyl]-2-
pyrrolidinyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 745072-98-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[[2-fluoro-5-(trifluoromethyl)phenyl)methyl]-2-
pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745072-99-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[[2-fluoro-4-(trifluoromethyl)phenyl)methyl]-2-
pyrrolidinyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745073-00-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(2-chloro-3,6-difluorophenyl)methyl]-2-pyrrolidinyl]methyl]-2-
(2-furanyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-01-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[[3-chloro-2-fluoro-6-(trifluoromethyl)phenyl]methyl]-2-
pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745073-03-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(3-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745073-04-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(4-pyridinylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)

Absolute stereochemistry.



RN 745073-06-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-2-
pyrrolidinyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745073-07-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(2-furanylmethyl)-2-pyrrolidinyl]methyl]- (CA
INDEX NAME)


Absolute stereochemistry.

10/552,304




RN 745073-08-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[[(2R)-1-[(5-chloro-2-furanyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 745073-09-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[[(2R)-1-[(3,5-dichloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 745073-10-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[[(2R)-1-[(2-chloro-4-pyridinyl)methyl]-2-pyrrolidinyl]methyl]-2-(2-
furanyl)- (CA INDEX NAME)

Absolute stereochemistry.


10/552,304



RN 745073-11-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[[(2R)-1-(2-benzofuranylmethyl)-2-pyrrolidinyl]methyl]-2-(2-furanyl)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 745073-12-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[(2R)-1-(2-quinolinylmethyl)-2-pyrrolidinyl]methyl]-
(CA INDEX NAME)

Absolute stereochemistry.



IT 139180-30-6, ZM-241385 745072-66-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as
potent and selective adenosine A2a receptor antagonists)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)


10/552,304



RN 745072-66-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[(5-methyl-3-isoxazolyl)methyl]amino]ethyl)- (CA
INDEX NAME)



IT 139181-28-5 745073-14-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel diamino derivs. of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as
potent and selective adenosine A2a receptor antagonists)
RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




RN 745073-14-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-pyrrolidinylmethyl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 745073-13-6
CMF C13 H16 N8 O


10/552,304



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 76 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:604078 CAPLUS
DN 141:168324
TI Striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats
AU Golembiowska, Krystyna; Dziubina, Anna
CS Institute of Pharmacology, Polish Academy of Sciences, Krakow, 31343, Pol.
SO Neuropharmacology (2004), 47(3), 414-426
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(striatal adenosine A2A receptor blockade increases extracellular dopamine release following L-DOPA administration in intact and dopamine-denervated rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 77 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:570030 CAPLUS

DN 141:99661

TI Identification of compounds suitable as agonists and/or antagonists of adenosine A2A receptor coupled to specific G proteins, and use of identified compounds in treatment of various disorders in mammals

IN Fredholm, Bertil B.; Kull, Bjoern

PA Actar Ab, Swed.

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058974	A1	20040715	WO 2003-SE2086	20031229
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003291608	A1	20040722	AU 2003-291608	20031229
PRAI	US 2002-436480P	P	20021227		
	WO 2003-SE2086	W	20031229		


IT 139180-30-6, ZM 241385

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(A2A receptor antagonist ZM 241385 has poorer selectivity towards Golf verses Gs)

RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 78 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:563751 CAPLUS

DN 141:167237

TI Piperazine Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A2a Receptor Antagonists

AU Vu, Chi B.; Peng, Bo; Kumaravel, Gnanasambandam; Smits, Glenn; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Grant, Donna; Hetu, Gregg; Chen, Liqing; Zhang, Jianbo; Petter, Russell C.

CS Department of Medicinal Chemistry, Biogen Idec Inc., Cambridge, MA, 02142, USA

SO Journal of Medicinal Chemistry (2004), 47(17), 4291-4299
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 141:167237

IT 735316-54-8P 735316-63-9P 735316-76-4P


735316-77-5P 735316-84-4P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure activity relationships of piperazine derivs. of triazolotriazine as adenosine A2a receptor antagonists)


RN 735316-54-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,6-dichlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 735316-63-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2,4,6-trifluorophenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 735316-76-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[[5-chloro-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)

Nc1nc2nc3c(nc12)c4ccoc4n3CNCCc5ccccc5nNc1nc2nc3c(nc12)c4ccoc4N3CCN(CCN3Cc4cccc5c(N)ncnc45)CC6=CC=CC=C6NNc1nc2nc3c(nc12)cc4ccccc43CN5CCNCC5c6nc7ccccc7n6

10/552,304

RN 735316-87-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chloro-6-methyl-3-quinolinyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)




IT 735316-45-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(structure activity relationships of piperazine derivs. of triazolotriazine as adenosine A2a receptor antagonists)

RN 735316-45-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1-piperazinyl)- (CA INDEX NAME)




IT 735316-46-8P 735316-47-9P 735316-50-4P
735316-51-5P 735316-57-1P 735316-73-1P
735316-74-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure activity relationships of piperazine derivs. of triazolotriazine as adenosine A2a receptor antagonists)

RN 735316-46-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 735316-47-9 CAPLUS

10/552,304


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-50-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2-methoxyphenyl)methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 735316-51-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-57-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,6-difluorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-73-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]- (CA INDEX NAME)

INDEX NAME)



RN 735316-74-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3,5-dimethyl-4-isoxazolyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)




IT 735316-48-0 735316-49-1 735316-52-6
735316-53-7 735316-55-9 735316-59-3
735316-61-7 735316-62-8 735316-64-0
735316-65-1 735316-66-2 735316-67-3
735316-68-4 735316-69-5 735316-70-8
735316-71-9 735316-72-0 735316-75-3
735316-78-6 735316-79-7 735316-80-0
735316-81-1 735316-82-2 735316-83-3
735316-85-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(structure activity relationships of piperazine derivs. of
triazolotriazine as adenosine A2a receptor antagonists)

RN 735316-48-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-49-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-phenylpropyl)-1-piperazinyl]- (CA INDEX NAME)

10/552,304




RN 735316-52-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)




RN 735316-53-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA INDEX
NAME)



RN 735316-55-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2,3,6-trichlorophenyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)




RN 735316-59-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2,3,6-trifluorophenyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)


10/552,304




RN 735316-61-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3-chloro-2,6-difluorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)



RN 735316-62-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(6-chloro-2,3-difluorophenyl)methyl]-1-piperazinyl]-2-(2-furanyl)-
(CA INDEX NAME)




RN 735316-64-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1H-imidazol-5-ylmethyl)-1-piperazinyl]- (CA INDEX
NAME)



RN 735316-65-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(1,2,3-thiadiazol-4-ylmethyl)-1-piperazinyl]- (CA


10/552,304

INDEX NAME)




RN 735316-66-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-furanylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-67-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(4-thiazolylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-68-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-(2-benzofuranylmethyl)-1-piperazinyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 735316-69-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-thienylmethyl)-1-piperazinyl]- (CA INDEX NAME)


10/552,304




RN	735316-70-8	CAPLUS	
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[4-[[2-(methylthio)-3-thienyl]methyl]-1-piperazinyl]- (CA INDEX NAME)		



RN	735316-71-9	CAPLUS
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[4-[(2-methyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]- (CA INDEX NAME)	




RN	735316-72-0	CAPLUS
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[4-[(4-methyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]- (CA INDEX NAME)	




RN	735316-75-3	CAPLUS
CN	<chem>[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,</chem> <chem>5-[4-[(3-chloro-1-methyl-1H-pyrazol-4-yl)methyl]-1-piperazinyl]-2-(2-furanyl)-</chem> (CA INDEX NAME)	


10/552,304




RN 735316-78-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-79-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(4-pyridinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 735316-80-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-[(2-methyl-3-pyridinyl)methyl]-1-piperazinyl]- (CA
INDEX NAME)




RN 735316-81-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(2,4-dimethyl-3-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)

10/552,304




RN 735316-82-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[4-[(3,5-dichloro-4-pyridinyl)methyl]-1-piperazinyl]-2-(2-furanyl)- (CA
INDEX NAME)




RN 735316-83-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(2-quinolinylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 735316-85-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(3-quinolinylmethyl)-1-piperazinyl]- (CA INDEX NAME)




IT 139181-28-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(structure activity relationships of piperazine derivs. of
triazolotriazine as adenosine A2a receptor antagonists)

RN 139181-28-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)


10/552,304



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 79 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:551512 CAPLUS
DN 141:99601
TI Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum
AU Tebano, Maria Teresa; Pintor, Annita; Frank, Claudio; Domenici, Maria Rosaria; Martire, Alberto; Pepponi, Rita; Potenza, Rosa Luisa; Grieco, Rosa; Popoli, Patrizia
CS Department of Pharmacology, Istituto Superiore di Sanita, Rome, Italy
SO Journal of Neuroscience Research (2004), 77(1), 100-107
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuroprotective potential of A2A receptor antagonists against excitotoxicity in rat striatum and role of presynaptic mechanisms)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 80 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:509593 CAPLUS
DN 141:405812
TI A2A adenosine receptor activation improves survival in mouse models of
endotoxemia and sepsis
AU Sullivan, Gail W.; Fang, Guodong; Linden, Joel; Scheld, W. Michael
CS Department of Internal Medicine, University of Virginia, Charlottesville,
VA, USA
SO Journal of Infectious Diseases (2004), 189(10), 1897-1904
CODEN: JIDIAQ; ISSN: 0022-1899
PB University of Chicago Press
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective A2A AR antagonist ZM241385 did not significantly increase
mortality in absence of AR agonist and reduced protective effect of
ATL146e, IB-MECA in mouse model of endotoxemia and sepsis)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 81 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:353631 CAPLUS
DN 141:1715
TI Direct interaction of adenosine with the TRPV1 channel protein
AU Puntambekar, Preeti; Van Buren, Jeremy; Raisinghani, Manish; Premkumar, Louis S.; Ramkumar, Vickram
CS Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, 62794-9629, USA
SO Journal of Neuroscience (2004), 24(14), 3663-3671
CODEN: JNRSDS; ISSN: 0270-6474
PB Society for Neuroscience
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(direct interaction of adenosine with TRPV1 channel protein as evaluated in HEK293 cells, fetal rat dorsal root ganglia cultures and Xenopus oocytes)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 82 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:213189 CAPLUS
DN 141:17782
TI The mouse brain adenosine A1 receptor: functional expression and pharmacology
AU Wittendorp, Maria C.; Von Frijtag Drabbe Kunzel, Jacobien; IJzerman, Adriaan P.; Boddeke, Hendrikus W. G. M.; Biber, Knut
CS Department of Medical Physiology, University of Groningen, Groningen, 9713 AV, Neth.
SO European Journal of Pharmacology (2004), 487(1-3), 73-79
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study) (mouse brain adenosine A1 receptor in relation to mol. cloning, functional expression and pharmacol.)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 83 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:188255 CAPLUS
 DN 141:119341
 TI Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors
 AU Sihver, W.; Bier, D.; Holschbach, M. H.; Schulze, A.; Wutz, W.; Olsson, R. A.; Coenen, H. H.
 CS Institut fur Nuklearchemie, Forschungszentrum Julich GmbH, Julich, 52425, Germany
 SO Nuclear Medicine and Biology (2004), 31(2), 173-177
 CODEN: NMBIEO; ISSN: 0969-8051
 PB Elsevier Science Inc.
 DT Journal
 LA English
 IT 316789-88-5P 724457-46-9P 724457-47-0P
 RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and binding to brain A2A adenosine receptor)
 RN 316789-88-5 CAPLUS
 CN Phen-2-t-ol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 724457-46-9 CAPLUS
 CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-(iodo-131I)- (9CI) (CA INDEX NAME)




RN 724457-47-0 CAPLUS
 CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2,6-di(iodo-131I)- (9CI) (CA INDEX NAME)


10/552,304



IT 724457-48-1P 724457-49-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and radioiodination of)
RN 724457-48-1 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2-iodo- (CA INDEX NAME)




RN 724457-49-2 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-2,6-diiodo- (CA INDEX NAME)



IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(tritiated and radioiodinated ZM241,385 binding by brain A2A adenosine
receptor)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)


10/552,304



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 84 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:119973 CAPLUS
DN 141:236035
TI Limitation of Myocardial Reperfusion Injury by AMP579, an Adenosine A1/A2A
Receptor Agonist: Role of A2A Receptor and Erk1/2
AU Kis, Adrienn; Baxter, Gary F.; Yellon, Derek M.
CS Hatter Institute, UCL Hospitals and Medical School, London, UK
SO Cardiovascular Drugs and Therapy (2003), 17(5/6), 415-425
CODEN: CDTHET; ISSN: 0920-3206
PB Kluwer Academic Publishers
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective adenosine A2A antagonist ZM241385 caused raise in blood
pressure, completely blocked depressor action of AMP579 providing
confirmation of blockade of A2A receptor activation by ZM241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 85 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:51829 CAPLUS
DN 140:314424
TI Synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor
antagonists
AU Alanine, Alexander; Anselm, Lilli; Steward, Lucinda; Thomi, Stefan;
Vifian, Walter; Groaning, Michael D.
CS Lead Generation, Discovery Chemistry, Pharmaceuticals Division, F.
Hoffmann-La Roche AG, Basel, CH 4070, Switz.
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(3), 817-821
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:314424
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(synthesis and SAR evaluation of 1,2,4-triazoles as A2A receptor
antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 86 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2004:2642 CAPLUS
 DN 140:70996
 TI Enhancing treatment of MDR cancer with adenosine A3 antagonists
 IN Borea, Pier Andrea; Baraldi, Pier Giovanni; Chen, Shih-Fong; Leung, Edward
 PA King Pharmaceuticals Research & Development, Inc., USA
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000237	A2	20031231	WO 2003-US20118	20030624
	WO 2004000237	A3	20040226		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2464539	A1	20031231	CA 2003-2464539	20030624
	AU 2003245693	A1	20040106	AU 2003-245693	20030624
	US 20040067932	A1	20040408	US 2003-603406	20030624
	BR 2003005106	A	20040928	BR 2003-5106	20030624
	EP 1515719	A2	20050323	EP 2003-739312	20030624
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005530858	T	20051013	JP 2004-530977	20030624
	NZ 531327	A	20061222	NZ 2003-531327	20030624
	MX 2004001731	A	20040531	MX 2004-1731	20040224
PRAI	US 2002-391009P	P	20020624		
	US 2002-394395P	P	20020708		
	WO 2003-US20118	W	20030624		
OS	MARPAT 140:70996				
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(adenosine A3 antagonists for enhancing treatment of MDR cancer)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

10/552,304

L4 ANSWER 87 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:2631 CAPLUS
DN 140:70994
TI Enhancing treatment of MDR cancer with adenosine A3 antagonists
IN Borea, Pier Andrea; Baraldi, Pier Giovanni; Chen, Shih-Fong; Leung, Edward
PA King Pharmaceuticals Research & Development, Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004000224	A2	20031231	WO 2003-US19687	20030620
	WO 2004000224	A3	20040408		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003251595	A1	20040106	AU 2003-251595	20030620
	US 20050119289	A1	20050602	US 2003-600116	20030620
	ZA 2004001450	A	20050310	ZA 2004-1450	20040224
PRAI	US 2002-391009P	P	20020624		
	WO 2003-US19687	W	20030620		
OS	MARPAT 140:70994				
IT	139180-30-6				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(adenosine A3 antagonists for enhancing treatment of MDR cancer)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 88 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:924144 CAPLUS
DN 140:210302
TI Modulation of A2A Adenosine Receptors and Associated G α s Proteins by
ZM 241385 Treatment of Porcine Coronary Artery
AU Rekik, Moez; Mustafa, Jamal S.
CS Department of Pharmacology, Brody School of Medicine, East Carolina
University, Greenville, NC, USA
SO Journal of Cardiovascular Pharmacology (2003), 42(6), 736-744
CODEN: JCPCDT; ISSN: 0160-2446
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(modulation of A2A adenosine receptors and associated G α s proteins
by ZM 241385 treatment of porcine coronary artery)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 89 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:796432 CAPLUS

DN 139:302061

TI Synergy of dopamine D2 and adenosine A2 receptors activates protein kinase A (PKA) signaling via β/γ dimers, and use in the treatment of drug abuse and drug withdrawal

IN Gordon, Adrienne S.; Diamond, Ivan F.; Yao, Lina

PA The Regents of the University of California, USA

SO PCT Int. Appl., 152 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082211	A2	20031009	WO 2003-US9629	20030327
	WO 2003082211	A3	20041216		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003241281	A1	20031013	AU 2003-241281	20030327
PRAI	US 2002-368417P	P	20020327		
	WO 2003-US9629	W	20030327		


IT 139180-30-6, ZM 241385

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synergy of dopamine D2 and adenosine A2 receptors activates protein kinase A signaling via β/γ dimers, and use in treatment of drug abuse and drug withdrawal)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 90 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:690022 CAPLUS
DN 140:174918
TI Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig
and dog
AU Fozard, John R.; Baur, Francois; Wolber, Cedric
CS Research Department, Novartis Pharma AG, Basel, CH-4002, Switz.
SO European Journal of Pharmacology (2003), 475(1-3), 79-84
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
BIOL (Biological study)
(antagonist pharmacol. of adenosine A2B receptors from rat, guinea pig
and dog)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 91 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:519332 CAPLUS
DN 139:390718
TI Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic
action of trihexyphenidyl in rats
AU Villanueva-Toledo, Jairo; Moo-Puc, Rosa E.; Gongora-Alfaro, Jose L.
CS "Dr. Hideyo Noguchi", Centro de Investigaciones Regionales, Laboratorio de
Neurofisiologia, Universidad Autonoma de Yucatan, Merida, Yucatan, 97000,
Mex.
SO Neuroscience Letters (2003), 346(1,2), 1-4
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(selective A2A, but not A1 adenosine antagonists enhance the
anticataleptic action of trihexyphenidyl in rats)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 92 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:472597 CAPLUS

DN 139:47145

TI Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

IN Sitkovsky, Michail V.; Ohta, Akio

PA The Government of the United States of America as Represented by the Secretary, Department of Health and Human Services, USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003050241	A2	20030619	WO 2002-US36829	20021114
	WO 2003050241	A3	20040129		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2470104	A1	20030619	CA 2002-2470104	20021114
	AU 2002356962	A1	20030623	AU 2002-356962	20021114
	EP 1465634	A2	20041013	EP 2002-804693	20021114
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	JP 2005516917	T	20050609	JP 2003-551263	20021114
	US 20050220799	A1	20051006	US 2004-498416	20040610
PRAI	US 2001-340772P	P	20011212		
	US 2001-342585P	P	20011219		
	WO 2002-US36829	W	20021114		

IT 139180-30-6, ZM241385


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation)

RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 93 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:376384 CAPLUS
DN 138:396214
TI Methods and compositions for reducing ischemic injury of the heart by
administering adenosine receptor agonists and antagonists
IN Liang, Bruce T.; Jacobson, Kenneth A.
PA USA
SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. 6,211,165.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20030092668	A1	20030515	US 2001-800274	20010305
	US 6586413	B2	20030701		
	US 6211165	B1	20010403	US 1999-423129	19991105
PRAI	US 1999-423129	A2	19991105		
	US 1997-46030P	P	19970509		
	US 1997-61716P	P	19971010		
	WO 1998-US9031	W	19980508		
IT	139180-30-6, ZM241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (adenosine receptor agonists and antagonists for reducing cardiac ischemic injury)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304


L4 ANSWER 94 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:330660 CAPLUS
DN 139:270317
TI Binding of HTLV-1 virions to T cells occurs by a temperature and
calcium-dependent process and is blocked by certain type 2 adenosine
receptor antagonists
AU Hague, Bishop F.; Zhao, Tong Mao; Kindt, Thomas J.
CS National Institute of Allergy and Infectious Diseases, Molecular and
Cellular Immunogenetics Section, National Institutes of Health, Bethesda,
MD, 20892, USA
SO Virus Research (2003), 93(1), 31-39
CODEN: VIREFD; ISSN: 0168-1702
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, Zm241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(HTLV-1 virions binding to T cells is temperature and calcium-dependent and
is blocked by adenosine antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 95 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2002:793451 CAPLUS
 DN 137:289033
 TI Adenosine A2A receptor antagonists combined with neurotrophic activity
 compounds in the treatment of Parkinson's disease
 IN Peters, Dan; Ronn, Lars Christian; Nielsen, Karin Sandager
 PA Neurosearch A/S, Den.
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002080957	A1	20021017	WO 2002-DK228	20020404
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2440196	A1	20021017	CA 2002-2440196	20020404
	AU 2002338309	A1	20021021	AU 2002-338309	20020404
	EP 1379269	A1	20040114	EP 2002-759761	20020404
	EP 1379269	B1	20090304		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004529916	T	20040930	JP 2002-578996	20020404
	US 20040097540	A1	20040520	US 2003-473809	20031002
	US 7160899	B2	20070109		
	MX 2003009185	A	20040217	MX 2003-9185	20031008
PRAI	DK 2001-583	A	20010409		
	WO 2002-DK228	W	20020404		
IT	139180-30-6, ZM-241385				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(adenosine A2A receptor antagonists combined with neurotrophic compds. in treatment of Parkinson's disease)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 96 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:787957 CAPLUS
DN 138:148014
TI Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385
AU Demet, Edward M.; Chicz-Demet, Aleksandra
CS Mental Health Care Group, Veterans Affairs Medical Center (116A), Long Beach, CA, 90822, USA
SO Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 366(5), 478-481
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM-241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(localization of adenosine A2A-receptors in rat brain with
[3H]ZM-241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 97 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:616371 CAPLUS
DN 137:150232
TI Method and compositions using A2A adenosine receptor agonists for treating
the inflammatory response
IN Linden, Joel M.; Rieger, Jayson M.; Sullivan, Gail W.; MacDonald, Timothy
L.
PA University of Virginia Patent Foundation, USA
SO U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020111327	A1	20020815	US 2002-41776	20020107
	US 6670334	B2	20031230		
PRAI	US 2001-260059P	P	20010105		
OS	MARPAT 137:150232				
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); BIOL (Biological study) (A2A adenosine receptor agonists for treating inflammatory response)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304

L4 ANSWER 98 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:616265 CAPLUS
DN 137:150259
TI Method for screening molecules that exert a neurotrophic effect through
activation of neurotrophin receptors
IN Chao, Moses V.; Lee, Francis S.
PA New York University, USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 20020110837	A1	20020815	US 2001-982095	20011019
	US 7169568	B2	20070130		
PRAI	US 2000-255887P	P	20001218		
IT	139180-30-6, ZM 241385				
	RL: PAC (Pharmacological activity); BIOL (Biological study) (screening mols. that exert neurotrophic effect through activation of neurotrophin receptor)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 99 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2002:353649 CAPLUS

DN 136:365554

TI Polymorphic variants of human adenosine 2a receptor associated with diseases and diagnostic and therapeutic methods

IN Dowell, Simon Jeremy; Sheehan, Michael John

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 44 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036816	A2	20020510	WO 2001-GB4865	20011102
	WO 2002036816	A3	20030530		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002010761	A	20020515	AU 2002-10761	20011102
PRAI	GB 2000-26945	A	20001103		
	GB 2000-29577	A	20001202		
	WO 2001-GB4865	W	20011102		
IT	139180-30-6, ZM 241385				
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (as A2a receptor antagonist, in drug screening assays; polymorphic variants of human adenosine 2a receptor associated with diseases and diagnostic and therapeutic methods)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



10/552,304

L4 ANSWER 100 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:290503 CAPLUS
DN 137:179743
TI Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists
AU Behan, W. M. H.; Stone, T. W.
CS Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO British Journal of Pharmacology (2002), 135(6), 1435-1442
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 101 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:276273 CAPLUS
DN 136:273219
TI Diagnosing Huntington's disease and means of treating it
IN Cattabeni, Flaminio Nicola; Cattaneo, Elena; Abbracchio, Mariapia; Varani, Katia; Borea, Pier Andrea
PA Universita' Degli Studi Di Milano, Italy; Universita' Degli Studi Di Ferrara
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002029408	A2	20020411	WO 2001-EP11425	20011003
	WO 2002029408	A3	20021212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	IT 1318960	B1	20030919	IT 2000-MI2137	20001003
	AU 2002013990	A	20020415	AU 2002-13990	20011003
	EP 1325335	A2	20030709	EP 2001-982391	20011003
	EP 1325335	B1	20060412		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	AT 323287	T	20060415	AT 2001-982391	20011003
	US 20040023312	A1	20040205	US 2003-398499	20030807
PRAI	IT 2000-MI2137	A	20001003		
	WO 2001-EP11425	W	20011003		
IT	139180-30-6, ZM-241385				
	RL: BSU (Biological study, unclassified); BIOL (Biological study) (diagnosing Huntington's disease and means of treating it)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 102 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:85503 CAPLUS
DN 136:227186
TI Purification and characterization of the human adenosine A2a receptor
functionally expressed in Escherichia coli
AU Weiss, H. Markus; Grisshammer, Reinhard
CS MRC Laboratory of Molecular Biology, Cambridge, UK
SO European Journal of Biochemistry (2002), 269(1), 82-92
CODEN: EJBCAI; ISSN: 0014-2956
PB Blackwell Publishing Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(purification and characterization of human adenosine A2a receptor
functionally expressed in Escherichia coli)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 103 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:54358 CAPLUS
DN 137:134868
TI Hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: effect of theophylline and ZM 241385
AU Higashi, Hisato; Meno, Joseph R.; Marwaha, Amitoj S.; Winn, H. Richard
CS Department of Neurological Surgery, University of Washington, Seattle, WA, USA
SO Journal of Neurosurgery (2002), 96(1), 117-126
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); BIOL (Biological study)
(hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: effect of theophylline and ZM 241385)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 104 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:38775 CAPLUS
DN 137:103775
TI Role of adenosine receptors in neuroprotective effect during global cerebral ischemia
AU Kulinsky, V. I.; Minakina, L. N.; Usov, L. A.
CS Department of Biochemistry, Irkutsk Medical University, Russia
SO Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2001), 131(5), 454-456
CODEN: BEXBAN; ISSN: 0007-4888
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of adenosine receptors in neuroprotective effect during global cerebral ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 105 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:915602 CAPLUS
DN 136:303408
TI New developments in A1 and A2 adenosine receptor antagonists
AU Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.; Michalak, B.; Miller, C.
E.; Schumacher, B.; Karolak-Wojciechowska, J.; Duddeck, H.; Rockitt, S.;
Wartchow, R.
CS IUPAC Commission, Medical College, Department of Chemical Technology of
Drugs, Jagiellonian University, Krakow, PL 30-688, Pol.
SO Pure and Applied Chemistry (2001), 73(9), 1411-1420
CODEN: PACHAS; ISSN: 0033-4545
PB International Union of Pure and Applied Chemistry
DT Journal; General Review
LA English
IT 139180-30-6P, Zm 241385
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(new developments in A1 and A2 adenosine receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 106 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:864519 CAPLUS
DN 136:129190
TI Solubilization and immunoprecipitation of rat striatal adenosine A2A
receptors
AU Harvey, Victoria; Jones, Julie; Misra, Anil; Knight, Antony R.; Quirk,
Kathleen
CS Department of Molecular Pharmacology, Vernalis Research Ltd., Winnersh,
Wokingham, RG41 5UA, UK
SO European Journal of Pharmacology (2001), 431(2), 171-177
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
ANST (Analytical study); BIOL (Biological study); USES (Uses)
(adenosine A2A receptors of rat striatum solubilization and
immunopptn.)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 107 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:749297 CAPLUS
DN 136:79626
TI Effects of adenosine receptor agonists and antagonists in a genetic animal
model of primary paroxysmal dystonia
AU Richter, Angelika; Hamann, Melanie
CS Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary
Medicine Hannover, Hannover, 30559, Germany
SO British Journal of Pharmacology (2001), 134(2), 343-352
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
unclassified); BIOL (Biological study)
(effects of adenosine receptor agonists and antagonists in a genetic
animal model of primary paroxysmal dystonia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 108 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:688889 CAPLUS
DN 136:48351
TI Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice
AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Bertorelli, Rosalia; Ongini, Ennio; Costentin, Jean; Vaugeois, Jean-Marie
CS UMR 6036 CNRS, IFRMP 23, U.F.R. de Medecine and Pharmacie, Rouen, 76183, Fr.
SO British Journal of Pharmacology (2001), 134(1), 68-77
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonists are potential antidepressants in A2A receptor knockout mice)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 109 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:597739 CAPLUS

DN 135:162508

TI Adenosine A2a receptor antagonist for treating and preventing hepatic fibrosis, cirrhosis and fatty liver

IN Cronstein, Bruce N.; Chan, Edwin

PA New York University, USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058241	A2	20010816	WO 2001-US4341	20010212
	WO 2001058241	A9	20021017		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2398908	A1	20010816	CA 2001-2398908	20010212
	AU 2001038124	A	20010820	AU 2001-38124	20010212
	US 20020002145	A1	20020103	US 2001-780365	20010212
	US 6555545	B2	20030429		
	JP 2004502640	T	20040129	JP 2001-557366	20010212
	AU 2001238124	B2	20060525	AU 2001-238124	20010212
	EP 1272897	B1	20080507	EP 2001-910529	20010212
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	AT 394104	T	20080515	AT 2001-910529	20010212
	ES 2307593	T3	20081201	ES 2001-910529	20010212
	AU 2006203699	A1	20060921	AU 2006-203699	20060825
PRAI	US 2000-181546P	P	20000210		
	WO 2001-US4341	W	20010212		


IT 139180-30-6, ZM 241385

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver)


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 110 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:216425 CAPLUS
DN 135:40644
TI Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by
substituted 2-propynylcyclohexyl adenosine A2A receptor agonists
AU Sullivan, Gail W.; Rieger, Jayson M.; Scheld, W. Michael; Macdonald,
Timothy L.; Linden, Joel
CS Department of Medicine, University of Virginia, Charlottesville, VA,
22908, USA
SO British Journal of Pharmacology (2001), 132(5), 1017-1026
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(cAMP-dependent inhibition of human neutrophil oxidative activity by
substituted 2-propynylcyclohexyl adenosine A2A receptor agonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 111 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:74904 CAPLUS
DN 134:142165
TI [3H]ZM241385-an antagonist radioligand for adenosine A2A receptors in rat brain
AU Alexander, S. P. H.; Millns, P. J.
CS Neuroscience and Pharmacology, School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK
SO European Journal of Pharmacology (2001), 411(3), 205-210
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385 316789-88-5
RL: ARG (Analytical reagent use); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(ZM 241385 as radioligand for adenosine A2A receptor characterization in rat brain)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RN 316789-88-5 CAPLUS
CN Phen-2-t-ol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 112 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2001:41889 CAPLUS

DN 134:100890

TI Preparation and effect of aromatic alkane derivatives as G protein inhibitors

IN Sawai, Toru; Hirakawa, Tetsuya; Kozasa, Michiko; Clark, Richard Steven John; Kimura, Akifumi; Harada, Kokichi; Chiba, Kenichi

PA Eisai Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 15 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001011064	A	20010116	JP 1999-179333	19990625
PRAI	JP 1999-179333		19990625		
OS	MARPAT 134:100890				
IT	319932-17-7P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(Preparation and effect of aromatic alkane derivs. as G protein inhibitors)

RN 319932-17-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-methylphenyl)-5-(methylthio)- (CA INDEX NAME)




IT 319932-15-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation and effect of aromatic alkane derivs. as G protein inhibitors)


RN 319932-15-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-methylphenyl)-5-(methylsulfonyl)- (CA INDEX NAME)




10/552,304

L4 ANSWER 113 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:21203 CAPLUS
DN 134:217113
TI Effect of the adenosine A2A-receptors on the brain stability with respect
to complete global cerebral ischemia
AU Kulinskii, V. I.; Minakina, L. N.; Usov, L. A.
CS Departments of Biochemistry and Pharmacology, Irkutsk Medical University,
Irkutsk, 664003, Russia
SO Eksperimental'naya i Klinicheskaya Farmakologiya (2000), 63(6), 9-11
CODEN: EKFAE9; ISSN: 0869-2092
PB Izdatel'stvo Folium
DT Journal
LA Russian
IT 139180-30-6, ZM 241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effect of the adenosine A2A-receptors on the brain stability with
respect to complete global cerebral ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



10/552,304


L4 ANSWER 114 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:893911 CAPLUS
DN 134:51525
TI Why are A2B receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-(1-hexynyl)adenosine
AU Beukers, Margot W.; den Dulk, Hans; Van Tilburg, Erica W.; Brouwer, Jaap; Ijerman, Adriaan P.
CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden University, Leiden, Neth.
SO Molecular Pharmacology (2000), 58(6), 1349-1356
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A2B receptors are low-affinity adenosine receptors and mutation of Asn273 to Tyr increases affinity of human A2B receptor for 2-substituted adenosines)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 115 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:526436 CAPLUS
DN 133:217854
TI Site-directed mutagenesis studies of human A2A adenosine receptors.
Involvement of glul3 and his278 in ligand binding and sodium modulation
AU Gao, Z.-G.; Jiang, Q.; Jacobson, K. A.; Ijzerman, A. P.
CS Leiden/Amsterdam Center for Drug Research, Division of Medicinal
Chemistry, Leiden University, Leiden, 2300 RA, Neth.
SO Biochemical Pharmacology (2000), 60(5), 661-668
CODEN: BCPA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(site-directed mutagenesis of glul3 and his278 in human A2A adenosine
receptor in relation to ligand binding and sodium modulation)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 116 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:480897 CAPLUS
DN 133:346544
TI Further characterization of a CNS adenosine A2a receptor ligand
[11C]KF18446 with in vitro autoradiography and in vivo tissue uptake
AU Ishiwata, Kiichi; Ogi, Nobuo; Shimada, Junichi; Nonaka, Hiromi; Tanaka,
Akira; Suzuki, Fumio; Senda, Michio
CS Positron Medical Center, Tokyo Metropolitan Institute of Gerontology,
Tokyo, 173-0022, Japan
SO Annals of Nuclear Medicine (2000), 14(2), 81-89
CODEN: ANMEEX; ISSN: 0914-7187
PB Japanese Society of Nuclear Medicine
DT Journal
LA English
IT 139180-30-6, ZM 241385 158747-27-4, ZD 9255
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(CNS adenosine A2a receptor ligand [11C]KF18446: blockade of binding in
brain by adenosine antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RN 158747-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 117 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:154677 CAPLUS
DN 132:274243
TI The anxiogenic-like effect of caffeine in two experimental procedures
measuring anxiety in the mouse is not shared by selective A2A adenosine
receptor antagonists
AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Costentin, Jean;
Vaugois, Jean-Marie
CS UPRESA 6036 CNRS, U.F.R. de Medecine and Pharmacie, Rouen, 76183, Fr.
SO Psychopharmacology (Berlin) (2000), 148(2), 153-163
CODEN: PSCHDL; ISSN: 0033-3158
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BUU (Biological use, unclassified); BIOL (Biological
study); USES (Uses)
(anxiogenic-like effect of caffeine in mouse is not shared by selective
A2A adenosine receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 118 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:97878 CAPLUS
DN 132:260556
TI Effects of P1 and P2 receptor antagonists on β,γ -methyleneATP-
and CGS21680-induced cyclic AMP formation in NG108-15 cells
AU Ohkubo, Satoko; Kimura, Junko; Nakanishi, Hironori; Matsuoka, Isao
CS Department of Pharmacology, School of Medicine, Fukushima Medical
University, Fukushima, 960-1295, Japan
SO British Journal of Pharmacology (2000), 129(2), 291-298
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(ATP-stimulated cAMP formation can be distinguished from A2A receptor
agonist-induced by using the several P1 and P2 receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 119 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:85698 CAPLUS
DN 132:220005
TI Antagonism of coronary artery relaxation by adenosine A2A-receptor
antagonist ZM241385
AU Hasan, A. Z. M. Arif; Abebe, Worku; Mustafa, S. Jamal
CS Department of Pharmacology, ECU School of Medicine, Greenville, NC, USA
SO Journal of Cardiovascular Pharmacology (2000), 35(2), 322-325
CODEN: JCPCDT; ISSN: 0160-2446
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(ZM241385 A2A receptor-selective antagonism: functional A2A adenosine
receptor in coronary artery)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 120 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 2000:27238 CAPLUS
 DN 132:202624
 TI Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity
 AU De Zwart, Maarten; Vollinga, Roel C.; Beukers, Margot W.; Slegers, Danielle F.; Von Frijtag Drabbe Kunzel, Jacobien K.; De Groote, Miriam; Ijzerman, Ad P.
 CS Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, 2300 RA, Neth.
 SO Drug Development Research (1999), 48(3), 95-103
 CODEN: DDREDK; ISSN: 0272-4391
 PB Wiley-Liss, Inc.
 DT Journal
 LA English
 IT 139179-78-5, LUF 5453 139179-82-1, LUF 5451
 139179-86-5, LUF 5452 139179-88-7, LUF 5461
 139180-17-9, LUF 5460 139180-30-6, ZM241385
 139181-13-8, LUF 5458 260370-68-1, LUF 5478
 260370-69-2, LUF 5455 260370-70-5, LUF 5456
 260370-71-6, LUF 5457 260370-72-7, LUF 5459
 260370-73-8, LUF 5479 260370-74-9, LUF 5462
 260370-75-0, LUF 5475 260370-76-1, LUF 5477
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (derivs. of triazolotriazine ZM241385 as potent antagonists for human adenosine A2B receptors with high affinity in relation to structure)
 RN 139179-78-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-phenyl- (CA INDEX NAME)




RN 139179-82-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-(phenylmethyl)- (CA INDEX NAME)



RN 139179-86-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-(2-phenylethyl)- (CA INDEX NAME)


10/552,304



RN 139179-88-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 139180-17-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-30-6 CAPLUS


CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 139181-13-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


10/552,304




RN 260370-68-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(3-phenylpropyl)- (CA INDEX NAME)



RN 260370-69-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(4-chlorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 260370-70-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(2-chlorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 260370-71-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(3,4-dichlorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 260370-72-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(4-methylphenyl)methyl]- (CA INDEX NAME)



RN 260370-73-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(diphenylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 260370-74-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-methyl-N5-(phenylmethyl)- (CA INDEX NAME)




RN 260370-75-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
2-(2-furanyl)-5-(2-phenylhydrazinyl)- (CA INDEX NAME)


10/552,304




RN 260370-76-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(cyclohexylmethyl)-2-(2-furanyl)- (CA INDEX NAME)



IT 139181-28-5 260273-22-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(derivs. of triazolotriazine ZM241385 as potent antagonists for human
adenosine A2B receptors with high affinity in relation to structure)
RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



RN 260273-22-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfinyl)- (CA INDEX NAME)




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/552,304

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 121 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:775949 CAPLUS
DN 132:88584
TI ZM 241385, an adenosine A2A receptor antagonist, inhibits hippocampal A1
receptor responses
AU Lopes, L. V.; Cunha, R. A.; Ribeiro, J. A.
CS Faculty of Medicine, Laboratory of Neurosciences, University of Lisbon,
Lisbon, 1649-028, Port.
SO European Journal of Pharmacology (1999), 383(3), 395-398
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(adenosine A2A receptor antagonist ZM 241385 inhibits hippocampal A1
receptor responses)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 122 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:745744 CAPLUS
DN 132:44931
TI Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors
AU Ji, Xiao-Duo; Jacobson, Kenneth A.
CS Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
SO Drug Design and Discovery (1999), 16(3), 217-226
CODEN: DDDIEV; ISSN: 1055-9612
PB Harwood Academic Publishers
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(use of triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 123 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:721665 CAPLUS
DN 132:30682
TI Effect of A2A adenosine receptor stimulation and antagonism on synaptic depression induced by in vitro ischemia in rat hippocampal slices
AU Latini, Serena; Bordoni, Francesca; Corradetti, Renato; Pepeu, Giancarlo; Pedata, Felicita
CS Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, 50139, Italy
SO British Journal of Pharmacology (1999), 128(5), 1035-1044
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(A2A adenosine receptor role in hippocampal synaptic transmission in ischemia: A2A and A1 receptor interaction as possible mechanism of protection against ischemia)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 124 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:693087 CAPLUS
DN 132:347
TI Autoradiographic comparison of the potency of several structurally
unrelated adenosine receptor antagonists at adenosine A1 and A2A receptors
AU Fredholm, Bertil B.; Lindstrom, Karin
CS Department of Physiology and Pharmacology, Section of Molecular
Neuropharmacology, Karolinska Institutet, Stockholm, S-171 77, Swed.
SO European Journal of Pharmacology (1999), 380(2/3), 197-202
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(autoradiog. comparison of the potency of several structurally
unrelated adenosine receptor antagonists at adenosine A1 and A2A
receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 125 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:644568 CAPLUS
DN 131:346931
TI Characterization of human A2B adenosine receptors: radioligand binding,
Western blotting, and coupling to Gq in human embryonic kidney 293 cells
and HMC-1 mast cells
AU Linden, Joel; Thai, Tami; Figler, Heidi; Jin, Xiaowei; Robeva, Anna S.
CS Departments of Internal Medicine Molecular Physiology and Biological
Physics, University of Virginia, Charlottesville, VA, USA
SO Molecular Pharmacology (1999), 56(4), 705-713
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(characterization of human A2B adenosine receptors in relation to
radioligand binding, Western blotting and coupling to Gq in human
embryonic kidney 293 cells and HMC-1 mast cells)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 126 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1999:451298 CAPLUS

DN 131:116251

TI Preparation of purine derivatives as adenosine A2 receptor antagonists for the treatment of diabetes

IN Asano, Osamu; Harada, Hitoshi; Hoshino, Yoriyhis; Yoshikawa, Seiji; Inoue, Takashi; Horizoe, Tatsuo; Yasuda, Nobuyuki; Nagata, Kaya; Nagaoka, Junsaku; Murakami, Manabu; Kobayashi, Seiichi

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9935147	A1	19990715	WO 1998-JP5870	19981224
	W: AU, BR, CA, CN, HU, KR, MX, NO, NZ, RU, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 11263789	A	19990928	JP 1998-363938	19981222
	JP 3990061	B2	20071010		
	CA 2315736	A1	19990715	CA 1998-2315736	19981224
	AU 9916885	A	19990726	AU 1999-16885	19981224
	EP 1054012	A1	20001122	EP 1998-961528	19981224
	EP 1054012	B1	20030611		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	EP 1300147	A1	20030409	EP 2002-29118	19981224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	AT 242775	T	20030615	AT 1998-961528	19981224
	US 6579868	B1	20030617	US 2000-582840	20000705
	US 39112	E1	20060530	US 2000-57854	20000705
PRAI	JP 1998-526	A	19980105		
	EP 1998-961528	A3	19981224		
	WO 1998-JP5870	W	19981224		

OS MARPAT 131:116251


IT 139180-30-6P 158747-27-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of purine derivs. as adenosine A2 receptor antagonists for treatment of diabetes)

RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 158747-27-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,

10/552,304


2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 127 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:292524 CAPLUS
DN 131:96959
TI Comparative molecular field analysis (CoMFA) of a series of selective
adenosine receptor A2A antagonists
AU Baraldi, Pier Giovanni; Borea, Pier Andrea; Bergonzoni, Manuela; Cacciari,
Barbara; Ongini, Ennio; Recanatini, Maurizio; Spalluto, Giampiero
CS Dipartimento di Scienze Farmaceutiche, Universita di Ferrara, Ferrara,
44100, Italy
SO Drug Development Research (1999), 46(2), 126-133
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
IT 139180-30-6P, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(comparative mol. field anal. of selective adenosine receptor A2A
antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 128 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:282105 CAPLUS
DN 130:306595
TI Methods for reducing ischemic injury of the heart via the sequential
administration of synergistic cardioprotective agents
IN Liang, Bruce T.; Jacobson, Kenneth A.
PA Trustees of the University of Pennsylvania, USA; National Institute of
Health
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9920284	A1	19990429	WO 1998-US22515	19981023
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9913636	A	19990510	AU 1999-13636	19981023
	US 6329349	B1	20011211	US 2000-530164	20000424
PRAI	US 1997-62737P	P	19971023		
	WO 1998-US22515	W	19981023		
IT	139180-30-6				
	RL: PRPH (Prophetic)				
	(Methods for reducing ischemic injury of the heart via the sequential administration of synergistic cardioprotective agents)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5- yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 129 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:797623 CAPLUS
DN 130:163466
TI Characterization of adenosine receptors evoking excitation of mesenteric afferents in the rat
AU Kirkup, A. J.; Eastwood, C.; Grundy, D.; Chessell, I. P.; Humphrey, P. P. A.
CS Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, UK
SO British Journal of Pharmacology (1998), 125(6), 1352-1360
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(characterization of adenosine receptors evoking excitation of mesenteric afferents in the rat)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 130 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:792698 CAPLUS
DN 130:261903
TI Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
AU Ongini, E.; Dionisotti, Silvio; Gessi, Stefania; Irenius, E.; Fredholm, Bertil B.
CS San Raffaele Science Park, Schering-Plough Research Institute, Milan, I-20132, Italy
SO Naunyn-Schmiedeberg's Archives of Pharmacology (1999), 359(1), 7-10
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(comparison of CGS 15943 and ZM 241385 and SCH 58261 as antagonists at human adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 131 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1998:744957 CAPLUS

DN 130:10632

TI Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists

IN Liang, Bruce T.; Jacobson, Kenneth A.

PA Trustees of the University of Pennsylvania, USA

SO PCT Int. Appl., 85 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850047	A1	19981112	WO 1998-US9031	19980508
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2289731	A1	19981112	CA 1998-2289731	19980508
	AU 9873677	A	19981127	AU 1998-73677	19980508
	AU 750322	B2	20020718		
	EP 991414	A1	20000412	EP 1998-920958	19980508
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6211165	B1	20010403	US 1999-423129	19991105
PRAI	US 1997-46030P	P	19970509		
	US 1997-61716P	P	19971010		
	WO 1998-US9031	W	19980508		
IT	139180-30-6, ZM241385				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(methods and compns. for reducing ischemic injury of heart by administering adenosine receptor agonists and antagonists)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304

L4 ANSWER 132 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1998:618821 CAPLUS

DN 129:225729

OREF 129:45749a

TI Methods and compositions for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists

IN Liang, Bruce T.; Jacobson, Kenneth A.

PA Trustees of the University of Pennsylvania, USA; National Institute of Health

SO PCT Int. Appl., 35 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9839008	A1	19980911	WO 1998-US4340	19980306
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5859019	A	19990112	US 1997-813787	19970307
	CA 2283449	A1	19980911	CA 1998-2283449	19980306
	AU 9863462	A	19980922	AU 1998-63462	19980306
	AU 745534	B2	20020321		
	EP 1021187	A1	20000726	EP 1998-907720	19980306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-813787	A	19970307		
	WO 1998-US4340	W	19980306		
IT	139180-30-6, ZMZ 41385				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(methods and compns. for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists)				
RN	139180-30-6 CAPLUS				
CN	Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 133 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:466874 CAPLUS
DN 129:211560
OREF 129:42807a,42810a
TI Protection against hippocampal kainate excitotoxicity by intracerebral
administration of an adenosine A2A receptor antagonist
AU Jones, P. A.; Smith, R. A.; Stone, T. W.
CS Laboratory of Human Anatomy, Institute of Biomedical and Life Sciences,
University of Glasgow, Glasgow, G12 8QQ, UK
SO Brain Research (1998), 800(2), 328-335
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
IT 139180-30-6, ZM241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(protection against hippocampal kainate excitotoxicity by intracerebral
administration of adenosine A2A receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 134 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:431231 CAPLUS
DN 129:170833
OREF 129:34589a,34592a
TI Binding affinity of adenosine receptor agonists and antagonists at human
cloned A3 adenosine receptors
AU Varani, K.; Cacciari, B.; Baraldi, P. G.; Dionisotti, S.; Ongini, E.;
Borea, P. A.
CS Dip. Med. Clin. Sperimentale-Sezione Farmacologia, Univ. Studi Ferrara,
Ferrara, 44100, Italy
SO Life Sciences (1998), 63(5), PL81-PL87
CODEN: LIFSAK; ISSN: 0024-3205
PB Elsevier Science Inc.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(binding affinity of adenosine receptor agonists and antagonists at
human cloned A3 adenosine receptors)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 135 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1998:274309 CAPLUS
DN 129:23325
OREF 129:4843a,4846a
TI Protection against kainate-induced excitotoxicity by adenosine A2A
receptor agonists and antagonists
AU Jones, P. A.; Smith, R. A.; Stone, T. W.
CS Division of Neuroscience and Biomedical Systems, Institute of Biomedical
and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK
SO Neuroscience (Oxford) (1998), 85(1), 229-237
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Science Ltd.
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(protection against kainate-induced excitotoxicity by adenosine A2A
receptor agonists and antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 136 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:801233 CAPLUS
DN 128:124022
OREF 128:24191a,24194a
TI Activation of two sites by adenosine receptor agonists to cause relaxation
in rat isolated mesenteric artery
AU Prentice, D. J.; Payne, S. L.; Hourani, S. M. O.
CS School of Biological Sciences, University of Surrey, Surrey, GU2 5XH, UK
SO British Journal of Pharmacology (1997), 122(7), 1509-1515
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(activation by adenosine receptor agonists causes relaxation in
mesenteric arteries)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 137 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:801204 CAPLUS
DN 128:123731
OREF 128:24115a
TI ZM241385 is an antagonist of the facilitatory responses produced by the
A2A adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus
AU Cunha, Rodrigo A.; Constantino, M. Dolores; Ribeiro, J. Alexandre
CS Department of Chemistry & Biochemistry, Faculty of Sciences, University
of Lisbon, Lisbon, 1700, Port.
SO British Journal of Pharmacology (1997), 122(7), 1279-1284
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(ZM241385 antagonism of responses produced by A2A adenosine receptor
agonists CGS21680 and HENECA in hippocampus)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/552,304


L4 ANSWER 138 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:704675 CAPLUS
DN 127:343393
OREF 127:67323a,67326a
TI Myocardial adenosine A2a receptor imaging of rabbit by PET with
[11C]KF17837
AU Ishiwata, Kiichi; Sakiyama, Yojiro; Sakiyama, Takayo; Shimada, Junichi;
Toyama, Hinako; Oda, Keiichi; Suzuki, Fumio; Senda, Michio
CS Positron Medical Center, Tokyo Metropolitan Institute of Gerontology,
Itabashi, 173, Japan
SO Annals of Nuclear Medicine (1997), 11(3), 219-225
CODEN: ANMEEX; ISSN: 0914-7187
PB Japanese Society of Nuclear Medicine
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(myocardial adenosine A2a receptor imaging by PET with [11C]KF17837)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 139 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1997:646525 CAPLUS
DN 127:326459
OREF 127:63925a,63928a
TI Relaxation of the ovine isolated iris sphincter by adenosine receptor agonists: Lack of effect of adenosine A1 and A2 receptor antagonists
AU Hourani, Susanna M. O.; Smith, Neil C.; Nettell, Julia J.; Hall, Judith M.
CS School of Biological Sciences, University of Surrey, Guildford Surrey, GU2 5XH, UK
SO European Journal of Pharmacology (1997), 334(1), 95-98
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(relaxation of the ovine isolated iris sphincter by adenosine receptor agonists and lack of effect of adenosine A1 and A2 receptor antagonists)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 140 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:481385 CAPLUS
DN 125:158440
OREF 125:29399a,29402a
TI Pharmacodynamics of ZM 241385, a potent A2a adenosine receptor antagonist, after enteric administration in rat, cat and dog
4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) is currently the most selective for the A2a adenosine receptor antagonist.
AU Poucher, S. M.; keddie, J. R.; Brooks, R.; Shaw, G. R.; McKillop, D.
CS Cardiovascular and Metabolism Department, Zeneca Pharmaceuticals, Macclesfield, SK10 5TG, UK
SO Journal of Pharmacy and Pharmacology (1996), 48(6), 601-606
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pharmacodynamics of potent A2a adenosine receptor antagonist ZM 241385 after enteric administration in rat and cat and dog in relation to role of A2a adenosine receptors in action of adenosine)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




10/552,304


L4 ANSWER 141 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1996:312987 CAPLUS
DN 125:49785
OREF 125:9357a,9360a
TI In vivo characterization of ZM 241385, a selective adenosine A2A receptor antagonist
AU Keddie, John R.; Poucher, Simon M.; Shaw, Graham R.; Brooks, Robert; Collis, Michael G.
CS Cardiovascular and Metabolism Department, Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK
SO European Journal of Pharmacology (1996), 301(1-3), 107-113
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(selective adenosine A2A receptor antagonist ZM 241385 characterization)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



L4 ANSWER 142 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1996:27287 CAPLUS
 DN 124:76661
 OREF 124:14057a
 TI 125I-4(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3-a}{1,3,5}triazin-5-yl-
 amino]ethyl)phenol, a high affinity antagonist radioligand selective for
 the A2a adenosine receptor
 AU Palmer, Timothy M.; Poucher, Simon M.; Jacobson, Kenneth A.; Stiles, Gary
 L.
 CS Dep. of Medicine and Pharmacology, Duke University Medical Center, Durham,
 NC, 27710, USA
 SO Molecular Pharmacology (1995), 48(6), 970-4
 CODEN: MOPMA3; ISSN: 0026-895X
 PB Williams & Wilkins
 DT Journal
 LA English
 IT 139181-28-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (in ZM 241385 preparation)
 RN 139181-28-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



IT 139180-30-6P, ZM 241385
 RL: ARG (Analytical reagent use); BPR (Biological process); BSU
 (Biological study, unclassified); RCT (Reactant); SPN (Synthetic
 preparation); ANST (Analytical study); BIOL (Biological study); PREP
 (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
 (125I-ZM 241385 preparation and selective detection of adenosine A2a
 receptor in bovine striatum)
 RN 139180-30-6 CAPLUS
 CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
 yl]amino]ethyl]- (CA INDEX NAME)




IT 139180-30-6DP, ZM 241385, iodo derivs., iodine-125 labeled
 RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST
 (Analytical study); PREP (Preparation); USES (Uses)
 (125I-ZM 241385 preparation and selective detection of adenosine A2a
 receptor in bovine striatum)

10/552,304


RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




10/552,304


L4 ANSWER 143 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1995:725707 CAPLUS
DN 123:187737
OREF 123:33053a,33056a
TI The in vitro pharmacology of ZM 241385, a potent, non-xanthine, A2a
selective adenosine receptor antagonist
AU Poucher, S. M.; Keddie, J. R.; Singh, P.; Stoggall, S. M.; Caulkett, P. W.
R.; Jones, G.; Collis, M. G.
CS Cardiovascular and Metabolism Dep., ZENECA Pharmaceuticals, Macclesfield,
SK10 4TG, UK
SO British Journal of Pharmacology (1995), 115(6), 1096-102
CODEN: BJPCBM; ISSN: 0007-1188
PB Macmillan Scientific & Medical Division
DT Journal
LA English
IT 139180-30-6, ZM 241385
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(in vitro pharmacol. of ZM 241385, a potent, non-xanthine, A2a
selective adenosine receptor antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-
yl]amino]ethyl]- (CA INDEX NAME)




L4 ANSWER 144 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1995:616574 CAPLUS
 DN 123:83325
 OREF 123:14913a,14916a
 TI Synthesis of 1,2,4-triazolo[1,5-a]-1,3,5-triazine derivatives for
 phytotoxic activity
 AU Miyamoto, Yoshiko; Kohno, Hitoshi; Pfleiderer, Wolfgang; Boeger, Peter;
 Wakabayashi, Ko
 CS Sch. Sci., Kitasato Univ., Sagamihara, 228, Japan
 SO Nippon Noyaku Gakkaishi (1995), 20(2), 119-28
 CODEN: NNGADV; ISSN: 0385-1559
 DT Journal
 LA English
 IT 28610-03-9P 28610-04-0P 165125-42-8P
 165125-43-9P 165125-44-0P 165125-45-1P
 165125-46-2P 165125-47-3P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (synthesis of triazolotriazines from (chlorobenzylidene)aminoguanidines
 and Et cyanoformimidate and their phytotoxicity)
 RN 28610-03-9 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-phenyl- (CA INDEX NAME)



RN 28610-04-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-methoxyphenyl)- (CA
 INDEX NAME)




RN 165125-42-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-chlorophenyl)- (CA
 INDEX NAME)



RN 165125-43-9 CAPLUS


10/552,304

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, N-methyl-2-phenyl- (CA INDEX NAME)




RN 165125-44-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, N-ethyl-2-phenyl- (CA INDEX NAME)




RN 165125-45-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-chloro-2-fluorophenyl)- (CA INDEX NAME)



RN 165125-46-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-chloro-2-fluorophenyl)-N-methyl- (CA INDEX NAME)



RN 165125-47-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-chlorophenyl)-N-methyl- (CA INDEX NAME)

10/552,304



L4 ANSWER 145 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1995:563495 CAPLUS

DN 122:299088

OREF 122:54325a,54328a

TI Depression remedy

IN Suzuki, Fumio; Koike, Nobuaki; Shimada, Junichi; Kitamura, Shigeto;
Ichikawa, Shunji; Nakamura, Joji; Shiozaki, Shizuo

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 21 pp.


CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9507282	A1	19950316	WO 1994-JP1455	19940902
	W: AU, CA, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2148502	A1	19950316	CA 1994-2148502	19940902
	AU 9475467	A	19950327	AU 1994-75467	19940902
	EP 667349	A1	19950816	EP 1994-925620	19940902
	EP 667349	B1	20010124		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 198890	T	20010215	AT 1994-925620	19940902
	ES 2156901	T3	20010801	ES 1994-925620	19940902
	US 5789407	A	19980804	US 1995-424397	19950425
PRAI	JP 1993-221431	A	19930906		
	WO 1994-JP1455	W	19940902		
OS	MARPAT 122:299088				
IT	139179-53-6P 139179-54-7P 139179-78-5P				
	139179-82-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(antidepressant activity and formulations of triazine derivs.)				
RN	139179-53-6 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy-				
	(CA INDEX NAME)				




RN 139179-54-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(phenylthio)- (CA INDEX NAME)

10/552,304


RN 139179-78-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-phenyl- (CA INDEX NAME)




RN 139179-82-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(phenylmethyl)- (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 146 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1995:517839 CAPLUS
 DN 123:228139
 OREF 123:40747a,40750a
 TI Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1,2,4]triazolo[1,5-a][1,3,5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions
 AU Caulkett, Peter W. R.; Jones, Geraint; McPartlin, Mary; Renshaw, Nigel D.; Stewart, Sarah K.; Wright, Brian
 CS Zeneca Pharmaceuticals, Macclesfield, SK10 4TG, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1995), (7), 801-8
 CODEN: JCPRB4; ISSN: 0300-922X
 PB Royal Society of Chemistry
 DT Journal
 LA English
 IT 139179-53-6P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of adenine isosteres)
 RN 139179-53-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy- (CA INDEX NAME)




IT 139181-27-4P 139181-28-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of adenine isosteres)
 RN 139181-27-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)




RN 139181-28-5 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)


10/552,304



IT 139180-66-8P 139181-06-9P 168211-35-6P
168211-36-7P 168211-39-0P 168211-44-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of adenine isosteres)
RN 139180-66-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(5-isoxazolyl)-5-phenoxy-
(CA INDEX NAME)




RN 139181-06-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-methyl-5-isoxazolyl)-5-phenoxy- (CA INDEX NAME)




RN 168211-35-6 CAPLUS
CN Phenol, 4-[2-[[5-amino-2-(2-furanyl)][1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]amino]ethyl- (CA INDEX NAME)


10/552,304



RN 168211-36-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N7-propyl- (CA INDEX NAME)




RN 168211-39-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-methyl-4-oxazolyl)-5-phenoxy- (CA INDEX NAME)



RN 168211-44-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-phenoxy-2-(3-pyridinyl)-
(CA INDEX NAME)

10/552,304



10/552,304

L4 ANSWER 147 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1995:501359 CAPLUS

DN 122:248318

OREF 122:45167a,45170a

TI Remedy for Parkinson's disease

IN Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Ichikawa, Shunji;
Nakamura, Joji; Kanda, Tomoyuki; Kitamura, Shigeto

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 27 pp.


CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9503806	A1	19950209	WO 1994-JP1196	19940720
	W: AU, CA, JP, KR, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2144330	A1	19950209	CA 1994-2144330	19940720
	AU 9472372	A	19950228	AU 1994-72372	19940720
	EP 666079	A1	19950809	EP 1994-921793	19940720
	EP 666079	B1	20011107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 208199	T	20011115	AT 1994-921793	19940720
	ES 2165393	T3	20020316	ES 1994-921793	19940720
	US 5565460	A	19961015	US 1995-367346	19950303
PRAI	JP 1993-184295	A	19930727		
	WO 1994-JP1196	W	19940720		
OS	MARPAT 122:248318				
IT	139179-53-6				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(polycyclic compds. for treatment of Parkinson's disease)				
RN	139179-53-6 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy-				
	(CA INDEX NAME)				



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 148 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1995:444109 CAPLUS

DN 122:214109

OREF 122:39143a,39146a

TI Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazines and analogs as adenosine antagonists

IN Rodney, Peter W.; Jones, Geraint; Collis, Michael G.; Poucher, Simon M.

PA UK

SO U.S., 31 pp. Cont.-in-part of U.S. 5,270,311.


CODEN: USXXAM

DT Patent

LA English


FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5356894	A	19941018	US 1993-94572	19930721
	US 5270311	A	19931214	US 1991-708265	19910528
	PL 167014	B1	19950731	PL 1991-290445	19910528
	CN 1056879	A	19911211	CN 1991-103744	19910529
	ZA 9104094	A	19920226	ZA 1991-4094	19910529
PRAI	GB 1990-11913	A	19900529		
	GB 1990-11914	A	19900529		
	GB 1991-1379	A	19910122		
	GB 1991-1380	A	19910122		
	GB 1991-4125	A	19910227		
	US 1991-708265	A2	19910528		
	GB 1992-26735	A	19921222		
OS	MARPAT 122:214109				
IT	139181-27-4P 139181-28-5P 139181-30-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of triazolotriazines and analogs as adenosine antagonists)				
RN	139181-27-4 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)				




RN 139181-28-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




10/552,304


RN 139181-30-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



IT 139179-53-6P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolotriazines and analogs as adenosine antagonists)
RN 139179-53-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy-
(CA INDEX NAME)




IT 139179-60-5P 139179-96-7P 139179-97-8P
139179-98-9P 139180-09-9P 139180-63-5P
139181-06-9P 139181-08-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of triazolotriazines and analogs as adenosine antagonists)
RN 139179-60-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(phenylmethoxy)phenoxy]- (CA INDEX NAME)




RN 139179-96-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-furanyl)-5-(methylthio)- (CA INDEX NAME)


10/552,304




RN 139179-97-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(methylthio)- (CA INDEX NAME)



RN 139179-98-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-(methylthio)- (CA INDEX NAME)




RN 139180-09-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(methylthio)-2-(2-thienyl)- (CA INDEX NAME)




RN 139180-63-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-N-methyl-5-phenoxy- (CA INDEX NAME)


10/552,304



RN 139181-06-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-methyl-5-isoxazolyl)-5-phenoxy- (CA INDEX NAME)



RN 139181-08-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




IT 139179-54-7P 139179-55-8P 139179-56-9P
139179-57-0P 139179-58-1P 139179-59-2P
139179-61-6P 139179-62-7P 139179-63-8P
139179-64-9P 139179-65-0P 139179-66-1P
139179-67-2P 139179-68-3P 139179-69-4P
139179-70-7P 139179-71-8P 139179-72-9P
139179-73-0P 139179-74-1P 139179-75-2P
139179-76-3P 139179-77-4P 139179-78-5P
139179-79-6P 139179-80-9P 139179-81-0P
139179-82-1P 139179-83-2P 139179-84-3P
139179-85-4P 139179-86-5P 139179-87-6P
139179-88-7P 139179-89-8P 139179-90-1P
139179-91-2P 139179-92-3P 139179-93-4P
139179-94-5P 139179-95-6P 139179-99-0P
139180-00-0P 139180-01-1P 139180-02-2P
139180-03-3P 139180-04-4P 139180-05-5P
139180-06-6P 139180-07-7P 139180-08-8P
139180-10-2P 139180-11-3P 139180-12-4P
139180-13-5P 139180-14-6P 139180-15-7P
139180-16-8P 139180-17-9P 139180-18-0P
139180-19-1P 139180-20-4P 139180-21-5P
139180-22-6P 139180-23-7P 139180-24-8P
139180-25-9P 139180-26-0P 139180-27-1P
139180-28-2P 139180-29-3P 139180-30-6P
139180-31-7P 139180-32-8P 139180-34-0P

139180-35-1P 139180-36-2P 139180-37-3P
 139180-38-4P 139180-39-5P 139180-40-8P
 139180-41-9P 139180-42-0P 139180-43-1P
 139180-44-2P 139180-45-3P 139180-46-4P
 139180-47-5P 139180-48-6P 139180-49-7P
 139180-50-0P 139180-51-1P 139180-52-2P
 139180-53-3P 139180-54-4P 139180-55-5P
 139180-56-6P 139180-57-7P 139180-58-8P
 139180-59-9P 139180-60-2P 139180-61-3P
 139180-62-4P 139180-64-6P 139180-65-7P
 139180-66-8P 139181-07-0P 139181-09-2P
 139181-10-5P 139181-11-6P 139181-12-7P
 139181-13-8P 139181-14-9P 139181-16-1P
 139181-17-2P 139181-19-4P 139181-20-7P
 139181-21-8P 139181-22-9P 139181-23-0P
 139181-24-1P 139181-25-2P 139211-51-1P
 139211-52-2P 146229-55-2P 158747-27-4P
 161792-98-9P 161792-99-0P 161793-00-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of triazolotriazines and analogs as adenosine antagonists)


RN 139179-54-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(2-furanyl)-5-(phenylthio)- (CA INDEX NAME)




RN 139179-55-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
 2-(2-furanyl)-N5-propyl- (CA INDEX NAME)



RN 139179-56-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
 2-(5-methyl-2-furanyl)-5-(phenylthio)- (CA INDEX NAME)



10/552,304


RN 139179-57-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-ethoxy-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-58-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-(4-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-59-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(phenylmethoxy)- (CA INDEX NAME)



RN 139179-61-6 CAPLUS


CN Phenol, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-62-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(4-methoxyphenoxy)- (CA INDEX NAME)


10/552,304




RN 139179-63-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-64-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-phenylethoxy)- (CA INDEX NAME)




RN 139179-65-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)




RN 139179-66-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-methoxyethoxy)- (CA INDEX NAME)

10/552,304




RN 139179-67-2 CAPLUS

CN Benzonitrile, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-68-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-butoxy-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-69-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(3-methoxyphenoxy)- (CA INDEX NAME)




RN 139179-70-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-propen-1-yloxy)- (CA INDEX NAME)


10/552,304




RN 139179-71-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-methoxyphenoxy)- (CA INDEX NAME)




RN 139179-72-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-73-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)




RN 139179-74-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(4-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)



10/552,304


RN 139179-75-2 CAPLUS

CN Benzonitrile, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-76-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(3-isoxazolyloxy)- (CA INDEX NAME)




RN 139179-77-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclohexyl-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-78-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-phenyl- (CA INDEX NAME)




RN 139179-79-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-2-propen-1-yl- (CA INDEX NAME)


10/552,304




RN 139179-80-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 139179-81-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-morpholinyl)- (CA INDEX NAME)



RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(phenylmethyl)- (CA INDEX NAME)




RN 139179-83-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-butyl-2-(2-furanyl)-
(CA INDEX NAME)



10/552,304


RN 139179-84-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-ethyl-2-(2-furanyl)-
(CA INDEX NAME)




RN 139179-85-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(1-methylethyl)- (CA INDEX NAME)




RN 139179-86-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-phenylethyl)- (CA INDEX NAME)



RN 139179-87-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-furanylmethyl)- (CA INDEX NAME)




RN 139179-88-7 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/552,304




RN 139179-89-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-methylpropyl)- (CA INDEX NAME)



RN 139179-90-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5,N5-dimethyl- (CA INDEX NAME)




RN 139179-91-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-92-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
5-(cyclopentylthio)-2-(2-furanyl)- (CA INDEX NAME)

10/552,304




RN 139179-93-4 CAPLUS

CN Acetic acid, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-, methyl ester (CA INDEX NAME)




RN 139179-94-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[(2-furanylmethyl)thio]- (CA INDEX NAME)



RN 139179-95-6 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 139179-99-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(3-furanyl)-5-phenoxy- (CA INDEX NAME)


10/552,304




RN 139180-00-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(2-fluorophenoxy)- (CA INDEX NAME)




RN 139180-01-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-phenoxy- (CA INDEX NAME)



RN 139180-02-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-methoxyethoxy)-2-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 139180-03-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclohexyl-2-(3-furanyl)- (CA INDEX NAME)




10/552,304


RN 139180-04-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(5-chloro-2-furanyl)-N5-cyclohexyl- (CA INDEX NAME)




RN 139180-05-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-furanyl)-5-(phenylthio)- (CA INDEX NAME)



RN 139180-06-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(4-fluorophenyl)thio]-2-(3-furanyl)- (CA INDEX NAME)




RN 139180-07-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(cyclopentylthio)-2-(3-furanyl)- (CA INDEX NAME)




RN 139180-08-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(phenylthio)- (CA INDEX NAME)


10/552,304




RN 139180-10-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-phenoxy-2-(2-thienyl)-
(CA INDEX NAME)




RN 139180-11-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-methoxyphenoxy)-2-(2-thienyl)- (CA INDEX NAME)



RN 139180-12-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclohexyl-2-(2-thienyl)- (CA INDEX NAME)




RN 139180-13-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-propyl-2-(2-thienyl)- (CA INDEX NAME)




10/552,304


RN 139180-14-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(phenylthio)-2-(2-thienyl)- (CA INDEX NAME)



RN 139180-15-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 139180-16-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-pentyl- (CA INDEX NAME)



RN 139180-17-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 139180-18-0 CAPLUS


10/552,304

RN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
CN N5-[2-(4-chlorophenyl)ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-19-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-bicyclo[2.2.1]hept-2-yl-2-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 139180-20-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 139180-21-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(2-fluorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-22-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)


10/552,304




RN 139180-23-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(1,3-benzodioxol-5-ylmethyl)-2-(2-furanyl)- (CA INDEX NAME)



RN 139180-24-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 139180-25-9 CAPLUS
CN Benzeneacetamide, N-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-4-hydroxy- (CA INDEX NAME)




RN 139180-26-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10/552,304




RN 139180-27-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-methoxyethyl)- (CA INDEX NAME)



RN 139180-28-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclopentyl-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-29-3 CAPLUS
CN Acetic acid, 2-[4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)

10/552,304




RN 139180-31-7 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenyl ester
(CA INDEX NAME)




RN 139180-32-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-methylphenoxy)- (CA INDEX NAME)



RN 139180-34-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-pyridinyloxy)- (CA INDEX NAME)




RN 139180-35-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1,2,5-thiadiazol-3-yloxy)- (CA INDEX NAME)


10/552,304




RN 139180-36-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)



RN 139180-37-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-38-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[2-(ethylsulfinyl)ethoxy]-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-39-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 139180-40-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2,3,4,5,6-pentafluorophenoxy)- (CA INDEX NAME)



RN 139180-41-9 CAPLUS
CN Benzonitrile, 3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139180-42-0 CAPLUS
CN Benzenesulfonamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 139180-43-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-nitrophenoxy)- (CA INDEX NAME)

10/552,304




RN 139180-44-2 CAPLUS

CN Benzoic acid, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 139180-45-3 CAPLUS

CN Benzoic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 139180-46-4 CAPLUS


CN Benzoic acid, 3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 139180-47-5 CAPLUS


CN Benzeneacetic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)

10/552,304




RN 139180-48-6 CAPLUS

CN Acetic acid, 2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenoxy]-, methyl ester (CA INDEX NAME)




RN 139180-49-7 CAPLUS

CN Acetamide, 2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenoxy]-N-propyl- (CA INDEX NAME)



RN 139180-50-0 CAPLUS


CN Acetamide, N-[2-(2-furanyl)-5-phenoxy[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]- (CA INDEX NAME)



RN 139180-51-1 CAPLUS


CN Acetamide, N-[2-(2-furanyl)-5-phenoxy[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]- (CA INDEX NAME)

10/552,304




RN 139180-52-2 CAPLUS

CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-cyclohexyl- (CA INDEX NAME)



RN 139180-53-3 CAPLUS


CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139180-54-4 CAPLUS


CN Benzenepropanoic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 139180-55-5 CAPLUS

CN Benzenepropanamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-cyclopentyl- (CA INDEX NAME)


10/552,304




RN 139180-56-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-methylphenoxy)- (CA INDEX NAME)



RN 139180-57-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-methylphenoxy)- (CA INDEX NAME)




RN 139180-58-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5(1H)-one, 7-amino-2-(2-furanyl)-
(CA INDEX NAME)




RN 139180-59-9 CAPLUS
CN Acetamide, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-N-cyclohexyl- (CA INDEX NAME)

10/552,304




RN 139180-60-2 CAPLUS

CN Ethanone, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 139180-61-3 CAPLUS

CN Acetamide, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-N-propyl- (CA INDEX NAME)



RN 139180-62-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, N-ethyl-2-(2-furanyl)-5-phenoxy- (CA INDEX NAME)



RN 139180-64-6 CAPLUS


CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-propyl- (CA INDEX NAME)

10/552,304




RN 139180-65-7 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(5-methyl-2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 139180-66-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(5-isoxazolyl)-5-phenoxy- (CA INDEX NAME)



RN 139181-07-0 CAPLUS


CN Phenol, 4-[2-[[7-amino-2-(3-methyl-5-isoxazolyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 139181-09-2 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)


10/552,304




RN 139181-10-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (CA INDEX
NAME)



RN 139181-11-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 139181-12-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 139181-13-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


10/552,304




RN 139181-14-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(2-phenylethyl)thio]- (CA INDEX NAME)




RN 139181-16-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)



RN 139181-17-2 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (CA INDEX NAME)




RN 139181-19-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-dimethylphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




10/552,304


RN 139181-20-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 139181-21-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(2-ethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139181-22-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-dimethoxyphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139181-23-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-difluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139181-24-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2,6-dichlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 139181-25-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(3-fluorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139211-51-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(5-methyl-2-furanyl)-N5-propyl- (CA INDEX NAME)




RN 139211-52-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(cyclopropylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 146229-55-2 CAPLUS
CN Phenol, 2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)


10/552,304




RN	158747-27-4	CAPLUS
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]-	(CA INDEX NAME)



RN	161792-98-9	CAPLUS
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-methylpropoxy)-	(CA INDEX NAME)




RN 161792-99-0 CAPLUS
CN Phenol, 4-[2-[[2-(2-furanyl)-7-(methylamino)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 161793-00-6 CAPLUS
CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (CA INDEX NAME)

10/552,304



IT 139180-63-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of triazolotriazines and analogs as adenosine antagonists)
RN 139180-63-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-N-methyl-5-phenoxy- (CA INDEX NAME)




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/552,304

L4 ANSWER 149 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1994:680678 CAPLUS
DN 121:280678
OREF 121:51247a,51250a
TI Preparation of azole derivatives as adenosine antagonists
IN Jones, Geraint
PA Zeneca Ltd., UK
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9414812	A1	19940707	WO 1993-GB2525	19931210
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9309045	A	19940622	ZA 1993-9045	19931202
	AU 9456564	A	19940719	AU 1994-56564	19931210
	CN 1093708	A	19941019	CN 1993-121279	19931222
PRAI	GB 1992-26735	A	19921222		
	WO 1993-GB2525	W	19931210		
OS	MARPAT 121:280678				
IT	139181-27-4P 139181-28-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, in preparation of adenosine antagonists)				
RN	139181-27-4 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)				



RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




IT 158747-27-4P 158747-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)

10/552,304

(preparation of, as adenosine antagonist)


RN 158747-27-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 158747-28-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(4-morpholinyl)ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


IT 139179-53-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of adenosine antagonists)

RN 139179-53-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine, 2-(2-furanyl)-5-phenoxy-
(CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 150 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1993:580833 CAPLUS

DN 119:180833

OREF 119:32335a,32338a

TI Preparation of furyltriazolotriazines as adenosine antagonists

IN Jones, Geraint; James, Roger; Hargreaves, Rodney Brian

PA Imperial Chemical Industries PLC, UK

SO Eur. Pat. Appl., 18 pp.


CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 544443	A1	19930602	EP 1992-310542	19921119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2082462	A1	19930526	CA 1992-2082462	19921109
	US 5380714	A	19950110	US 1992-979549	19921120
	JP 05222045	A	19930831	JP 1992-315384	19921125
PRAI	GB 1991-25002	A	19911125		
OS	MARPAT 119:180833				
IT	139181-27-4P 139181-28-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(preparation and reaction of, in preparation of adenosine antagonist)				
RN	139181-27-4 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)				



RN 139181-28-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)



IT 150221-57-1P 150221-58-2P 150221-59-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as adenosine antagonist)

RN 150221-57-1 CAPLUS


CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)

10/552,304




RN 150221-58-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[3-(dimethylamino)propyl]-N-methyl-
(CA INDEX NAME)




RN 150221-59-3 CAPLUS

CN Benzenesulfonamide, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-N-[4-(dimethylamino)butyl]-
(CA INDEX NAME)




L4 ANSWER 151 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1993:560324 CAPLUS
 DN 119:160324
 OREF 119:28741a,28744a
 TI Preparation of triazolo[1,5-a]-1,3,5-triazines as adenosine antagonists
 IN Hutton, Jonathan
 PA Imperial Chemical Industries PLC, UK
 SO Eur. Pat. Appl., 12 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 544444	A1	19930602	EP 1992-310543	19921119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	ZA 9208450	A	19930525	ZA 1992-8450	19921102
	AU 9228126	A	19930527	AU 1992-28126	19921104
	AU 656432	B2	19950202		
	CA 2082332	A1	19930526	CA 1992-2082332	19921106
	HU 67756	A2	19950428	HU 1992-3531	19921111
	US 5326869	A	19940705	US 1992-979096	19921120
	NO 9204532	A	19930526	NO 1992-4532	19921124
	JP 05194520	A	19930803	JP 1992-315387	19921125
	HU 71114	A2	19951128	HU 1994-2757	19940926
	FI 9503146	A	19950622	FI 1995-3146	19950622
PRAI	GB 1991-24968	A	19911125		
	HU 1992-3531	A	19921111		
	FI 1992-5259	A	19921119		
OS	CASREACT 119:160324; MARPAT 119:160324				
IT	139179-53-6P 139180-30-6P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as adenosine receptor antagonist)				
RN	139179-53-6 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy-				
	(CA INDEX NAME)				



RN 139180-30-6 CAPLUS
 CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



10/552,304

L4 ANSWER 152 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1993:428162 CAPLUS

DN 119:28162

OREF 119:5225a,5228a

TI Preparation of azolo[1,3,5]triazines as adenosine antagonists

IN Caulkett, Peter William Rodney; Jones, Geraint; Poucher, Simon Martin; Collis, Michael George

PA Imperial Chemical Industries PLC, UK

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 515107	A2	19921125	EP 1992-304409	19920515
	EP 515107	A3	19930113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	US 5290776	A	19940301	US 1992-886798	19920521
	CA 2069455	A1	19921124	CA 1992-2069455	19920522
	NO 9202028	A	19921124	NO 1992-2028	19920522
	AU 9217093	A	19921126	AU 1992-17093	19920522
	AU 654010	B2	19941020		
	ZA 9203767	A	19930428	ZA 1992-3767	19920522
	HU 62898	A2	19930628	HU 1992-1704	19920522
	HU 210764	B	19950728		
	JP 05155887	A	19930622	JP 1992-132526	19920525
PRAI	GB 1991-11130	A	19910523		

OS MARPAT 119:28162

IT 146351-74-8P 146351-75-9P 146351-76-0P

146351-77-1P 146351-78-2P 146351-79-3P

146351-80-6P 146351-81-7P 146351-82-8P

146351-83-9P 146351-84-0P 146351-85-1P

146351-86-2P 146351-87-3P 146351-88-4P


146351-89-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as adenosine antagonist)

RN 146351-74-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenyl- (CA INDEX NAME)




RN 146351-75-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-phenylethynyl)- (CA INDEX NAME)


10/552,304




RN 146351-76-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-phenylethyl)- (CA INDEX NAME)



RN 146351-77-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 146351-78-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-methoxyphenyl)- (CA INDEX NAME)




RN 146351-79-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-methylphenyl)- (CA INDEX NAME)


10/552,304




RN 146351-80-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-fluorophenyl)-2-(2-furanyl)- (CA INDEX NAME)



RN 146351-81-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-difluorophenyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 146351-82-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-thienyl)-
(CA INDEX NAME)




RN 146351-83-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[[4-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)


10/552,304




RN 146351-84-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-phenylpropyl)- (CA INDEX NAME)



RN 146351-85-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1-hexyn-1-yl)- (CA INDEX NAME)




RN 146351-86-2 CAPLUS
CN Acetamide, N-[2-(2-furanyl)-5-(4-methoxyphenyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]- (CA INDEX NAME)




RN 146351-87-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-buten-1-yl)-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 146351-88-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-hexyl- (CA INDEX NAME)



RN 146351-89-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-(3,5-difluorophenyl)-2-(2-furanyl)-N-methyl- (CA INDEX NAME)




IT 139181-27-4P 139181-28-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for adenosine antagonist)
RN 139181-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)



RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)

10/552,304




10/552,304


L4 ANSWER 153 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1993:124565 CAPLUS
DN 118:124565
OREF 118:21601a,21604a
TI Preparation of azolo[1,3,5]triazines as adenosine antagonists
IN Caulkett, Peter William Rodney; Jones, Geraint; Poucher, Simon Martin;
Collis, Michael George
PA Imperial Chemical Industries PLC, UK
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 515108	A2	19921125	EP 1992-304410	19920515
	EP 515108	A3	19930113		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	CA 2068747	A1	19921124	CA 1992-2068747	19920515
	US 5246932	A	19930921	US 1992-887211	19920521
	JP 05186471	A	19930727	JP 1992-132278	19920525
PRAI	GB 1991-11131	A	19910523		
OS	MARPAT 118:124565				
IT	146229-41-6P 146229-42-7P 146229-44-9P				
	146229-45-0P 146229-46-1P 146229-47-2P				
	146229-48-3P 146229-50-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(preparation of, as adenosine antagonist)				
RN	146229-41-6 CAPLUS				
CN	[1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)				

PAGE 1-A



PAGE 1-B




RN 146229-42-7 CAPLUS


10/552,304

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[4-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 146229-44-9 CAPLUS
CN Pyrazolo[1,5-a]-1,3,5-triazine-2,4-diamine,
N2-[2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-7-(2-furanyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




10/552,304

RN 146229-45-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[3-[[4-amino-7-(2-furanyl)pyrazolo[1,5-a]-1,3,5-triazin-2-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 146229-46-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]methyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 146229-47-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)


10/552,304



RN 146229-48-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenyl]ethyl]-2-(2-furanyl)- (CA INDEX NAME)




RN 146229-50-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5,N5'-1,6-hexanediylbis[2-(2-furanyl)- (9CI) (CA INDEX NAME)




IT 139180-30-6P 139181-09-2P 139181-18-3P
139181-27-4P 139181-28-5P 146229-53-0P
146229-54-1P 146229-55-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for adenosine antagonist)
RN 139180-30-6 CAPLUS
CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)


10/552,304




RN 139181-09-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)



RN 139181-18-3 CAPLUS
CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 139181-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)




RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)


10/552,304




RN 146229-53-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[[4-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 146229-54-1 CAPLUS
CN Phenol, 4-[[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]methyl]- (CA INDEX NAME)



RN 146229-55-2 CAPLUS
CN Phenol, 2-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



L4 ANSWER 154 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1992:571476 CAPLUS
 DN 117:171476
 OREF 117:29653a,29656a
 TI Preparation of (amino)heteroaryl[1,2,4]triazolo[1,5-a]triazines and
 related compounds as adenosine A2 receptor antagonists
 IN Caulkett, Peter William Rodney; Jones, Geraint; Collis, Michael George;
 Poucher, Simon Martin
 PA Imperial Chemical Industries PLC, UK
 SO Eur. Pat. Appl., 53 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 459702	A1	19911204	EP 1991-304665	19910523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	GB 2244487	A	19911204	GB 1991-11132	19910523
	GB 2244487	B	19940202		
	CA 2043424	A1	19911130	CA 1991-2043424	19910528
	FI 9102563	A	19911130	FI 1991-2563	19910528
	NO 9102051	A	19911202	NO 1991-2051	19910528
	NO 178401	B	19951211		
	NO 178401	C	19960320		
	AU 9177348	A	19911205	AU 1991-77348	19910528
	AU 642494	B2	19931021		
	RO 109542	B1	19950330	RO 1991-147639	19910528
	PL 167014	B1	19950731	PL 1991-290445	19910528
	CN 1056879	A	19911211	CN 1991-103744	19910529
	ZA 9104094	A	19920226	ZA 1991-4094	19910529
	HU 61311	A2	19921228	HU 1991-1789	19910529
	JP 05097855	A	19930420	JP 1991-235332	19910529
	IL 98316	A	19950526	IL 1991-98316	19910530
PRAI	GB 1990-11913	A	19900529		
	GB 1990-11914	A	19900529		
	GB 1991-1379	A	19910122		
	GB 1991-1380	A	19910122		
	GB 1991-4125	A	19910227		
OS	CASREACT 117:171476; MARPAT 117:171476				
IT	139179-53-6P 139179-54-7P 139179-55-8P				
	139179-56-9P 139179-57-0P 139179-58-1P				
	139179-59-2P 139179-60-5P 139179-61-6P				
	139179-62-7P 139179-63-8P 139179-64-9P				
	139179-65-0P 139179-66-1P 139179-67-2P				
	139179-68-3P 139179-69-4P 139179-70-7P				
	139179-71-8P 139179-72-9P 139179-73-0P				
	139179-74-1P 139179-75-2P 139179-76-3P				
	139179-77-4P 139179-78-5P 139179-79-6P				
	139179-80-9P 139179-81-0P 139179-82-1P				
	139179-83-2P 139179-84-3P 139179-85-4P				
	139179-86-5P 139179-87-6P 139179-88-7P				
	139179-89-8P 139179-90-1P 139179-91-2P				
	139179-92-3P 139179-93-4P 139179-94-5P				
	139179-95-6P 139179-96-7P 139179-97-8P				
	139179-98-9P 139179-99-0P 139180-00-0P				
	139180-01-1P 139180-02-2P 139180-03-3P				
	139180-04-4P 139180-05-5P 139180-06-6P				
	139180-07-7P 139180-08-8P 139180-09-9P				
	139180-10-2P 139180-11-3P 139180-12-4P				


139180-13-5P 139180-14-6P 139180-15-7P
 139180-16-8P 139180-17-9P 139180-18-0P
 139180-19-1P 139180-20-4P 139180-21-5P
 139180-22-6P 139180-23-7P 139180-24-8P
 139180-25-9P 139180-26-0P 139180-27-1P
 139180-28-2P 139180-29-3P 139180-30-6P
 139180-31-7P 139180-32-8P 139180-33-9P
 139180-34-0P 139180-35-1P 139180-36-2P
 139180-37-3P 139180-38-4P 139180-39-5P
 139180-40-8P 139180-41-9P 139180-42-0P
 139180-43-1P 139180-44-2P 139180-45-3P
 139180-46-4P 139180-47-5P 139180-48-6P
 139180-49-7P 139180-50-0P 139180-51-1P
 139180-52-2P 139180-53-3P 139180-54-4P
 139180-55-5P 139180-56-6P 139180-57-7P
 139180-58-8P 139180-59-9P 139180-60-2P
 139180-61-3P 139180-62-4P 139180-63-5P
 139180-64-6P 139180-65-7P 139180-66-8P
 139181-06-9P 139181-07-0P 139181-08-1P
 139181-09-2P 139181-10-5P 139181-11-6P
 139181-12-7P 139181-13-8P 139181-14-9P
 139181-16-1P 139181-17-2P 139181-18-3P
 139181-19-4P 139181-20-7P 139181-21-8P
 139181-22-9P 139181-23-0P 139181-24-1P
 139181-25-2P 139211-51-1P 139211-52-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as adenosine A2 receptor antagonist)


RN 139179-53-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-phenoxy-
(CA INDEX NAME)



RN 139179-54-7 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(phenylthio)- (CA INDEX NAME)




RN 139179-55-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-propyl- (CA INDEX NAME)


10/552,304




RN 139179-56-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-(phenylthio)- (CA INDEX NAME)




RN 139179-57-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-ethoxy-2-(2-furanyl)- (CA
INDEX NAME)



RN 139179-58-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(4-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-59-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(phenylmethoxy)- (CA INDEX NAME)



10/552,304


RN 139179-60-5 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[4-(phenylmethoxy)phenoxy]- (CA INDEX NAME)




RN 139179-61-6 CAPLUS

CN Phenol, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-62-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-methoxyphenoxy)- (CA INDEX NAME)



RN 139179-63-8 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-64-9 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-phenylethoxy)- (CA INDEX NAME)


10/552,304




RN 139179-65-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-(2-phenoxyethoxy)- (CA INDEX NAME)




RN 139179-66-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-(2-furanyl)-5-(2-methoxyethoxy)- (CA INDEX NAME)



RN 139179-67-2 CAPLUS
CN Benzonitrile, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-68-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-butoxy-2-(2-furanyl)- (CA INDEX NAME)




10/552,304


RN 139179-69-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-methoxyphenoxy)- (CA INDEX NAME)




RN 139179-70-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-propen-1-yloxy)- (CA INDEX NAME)



RN 139179-71-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2-methoxyphenoxy)- (CA INDEX NAME)




RN 139179-72-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-73-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[2-(phenylthio)ethoxy]- (CA INDEX NAME)


10/552,304




RN 139179-74-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(4-fluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-75-2 CAPLUS
CN Benzonitrile, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139179-76-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-isoxazolyloxy)- (CA INDEX NAME)




RN 139179-77-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclohexyl-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 139179-78-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-phenyl- (CA INDEX NAME)




RN 139179-79-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-2-propen-1-yl- (CA INDEX NAME)



RN 139179-80-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 139179-81-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-morpholinyl)- (CA INDEX NAME)




10/552,304


RN 139179-82-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(phenylmethyl)- (CA INDEX NAME)




RN 139179-83-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-butyl-2-(2-furanyl)-
(CA INDEX NAME)



RN 139179-84-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-ethyl-2-(2-furanyl)-
(CA INDEX NAME)




RN 139179-85-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(1-methylethyl)- (CA INDEX NAME)




RN 139179-86-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-phenylethyl)- (CA INDEX NAME)

10/552,304




RN 139179-87-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-furanylmethyl)- (CA INDEX NAME)




RN 139179-88-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 139179-89-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(2-methylpropyl)- (CA INDEX NAME)




RN 139179-90-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5,N5-dimethyl- (CA INDEX NAME)


10/552,304




RN 139179-91-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-(dimethylamino)ethyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139179-92-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(cyclopentylthio)-2-(2-furanyl)- (CA INDEX NAME)




RN 139179-93-4 CAPLUS
CN Acetic acid, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-, methyl ester (CA INDEX NAME)




RN 139179-94-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(2-furanylmethyl)thio]- (CA INDEX NAME)


10/552,304




RN 139179-95-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[(phenylmethyl)thio]- (CA INDEX NAME)




RN 139179-96-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-furanyl)-5-(methylthio)- (CA INDEX NAME)



RN 139179-97-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(methylthio)- (CA INDEX NAME)




RN 139179-98-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-(methylthio)- (CA INDEX NAME)



10/552,304


RN 139179-99-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(3-furanyl)-5-phenoxy-
(CA INDEX NAME)




RN 139180-00-0 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(2-fluorophenoxy)- (CA INDEX NAME)




RN 139180-01-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-phenoxy- (CA INDEX NAME)



RN 139180-02-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-methoxyethoxy)-2-(5-methyl-2-furanyl)- (CA INDEX NAME)




RN 139180-03-3 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclohexyl-2-(3-furanyl)- (CA INDEX NAME)


10/552,304




RN 139180-04-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(5-chloro-2-furanyl)-N5-cyclohexyl- (CA INDEX NAME)




RN 139180-05-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(3-furanyl)-5-(phenylthio)- (CA INDEX NAME)



RN 139180-06-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[(4-fluorophenyl)thio]-2-(3-furanyl)- (CA INDEX NAME)




RN 139180-07-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(cyclopentylthio)-2-(3-furanyl)- (CA INDEX NAME)




10/552,304


RN 139180-08-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-chloro-2-furanyl)-5-(phenylthio)- (CA INDEX NAME)




RN 139180-09-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(methylthio)-2-(2-thienyl)- (CA INDEX NAME)



RN 139180-10-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-phenoxy-2-(2-thienyl)-
(CA INDEX NAME)




RN 139180-11-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-methoxyphenoxy)-2-(2-thienyl)- (CA INDEX NAME)




RN 139180-12-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-cyclohexyl-2-(2-thienyl)- (CA INDEX NAME)


10/552,304




RN 139180-13-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-propyl-2-(2-thienyl)- (CA INDEX NAME)



RN 139180-14-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
5-(phenylthio)-2-(2-thienyl)- (CA INDEX NAME)




RN 139180-15-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 139180-16-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-pentyl- (CA INDEX NAME)


10/552,304



RN 139180-17-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 139180-18-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[2-(4-chlorophenyl)ethyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139180-19-1 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-bicyclo[2.2.1]hept-2-yl-2-(2-furanyl)-, exo- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 139180-20-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)


10/552,304




RN 139180-21-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(2-fluorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139180-22-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 139180-23-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(1,3-benzodioxol-5-ylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-24-8 CAPLUS
CN Benzenepropanoic acid, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

10/552,304



RN 139180-25-9 CAPLUS


CN Benzeneacetamide, N-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]-4-hydroxy- (CA INDEX NAME)



RN 139180-26-0 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 139180-27-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-(2-methoxyethyl)- (CA INDEX NAME)



RN 139180-28-2 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5-cyclopentyl-2-(2-furanyl)- (CA INDEX NAME)

10/552,304




RN 139180-29-3 CAPLUS

CN Acetic acid, 2-[4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 139180-30-6 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RN 139180-31-7 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]phenyl ester (CA INDEX NAME)




RN 139180-32-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(3-methylphenoxy)- (CA INDEX NAME)


10/552,304




RN 139180-33-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1-methylpropoxy)- (CA INDEX NAME)



RN 139180-34-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(3-pyridinyloxy)- (CA INDEX NAME)




RN 139180-35-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(1,2,5-thiadiazol-3-yloxy)- (CA INDEX NAME)




RN 139180-36-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-[3-(trifluoromethyl)phenoxy]- (CA INDEX NAME)


10/552,304




RN 139180-37-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)



RN 139180-38-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-[2-(ethylsulfinyl)ethoxy]-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-39-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2-chlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139180-40-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(2,3,4,5,6-pentafluorophenoxy)- (CA INDEX NAME)

10/552,304




RN 139180-41-9 CAPLUS

CN Benzonitrile, 3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]- (CA INDEX NAME)




RN 139180-42-0 CAPLUS

CN Benzenesulfonamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 139180-43-1 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-nitrophenoxy)- (CA INDEX NAME)



RN 139180-44-2 CAPLUS


CN Benzoic acid, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)

10/552,304




RN 139180-45-3 CAPLUS

CN Benzoic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 139180-46-4 CAPLUS

CN Benzoic acid, 3-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 139180-47-5 CAPLUS


CN Benzeneacetic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 139180-48-6 CAPLUS


CN Acetic acid, 2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenoxy]-, methyl ester (CA INDEX NAME)

10/552,304




RN 139180-49-7 CAPLUS

CN Acetamide, 2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenoxy]-N-propyl- (CA INDEX NAME)




RN 139180-50-0 CAPLUS

CN Acetamide, 2-[4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]phenoxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)



RN 139180-51-1 CAPLUS


CN Acetamide, N-[2-(2-furanyl)-5-phenoxy[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl]- (CA INDEX NAME)



RN 139180-52-2 CAPLUS


CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-cyclohexyl- (CA INDEX NAME)

10/552,304



RN 139180-53-3 CAPLUS


CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 139180-54-4 CAPLUS

CN Benzenepropanoic acid, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 139180-55-5 CAPLUS


CN Benzenepropanamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-cyclopentyl- (CA INDEX NAME)




RN 139180-56-6 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(2-methylphenoxy)- (CA INDEX NAME)


10/552,304




RN 139180-57-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(4-methylphenoxy)- (CA INDEX NAME)



RN 139180-58-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-5(1H)-one, 7-amino-2-(2-furanyl)-
(CA INDEX NAME)




RN 139180-59-9 CAPLUS
CN Acetamide, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-N-cyclohexyl- (CA INDEX NAME)




RN 139180-60-2 CAPLUS
CN Ethanone, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-1-(1-piperidinyl)- (CA INDEX NAME)

10/552,304




RN 139180-61-3 CAPLUS

CN Acetamide, 2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]thio]-N-propyl- (CA INDEX NAME)




RN 139180-62-4 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
N-ethyl-2-(2-furanyl)-5-phenoxy- (CA INDEX NAME)



RN 139180-63-5 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-N-methyl-5-phenoxy- (CA INDEX NAME)



RN 139180-64-6 CAPLUS


CN Benzeneacetamide, 4-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]oxy]-N-propyl- (CA INDEX NAME)

10/552,304




RN 139180-65-7 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(5-methyl-2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)




RN 139180-66-8 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(5-isoxazolyl)-5-phenoxy- (CA INDEX NAME)



RN 139181-06-9 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(3-methyl-5-isoxazolyl)-5-phenoxy- (CA INDEX NAME)




RN 139181-07-0 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(3-methyl-5-isoxazolyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)


10/552,304




RN 139181-08-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 139181-09-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-[2-(phenylmethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 139181-10-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[4-methoxy-3-(phenylmethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 139181-11-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[2-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)


10/552,304




RN 139181-12-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 139181-13-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-furanyl)-N5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 139181-14-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
2-(2-furanyl)-5-[(2-phenylethyl)thio]- (CA INDEX NAME)




RN 139181-16-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
5-(3,4-dimethoxyphenyl)-2-(2-furanyl)- (CA INDEX NAME)

10/552,304




RN 139181-17-2 CAPLUS

CN Phenol, 4-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethoxy]- (CA INDEX NAME)




RN 139181-18-3 CAPLUS

CN Phenol, 3-[2-[[7-amino-2-(2-furanyl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]ethyl]- (CA INDEX NAME)



RN 139181-19-4 CAPLUS


CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 5-(3,5-dimethylphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139181-20-7 CAPLUS

CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-(2-furanyl)-N5-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)


10/552,304




RN 139181-21-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(2-ethoxyphenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139181-22-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-dimethoxyphenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139181-23-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(3,5-difluorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)




RN 139181-24-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
5-(2,6-dichlorophenoxy)-2-(2-furanyl)- (CA INDEX NAME)


10/552,304




RN 139181-25-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-[(3-fluorophenyl)methyl]-2-(2-furanyl)- (CA INDEX NAME)



RN 139211-51-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(5-methyl-2-furanyl)-N5-propyl- (CA INDEX NAME)




RN 139211-52-2 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5-(cyclopropylmethyl)-2-(2-furanyl)- (CA INDEX NAME)




IT 139181-27-4P 139181-28-5P 139181-30-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for adenosine A2 receptor antagonists)
RN 139181-27-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-7-amine,
2-(2-furanyl)-5-(methylthio)- (CA INDEX NAME)


10/552,304



RN 139181-28-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




RN 139181-30-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine,
2-(5-methyl-2-furanyl)-5-(methylsulfonyl)- (CA INDEX NAME)




10/552,304


L4 ANSWER 155 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1991:143359 CAPLUS
DN 114:143359
OREF 114:24329a,24332a
TI Synthesis of nitrogen-containing heterocycles. 5. A new route to
5-amino[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives
AU Miyamoto, Yoshiko; Yamazaki, Chiji; Matzui, Megumi
CS Sch. Hyg. Sci., Kitasato Univ., Sagamihara, 228, Japan
SO Journal of Heterocyclic Chemistry (1990), 27(6), 1553-7
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 114:143359
IT 28610-03-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28610-03-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-phenyl- (CA INDEX NAME)



L4 ANSWER 156 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
 AN 1984:530664 CAPLUS
 DN 101:130664
 OREF 101:19881a,19884a
 TI Triazines and related products. Part 26. Synthesis and chemistry of bicyclic analogs of the antitumor drug 2,4,6-tris(dimethylamino)-1,3,5-triazine (hexamethylmelamine)
 AU Langdon, Simon P.; Simmonds, Richard J.; Stevens, Malcolm F. G.
 CS Dep. Pharm., Univ. Aston, Birmingham, B4 7ET, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1984), (5), 993-8
 CODEN: JCPRB4; ISSN: 0300-922X
 DT Journal
 LA English
 OS CASREACT 101:130664
 IT 54807-00-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and nitration of)
 RN 54807-00-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5,N5,N7,N7-tetramethyl-2-phenyl- (CA INDEX NAME)




IT 91892-55-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 91892-55-6 CAPLUS
 CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, N5,N5,N7,N7-tetramethyl-2-(2-nitrophenyl)- (CA INDEX NAME)




IT 91892-36-3P 91892-56-7P 91892-57-8P
 91892-58-9P 91892-59-0P 91892-60-3P
 91892-62-5P 91892-63-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 91892-36-3 CAPLUS
 CN Acetamide, N-[2-[5,7-bis(dimethylamino)[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl]phenyl]- (CA INDEX NAME)


10/552,304




RN 91892-56-7 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5,N5,N7,N7-tetramethyl-2-(3-nitrophenyl)- (CA INDEX NAME)



RN 91892-57-8 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5,N5,N7,N7-tetramethyl-2-(4-nitrophenyl)- (CA INDEX NAME)




RN 91892-58-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-chlorophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)




RN 91892-59-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(3-chlorophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)


10/552,304




RN 91892-60-3 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(4-chlorophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)



RN 91892-62-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(3,5-dinitrophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)




RN 91892-63-6 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-azidophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)




IT 91892-54-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation, acetylation, and azidation of)
RN 91892-54-5 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
2-(2-aminophenyl)-N5,N5,N7,N7-tetramethyl- (CA INDEX NAME)

10/552,304




10/552,304

L4 ANSWER 157 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1981:47278 CAPLUS
DN 94:47278
OREF 94:7717a,7720a
TI Reaction of N-cyanoformimidates with some heterocyclic compounds. A new
synthesis of 5-azaadenine and related compounds
AU Lalezari, I.; Nabahi, S.
CS Dep. Med., Montefiore Hosp. Med. Cent., Bronx, NY, 10467, USA
SO Journal of Heterocyclic Chemistry (1980), 17(5), 1121-3
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 94:47278
IT 28610-03-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28610-03-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-phenyl- (CA INDEX NAME)




10/552,304

L4 ANSWER 158 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1975:125364 CAPLUS
DN 82:125364
OREF 82:20027a,20030a
TI Synthesis of s-triazolo[4,3-a]-s-triazines and their isomerization to
s-triazolo[2,3-a]-s-triazines
AU Deshpande, R. J.; Roa, A. V. Rama
CS Natl. Chem. Lab., Poona, India
SO Synthesis (1974), (12), 863-5
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
IT 54807-00-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 54807-00-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine,
N5,N5,N7,N7-tetramethyl-2-phenyl- (CA INDEX NAME)




10/552,304


L4 ANSWER 159 OF 159 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1970:487897 CAPLUS
DN 73:87897
OREF 73:14369a,14372a
TI 2-Substituted 7-amino-1,2,4-triazolo[1,5-a]-1,3,5-triazines
AU Bokaldere, R.; Grinsteins, V.
CS Inst. Org. Sin., Riga, USSR
SO Khimiya Geterotsiklicheskikh Soedinenii (1970), (4), 563-4
CODEN: KGSSAQ; ISSN: 0132-6244
DT Journal
LA Russian
IT 28610-03-9P 28610-04-0P 28610-05-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28610-03-9 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-phenyl- (CA INDEX NAME)



RN 28610-04-0 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 28610-05-1 CAPLUS
CN [1,2,4]Triazolo[1,5-a][1,3,5]triazine-5,7-diamine, 2-phenyl- (CA INDEX NAME)



10/552,304

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

620.01

806.59

STN INTERNATIONAL LOGOFF AT 13:33:58 ON 24 MAR 2009